KOLLA 2-DESICCATED AVIAN STERNAL CARTILAGE POWDER

Kolla2 powder compositions, method of preparing the compositions and use of the compositions in treating arthritic joint cartilage diseases. The compositions are orally administered to humans in need of cartilage cell repair in a daily dietary supplement dosage of between about 2,400 mg and 3,600 mg.

SERINE PROTEASE INHIBITOR

The invention provides a protein which exhibits, inter alia, anti-thrombin activity and divalent metal cation binding activity. The protein can be readily extracted from the green-lipped mussell, Perna canaliculus, and formulated into foodstuffs, nutraceuticals and the like, and has a molecular weight of about 55 kDa and an amino acid sequence which includes one or more of the following: (a) DGEQCNDGQN (SEQ ID NO.1), (b) QGGHEVESERVACCVIGRA (SEQ ID NO. 2), (c) GQSHPEIVH (SEQ ID NO. 3), (d) YHGHDDA (SEQ ID NO. 4), (e) VVNEVHH (SEQ ID NO. 5) ...

HUMAN DESATURASE GENE AND USES THEREOF

... ▓▓▓The subject invention relates to the identification of a gene involved in the ▓desaturation of polyunsaturated fatty acids at carbon 5 (i.e., "human .DELTA.5-▓desaturase") and to uses thereof. In particular, human .DELTA.5-desaturase may ▓be utilized, for example, in the conversion of dihomo-.gamma. - linolenic acid ▓(DGLA) to arachidonic acid (AA) and in the conversion of 20:4n-3 to ▓eicosapentaenoic acid (EPA). AA or polyunsaturated fatty acids produced ▓therefrom may be added to pharmaceutical compositions, nutritional ▓compositions, animal feeds, as well as other products such as cosmetics.▓ ...

PREVENTIVES FOR ARTHRITIS

Preventives for arthritis, foods, drinks, food additives, animal feeds and feed additives containing as the active ingredient an N-acylated derivative of hydroxyproline or its salt; utilization of an N-acylated derivative of hydroxyproline or its salt in producing preventives for arthritis; and a method of preventing arthritis characterized by administering an N-acylated derivative of hydroxyproline or its salt.

BEVERAGES AND THEIR PREPARATION

A process for making a powdered precursor for preparing an acidic beverage upon admixture of the powdered precursor with a liquid, the process comprising the steps: (a) preparing a first slurry comprising a protein source and a polysaccharide stabiliser, said first slurry having a neutral or an acidic pH; (b) adjusting the pH of the first slurry, if necessary, to a value in the range of from 5.5 to 7.5, preferably 6 to 7.5, more preferably from 6 to 7; and (c) spray drying the first slurry after step (a) or step (b).

COMPOSITIONS AND METHODS RELATING TO THE INHIBITION OF CASOMORPHIN AND GLUTEOMORPHIN

Compositions and methods able to reduce opioid-related symptoms in a human patient of an exorphin selected from the group consisting of a gluteomorphin and a caseomorphin, comprising a physiologically effective amount of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, a physiologically effective amount of a purified gluteomorphin inhibitor selected from the group consisting of a gluteomorphinase and a gluteomorphin ligand, and at least one of the group consisting of a physiologically acceptable carrier, adjuvant, excipient, buffer and diluent. In some embodiments, the compositions and methods further comprise a physiologically effective amount of an enkephalin inhibitor, preferably an enkephalinase, and a physiologically effective amount of an endorphin inhibitor, preferably an endorphinase.

EXO-SPECIFIC AMYLASE POLYPEPTIDES, NUCLEIC ACIDS ENCODING THOSE POLYPEPTIDES AND USES THEREOF

This invention relates to amylase polypeptides, and nucleic acids encoding the polpypeptides and uses thereof. The amylases of the present invention have been engineered to have more beneficial qualities. Specifically, the amylases of the current invention show an altered exospecifity.

USE OF CARBOHYDRATE SOURCE TO LIMIT WEIGHT GAIN IN CATS

A process is provided for limiting weight gain in cats. The process includes feeding the cat a pet food composition that includes a source of protein, a source of fat, and a source of carbohydrates from a grain source that excludes rice. Use of the preferred low glycemic index grain sources that comprise a blend of corn and sorghum; a blend of corn, sorghum, and barley; or a blend of corn, soghum, and oats, has the effect of decreasing the postprandial blood glucose and insulin response of the cat as compared to when feeding a rice- based diet. The result is that the animal becomes satiated and voluntarily decreases its intake of food, causing less weight gain. This effect is even more marked when the composition is fed to male cats.

NOVEL MUCIN-TYPE GLYCOPROTEIN AND USE THEREOF

... ²The present invention relates to a novel mucin-type glycoprotein and to a ²method for ²producing the same. Specifically, the present invention provides a mucin-type ²glycoprotein ²having a repeat structure which comprises 3 to 2000 repeating units each ²having an amino acid ²sequence represented by the formula I: Val-Xaa-Glu-Thr-Thr-Ala-Ala-Pro ²[wherein Xaa ²represents Val or Ile], wherein one or more amino acid residues in the ²structure are bound to a ²sugar chain consisting of one or more monosaccharides. The present invention ²also relates to ²a composition comprising the novel mucin-type glycoprotein. Furthermore, the ²present ²invention relates to a molecular weight marker comprising the novel mucin-type ²glycoprotein.² ...

ОЛИГОСАХАРИДНЫЙ ИНГРЕДИЕНТ

Олигосахаридный ингредиент содержит гликозилированные аминокислоты и пептиды общей формулы RnSacm, где R - остаток аминокислоты, Sac - моносахарид, выбранный из группы, в которую входят N-ацетил-нейраминовая кислота, N-ацетил галактозамин и галактоза, n имеет значение между 1 и 10, причем, если n имеет значение 1, то R - треониновый остаток или сериновый остаток, а, если n имеет значение между 2 и 10, пептид содержит, по крайней мере, один треониновый или сериновый остаток, m имеет значение между 2 и 4, и по крайней мере 20 мол. % ингредиента является N-ацетил-нейраминовой кислотой, причем указанный олигосахаридный ингредиент содержит от 15 до 25 мол. % N-ацетил галактозамина, от 15 до 25 мол.% галактозы, 20-50 мол. % N-ацетил-нейраминовой кислоты и 15-25 мол. % треонина или серина или их смеси.

КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПОЛИФЕНОЛ

Настоящее изобретение относится к композиции, содержащей полифенол и полимер, содержащий аминогруппы, где по меньшей мере 0,1% полифенола по массе композиции присутствует в виде части комплекса с полимером, и где комплекс находится в форме частиц. Также предоставлены применение полимеров, содержащих аминогруппы, для контроля свойств полифенола и способ получения композиции, содержащей комплекс полифенола и полимера.

ЖИДКАЯ ПАНИРОВКА, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ПРИГОТОВЛЕНИЯ В МИКРОВОЛНОВОЙ ПЕЧИ

Состав панировки продуктов питания, которые готовят или разогревают при помощи микроволновой печи, включающий водяную смесь с содержанием следующего: а) крахмал; б) мучной компонент, содержащий безглютеновую муку и кукурузную муку; в) желирующий агент; г) энзимная добавка, включающая α-амилазу; и д) необязательные дополнительные ингредиенты.

КАПСУЛИРОВАННЫЙ БЕЛОКСОДЕРЖАЩИЙ ПРОДУКТ И СПОСОБ ЕГО ПОЛУЧЕНИЯ

Изобретение относится к медицинской, химической, фармацевтической, пищевой промышленности, животноводству, рыбной промышленности, диетологии и биотехнологии и может использоваться при создании капсулированных белоксодержащих продуктов. Изобретение заключается в создании альгиновой оболочки с солями кальция, бария или их смеси, которые находятся в составе внутреннего содержимого капсулированного белоксодержащего продукта, указанное внутреннее содержимое капсулируется через раствор альгината натрия 0,5 ... 3,0 %, в ​​результате чего образуется альгиновая оболочка с соотношением: внутреннее содержимое:оболочка 100:(20-50), рН внутреннего содержимого составляет 7,5 ... 8,5.

ПИЩЕВАЯ ДОБАВКА

Пищевая добавка, способствующая хорошему заглатыванию и хорошему перевариванию животных и/или растительных белков. Она состоит из смеси ферментов, включающей амилазу, лактазу и бромелаин, и их весовая дозировка является следующей: от 15 до 90 мг амилазы; от 18 до 90 мг лактазы; от 6 до 80 мг для бромелаина.

Non-dairy protein beverage products

The present invention relates to a non dairy beverage products including products manufactured with superior creaminess. In particular, the invention is concerned with a partially denatured protein system induced by controlled denaturation of protein which imparts outstanding sensory attributes RTD beverage. A method for producing such beverage and product obtainable from the method are also part of the invention.

Lipid metabolism ameliorant

FOOD COMPLEMENT INCLUDING/UNDERSTANDING an ASSOCIATION Of ANTIOXYDANT AGENTS AND CARNITINE, OBTAINED BY ENDOGENOUS OR EXOGENIC SYNTHESIS, LIKE HELPS WITH the FERTILITY AT the MAN AND the WOMAN

Use of human food composition with low polyamine content in production of food for combating syndromes or disorders involving NR2-N subunit of N-methyl-D-aspartate receptor e.g. sensitization to pain, ischemia and neurodegenerative diseases

L'invention concerne l'utilisation nouvelle d'une composition alimentaire à usage humain présentant moins de 1600 picomoles de polyamines pour la réalisation d'un aliment thérapeutique destiné à lutter contre un syndrome ou une pathologie dans lequel ou dans laquelle la sous-unité NR2-B du récepteur N-méthyl-D-aspartate est impliquée.

METHOD OF PREPARATION Of a FOOD HYPOALLERGENIQUE

L'invention concerne un procédé de préparation d'un aliment à allergénicité réduite à partir d'une matrice alimentaire solide particulaire à plus forte allergénicité, contenant des protéines allergènes, notamment d'une matrice à base d'arachide et/ou de fruits à coque, qui comprend une étape de traitement d'une dispersion de ladite matrice alimentaire solide dans un véhicule aqueux, par homogénéisation à haute pression, de sorte à obtenir un homogénéisât constitué d'une dispersion de protéines allergènes initialement contenues dans la matrice en mélange avec des particules solides de cette matrice. Cette étape d'homogénéisation peut être précédée d'une étape de broyage de la matrice en dispersion, et suivie d'une étape de traitement de l'homogénéisât par un agent de dégradation des protéines, notamment par un micro-organisme probiotique.

High protein food composition, useful as salt and sweet composition, comprises proteins comprising milk protein and soy protein, lipid comprising vegetable oils, lactose as carbohydrate, vitamins and minerals, and flavoring compounds

Composition alimentaire hyperprotéinée contenant : a) des protéines choisies dans le groupe consistant en protéines lactées et protéines de soja selon un pourcentage en poids compris entre 38% et 50% de la composition, b) des lipides consistant en huiles végétales selon un pourcentage en poids compris entre 18% et 30% de la composition, c) du lactose comme glucide selon un pourcentage en poids compris entre 7% et 22% de la composition, d) des vitamines et des minéraux selon un pourcentage en poids compris entre 1% et 2% de la composition, et e) des composés aromatisants selon un pourcentage en poids compris entre 6% et 10% de la composition. Cette composition peut être utilisée comme fourrage pour réaliser une gaufrette comportant 3 couches de fourrage (10, 12, 14), deux couches de biscuit extérieurs (16, 18) et deux couches de biscuit intermédiaires (20, 22).

HEPATIC PROTECTION AGENT CONTAINING EGGSHELL MEMBRANE AND PHARMACEUTICAL COMPOSITION, FOOD ADDITIVE AND FOOD USING THE SAME

MATRIX-TYPE ENTERIC COATED SUSTAINED RELEASE COMPOSITION

A matrix-type enteric coated sustained release composition comprising a physiologically active substance, a gelling agent, a basic organic compound and an excipient; a process for producing the composition; and a food, pharmaceutical product, feed or the like comprising the composition, characterized in that the physiologically active substance is a protein, a polypeptide, a peptide or a microorganism, the physiologically active substance and the gelling agent are both in the form of powder particles coated with a lipid coating, and each of the components described above and other auxiliary components has one or more elements selected from the group consisting of an alkaline metal, an alkaline earth metal, manganese, cupper, iron, zinc and cobalt.

AN ORGANOLEPTICALLY IMPROVED DIETARY FIBER COMPOSITION AND A PROCESS THEREOF (TEESTAR)

The present invention is in relation to an organoleptically improved dietary fiber composition from Tngonella foenum-graecum. In addition, the present invention provides a process to obtain an organoleptically improved dietary fiber composition comprising protein and galactomannans for treatment of diabetes.

METHOD FOR PRODUCING NUTRITIONAL COMPOSITION

A method for producing a nutritional composition according to the present invention is a method for producing a nutritional composition containing a protein and a mineral group comprising at least two minerals, and comprises adding (a) a powder or an aqueous solution of at least one mineral that can be converted into the form of a bivalent ion when prepared into an aqueous solution or (b) a mineral powder mixture comprising at least one mineral that can be converted into the form of a bivalent ion when prepared into an aqueous solution and at least one another mineral that is included in the mineral group to an aqueous protein-rich solution containing a whey protein in such an amount that the mass of a protein derived from the whey protein becomes 2 to 12 g/100 ml and agitating the resultant mixture. In the method, when there is any remaining mineral spices among the mineral group, a powder of the remaining mineral spices is also added to the above-mentioned aqueous protein-rich solution ...

AERATED FOOD PRODUCTS

The present invention has as an objective to provide aerated food products containing solid particles at the gas bubble interface, and proteins which do not interfere with the solid particles, and of which the texture remains stable during storage. This objective is met by an aerated food product which contains aggregated protein particles which are not surface active.

SHELF STABLE NUTRITIONAL LIQUIDS COMPRISING BETA ALANINE

Disclosed are shelf-stable nutritional liquids comprising beta alanine, protein, and a carbohydrate system, wherein the shelf-stable nutritional liquid includes a molar ratio of the DE of the carbohydrate system to the lysine amino nitrogen of the protein of less than about 1.0 and or a molar ratio of the DE of the carbohydrate system to the beta alanine of less than about 3.0. The nutritional liquids are surprisingly stable over extended periods of time and exhibit minimal reduction in the concentration of beta alanine over shelf life.

NUTRITIONAL COMPOSITIONS INCLUDING A HIGH PROTEIN COMPONENT AND EXOGENOUS NUCLEOTIDES

Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including a high protein component and one or more exogenous nucleotides. The nutritional compositions can be specifically used to accelerate and improve wound healing in a mammal.

PRETERM FORMULA

The present invention relates to a method and a composition for feeding low birthweight infants (LBW infants), very low birthweight infants (VLBW infants), extremely low birthweight infants (ELBW infants) and preterm infants for improving oral tolerance.

SATIETY ENHANCING FOOD PRODUCTS

The present invention relates to an food product comprising at least 0.1 wt.% of oil bodies, said oil bodies having a volume weighted mean diameter within the range of 0.1- 100 m and comprising a lipid matrix surrounded by a layer of phospholipids embedded with structural proteins, wherein said structural proteins have been cross-linked. Furthermore the invention concerns the use of such cross-linked oil bodies in the treatment or prevention of overweight. The inventors have found that resistance of oil bodies against digestion may be improved dramatically by cross-linking the structural proteins contained therein. It is believed that the cross-linked oil bodies according to the present invention have a positive influence on appetite suppression because the oil contained in the oil bodies will reach the distal gut and thus inhibit transit through the proximal small intestine by means of the so called ileal brake mechanism.

THE PRODUCT INTENDED FOR FACILITATION OF BONE OSSIFICATION, THE METHOD OF ITS MANUFACTURE AND USE

The product for facilitation of bone ossification consists of the native composite of hydroxyapatite structure with collagen. The principle of this new solution lies in the fact that the collagen contained in the native bone composite is modified and at least partially devoid of the terminal antigenic telopeptides, which is a reaction product of enzymatic atelopeptidation. The method of manufacture of the product that facilitates bone ossification lies in the fact that proteolytic enzymes are applied on the purified bone mash and these enzymes catalyze hydrolysis of the terminal collagen telopeptides and so they modify collagen by means of atelopeptidation. The use of the product that facilitates ossification of bones may consist in its surgical implantation in the processes of controlled bone regeneration or for filling of bone cysts and smaller missing parts of bones or in the application of this product as a food supplement that supports ossification. ˙ ...

MANGOSTEEN PROTEIN SUPPLEMENT

A nutraceutical protein supplement composition containing xanthones and proteins is disclosed. The protein supplement, preferably, contains xanthones derived from fruit of the Garcinia mangostana L. plant, otherwise known as the mangosteen plant, especially from the pericarp or the whole fruit of the mangosteen plant.

HIGH PROTEIN CONTENT PASTA AND ENERGY-RESTRICTED FOOD PREPARATION INCLUDING SAID PASTA

The invention relates to a dietary product for use in energy-restricted diets for weight reduction and, more particularly, to a high protein content pasta and to an energy-restricted food preparation including said pasta. Such pasta has an energy content comprised between 1380 and 1505 kJ/100g (330 - 360 kcal/100g) and comprises an amount of high biological value proteins having (per se) a chemical index equal to or higher than 80 comprised between 14 and 24 % by weight, and a total amount of proteins comprised between 22 and 36 % by weight based on the total weight of the pasta. The pasta of the invention and the energy-restricted food preparation including the same are advantageously capable not only to comply with the energy supply and nutritional requirements dictated for the so-called meal replacements, but also to show physical and organoleptic characteristics capable to entirely meet consumers' taste.

THERAPEUTIC FOOD COMPOSITION AND METHOD TO DIMINISH BLOOD SUGAR FLUCTUATIONS

A therapeutic food composition for treatment of diabetic patients to diminish fluctuations in blood sugar levels and prevent hypoglycemic episodes, comprising per unit about 20-50 grams of nutrients including a slowly absorbed or digested complex carbohydrate, preferably cornstarch; a more rapidly absorbed complex carbohydrate; protein; and fat, but substantially no simple sugars. Diabetic patients may be treated to diminish blood sugar fluctuations and prevent hypoglycemia via the administration of the novel food composition as an evening or pre-bedtime snack or during the daytime hours to patients receiving insulin therapy or engaging in activities that might provoke hypoglycemia.

ANTICARIES COMPOSITIONS

The present invention relates to oral and edible compositions intended to provide an anticaries benefit. The primary active ingredient in these compositions is a protein selected from the group consisting of cystatin S, cystatin SA, cystatin SN and mixtures thereof which are salivary proteins. Also included are fragments of the proteins which may be used in place of the total proteins.

Extruded crunch and method of making

The present invention includes a process for making a mixture of homogeneous texturizing or flavoring particles that include fiber and protein from a mixture of heterogeneous particles by providing a mixture of heterogeneous particles of particles of a cereal grain having a flavor and a fiber concentration of at least about 25% by dry weight. The process also includes moistening the particles to form a dough-like mixture, extruding the mixture and cutting the extruded mixture to form homogeneous texturizing and flavoring particles.

Enteral diet and method for providing nutrition to a diabetic

A composition and method for providing nutrition, or a nutritional supplement, to a diabetic patient. Pursuant to the present invention, a low carbohydrate, high fat enteral formulation is provided. The fat comprises, in part, medium chain triglycerides (MCTs). Preferably, the composition includes a high percent of mono-unsaturated fats, high amylose starch, and soluble dietary fiber.

High protein liquid enteral nutritional composition

The present invention relates in general to a shelf-stable liquid enteral composition for providing nutrition, either as a supplement, or as a complete nutrition, with a high protein content of a non-hydrolysed globular protein, in particular a whey protein.

AERATED PRODUCT

Immuno-nutritional composition

FOOD PRODUCTS COMPRISING HYDROLYZED WHOLE GRAIN

Food supplement

Supplément alimentaire favorisant une bonne ingestion et une bonne digestion de protéines animales et/ou végétales. Il est constitué d'un mélange d'enzymes comprenant l'amylase, la lactase et la bromélaïne,et leur dosage pondéral est le suivant : - 15 mg à 90 mg pour l'amylase ; - 18 mg à 90 mg pour la lactase ; et - 6 mg à 80 mg pour la bromélaïne, ...

Composition for improving membrane composition and functioning of cells

It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises a/ a lipid fraction comprising at least one of docosahexaneoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b/ a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c/ a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or ...

OMEGA-3 FATTY ACID ENRICHED SOUPS AND SAUCES

ANIMAL FEED FOR CALVES FOR CONDITIONING THE INTESTINAL FLORA

Composition for improving membrane composition and functioning of cells

It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises a/ a lipid fraction comprising at least one of docosahexaneoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b/ a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c/ a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or ...

Dry plasma product and process for the production thereof

Food product providing sustained blood levels of exogenous substances

The present invention relates to a food product comprising soluble fibre and at least one exogenous biologically active substance. It further relates to the uses of a mixture comprising at least soluble fibre and at least one exogenous substance in the preparation of a food product to avoid short-term peaks of the exogenous substance in scrum, for example. Preferably the food product is a bar comprising caffeine.

MICROCAPSULES WITH WALLS MADE OF CROSS-LINKED PLANT POLYPHENOLS, AND COMPOSITIONS CONTAINING SAME

BONE-STRENGTHENING AGENT, BONE-STRENGTHENING FOOD AND BONE-STRENGTHENING FEED COMPOSITION

Novel bone-strengthening agents, food compositions for strengthening bone and feed compositions for strengthening bone which aim at preventing a decrease in bone density in association with the onset or progress of osteoporosis. It is found out that not merely added-up effects but synergistic effects can be achieved by the combined use of CPP, which is known as promoting the absorption of calcium essentially required in normal bone and thus exerting an effect of strengthening bone, with genistein which promotes osteogenesis and thus exert an effect of strengthening bone.

USE OF ASPARTATE FOR REGULATING GLUCOSE LEVELS IN BLOOD

PHARMACEUTICAL COMPOSITION FOR TREATING MOOD DISORDERS

A pharmaceutical composition for treating or preventing mood disorders, comprising theanine. A food or beverage for ameliorating ox preventing mood disorders, comprising theanine. The pharmaceutical composition and the food and beverage are safe and have a significant suppressive effect on the depression in a mood disorder.

INDEX AND METHOD OF USE OF ADAPTED FOOD COMPOSITIONS FOR DYSPHAGIC PERSONS

The present invention provides a method in which a quantitative and descriptive approach is used to adapt the food texture in the clinical management of dysphagia. There is provided a new index, ST index, and method of use for determining and modulating the physical characteristics of foods in a manner to allow the food composition at serving temperature to have a desired combination of firmness, adhesiveness, springiness and cohesiveness to overcome dysphagia-related problems.

MULTIPLE CHAMBER CONTAINER

... ²²²A multiple chamber container for separately storing components of a parenteral ²nutritional formulation is provided. The multiple chamber container may ²include frangible barriers, preferably peelable seals separating the chambers ²from each other. The container preferably facilitates the selective activation ²of the peelable seals to permit the admixing of less than all the separately ²stored components. The container may include a chamber positioned at each of ²the opposite lateral ends of the container and at least one additional chamber ²between the lateral chambers. The at least one additional chamber may have a ²longitudinal length substantially less than the longitudinal length of at ²least one of the lateral chambers. This configuration allows for selective ²opening of the seals since when rolling the container from the top avoids ²pressurizing the at least one additional chamber and inadvertent activation of ²a seal. The longitudinal length of the at least one additional chamber ...

INFANT FORMULA WITH IMPROVED PROTEIN CONTENT

An improved infant formula resulting in reduced constipation, abdominal discomfort and gastrointestinal problems, comprises at least one protein component having a phosphorus content of less than 0.75 g P/100 g protein, and at least one lipid component that can be easily digested by an infant. Preferably, it further comprises at least one prebiotic component, and at least one viscosity-improving component. The protein fraction of the formula is preferably a hydrolysate prepared by hydrolysing a protein starting material, especially a whey protein with a combination of at least one endo- and at least one exoproteinase.

DEEP-FROZEN DIETETIC CAKE

L'invention a pour objet un produit diététique hyperprotéiné et hypocalorique, se présentant sous la forme d'un gâteau sucré ou salé, cuit et surgelé. Ce gâteau cuit surgelé hyperprotéiné et hypocalorique présente une teneur en protéines comprise entre 15 et 25 %, une teneur en glucides comprise entre 5 et 10 % et une teneur en lipides comprise entre 1 et 5 %. Sa teneur en eau est comprise entre 40 et 72 % et son pouvoir calorique est compris entre 120 et 200 Kcal pour 100 g.

OXYGEN INDICATOR FOR USE IN MEDICAL PRODUCTS

An oxygen indicator is provided for revealing the presence of oxygen in a container housing a medical formulation. The indicator can be formulated with components deemed safe for use with medical products. A preferred oxygen indicator can withstand heat sterilization and prolonged storage and can provide a distinct and marked color change to indicate oxygen is present. Preferably, the indicator can be manufactured in its oxidized form and reduced upon steam sterilization. Additionally, both the color of the reduced form and the color of the oxidized form should not fade or significantly change during storage. Moreover, once a color change has occurred indicating the presence of oxygen, the oxidized color preferably remains substantially unchanged visually to the observer even after prolonged storage. The oxygen indicator can be housed in a polymeric pouch or packet having a transparent portion for viewing the color of the indicator.

КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ БЕЛОК И ДИСПЕРГИРОВАННЫЙ ЖИР

Изобретение относится к способу производства композиции, содержащей белки и жиры, включающему простой и недорогой путь получения жиросодержащих белковых продуктов высокой питательной ценности, легкими в обращении и в то же время обладающими высокой устойчивостью против слипания частиц и окисления. Более конкретно, предлагаемый способ включает следующие стадии: (i) получения суспензии, имеющей рН выше 7,0, причем указанная суспензия содержит воду, белковый материал, жир и, если требуется, щелочь; (ii) инкубирования суспензии со стадии (i) при температуре в интервале 50-150°С; (iii) гомогенизации суспензию со стадии (ii) с образованием дисперсии; (iv) и, если требуется, подвергания дисперсии со стадии (iii) последующей обработке; причем белковый материал на стадии (i) содержит ферментированный измельченный белковый материал на растительной основе и/или белковый материал на дрожжевой основе; а суспензия на стадии (i) содержит по меньшей мере 5 вес.% жира по сухому веществу. Изобретение также ...

ПИЩЕВАЯ ДОБАВКА

Пищевая добавка, способствующая хорошему заглатыванию и хорошему пищеварению животных и/или растительных белков. Она содержит смесь ферментов, состоящую из амилазы, лактазы и бромелайна, которые используют в смеси в слабых дозировках. Сочетание дозировок ферментов, которые квалифицируются как слабые дозировки, показаны при лечении расстройств пищеварения.

VERSIONS OF OSTEOPONTINE FOR USE IN SUPPRESSION OF OR PREVENTING TUMOR GROWTH AND COMPOSITION, CONTAINING SUCH VERSIONS OF OSTEOPONTINE

СТАБИЛИЗИРОВАННЫЕ ПИЩЕВЫЕ ПРОДУКТЫ С ПОКРЫТИЕМ, НАГРЕВАЕМЫЕ МИКРОВОЛНОВЫМ ИЗЛУЧЕНИЕМ

Способ производства приготовляемого или разогреваемого с использованием микроволнового излучения или тепловой обработки пищевого продукта, содержащего субстрат, включающий куски домашней птицы, рыбы, красного мяса, молочного продукта или пищевого полуфабриката, заключающийся в выполнении следующих операций: наносят на субстрат покрытие из композиции для покрытия на водной основе; причем композиция для покрытия на водной основе содержит воду и от 0,1 до 5% смеси, содержащей по массе в сухом состоянии: где процентное содержание ингредиентов выбрано из диапазонов, приведенных к общей сумме 100%; и другие ингредиенты по выбору; наносят на покрытие на водной основе первое покрытие из панировочной крошки, состоящее из мелкой панировочной крошки, с образованием в результате слоя мелкой панировочной крошки, закрывающего субстрат; наносят на первое покрытие жидкую панировочную композицию с образованием в результате жидкого панировочного покрытия и по выбору наносят на жидкое панировочное покрытие ...

СТАБИЛИЗАЦИЯ СУБСТРАТОВ ПРОДУКТОВ ПИТАНИЯ, ПОДОГРЕВАЕМЫХ В МИКРОВОЛНОВОЙ ПЕЧИ

Способ обработки пищевого продукта, состоящий из следующих этапов: полная или частичная пропитка субстрата составом стабилизатора, где субстрат содержит кусочки мяса, домашнюю птицу или рыбу; где в состав стабилизатора входит водный раствор: где процентное содержание ингредиентов в сухом весе выбрано из диапазона, в итоге составляющего 100%; и где на пропитанный субстрат нанесено покрытие на водной основе, содержащее от 0,1 до 5% в сухом весе: ...

КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ БЕЛОК И ДИСПЕРГИРОВАННЫЙ ЖИР

Настоящее изобретение относится к способу производства композиции, содержащей белки и жиры, включающему простой и недорогой путь получения жиросодержащих белковых продуктов высокой питательной ценности, легкими в обращении и в то же время обладающими высокой устойчивостью против слипания частиц и окисления. Более конкретно, предлагаемый способ включает следующие стадии: (i) получения суспензии, имеющей рН выше 7,0, причем указанная суспензия содержит воду, белковый материал, жир и, если требуется, щелочь; (ii) инкубирования суспензии со стадии (i) при температуре в интервале 50-150°С; (iii) гомогенизации суспензии со стадии (ii) с образованием дисперсии; (iv) и, если требуется, подвергания дисперсии со стадии (iii) последующей обработке; причем белковый материал на стадии (i) содержит ферментированный измельченный белковый материал на растительной основе и/или белковый материал на дрожжевой основе; а суспензия на стадии (i) содержит по меньшей мере 5 вес.% жира по сухому веществу. Изобретение ...

ПОХІДНІ ФАКТОРА КОАГУЛЯЦІЇ VII

Заявленное изобретение относится к новым полипептидам фактора коагуляции VII человека, производных фактора VII, а также полинуклеотидных конструктов, кодирующих такие полипептиды, векторов и клеток-хозяев, содержащих и экспрессирующих полинуклеотиды, фармацевтических композиций, их использование и методов лечения. Официальный бюлетень "Промышленная собственность". Книга 1 "Изобретения, полезные модели, топографии интегральных микросхем", 2008, N 23, 10.12.2008. Государственный департамент интеллектуальной собственности Министерства образования и науки Украины.

Diabetic supplement bar

FOOD COMPLEMENT INCLUDING/UNDERSTANDING an ASSOCIATION Of ANTIOXYDANT AGENTS AND DECARNITINE, OBTAINED BY ENDOGENOUS OR EXOGENIC SYNTHESIS, LIKE HELPS With the FERTILITECHEZ the MAN AND AT the WOMAN

La présente invention concerne un complément alimentaire comprenant une association : ((a) d'un mélange d'agents antioxydants et énergisants : vitamines C et E, coenzyme Q10 et/ou association de vitamines B2, B5, B6, B9, B12 et C, zinc, glutathion ou lactoferrine, superoxyde dismutase, sélénium et acides gras insaturés ; (b) d'un mélange d'agents énergisants : carnitine et/ou un produit capable de générer la carnitine par synthèse endogène, et magnésium. L'invention concerne également l'utilisation de ce complément alimentaire dans l'aide à la fertilité, dans la prévention des fausses couches, et dans la prévention des malformations embryonnaires.

Metal-phycocyanin comprising combination of protein constituent of cyanobacteria, and phycocyanin, with a divalent metal e.g. chromium and copper, useful for the preparation of compositions e.g. for micro-nutrition and cosmetics

La présente invention à pour objet la fabrication d'une métalloprotéine, la Phycocyanine -métal selon deux procédés. L'un est l'extraction de cette Phycocyanine-métal à partir de cyanobactéries chargées en métal divalent. L'autre consiste en la fixation directe du métal sur une phycocyanine extraite ou commerciale. Du fait de son homologie structurelle avec l'hémoglobine, le métal de la phycocyanine-métal est biodisponible. De ces procédés sont isssus des produits qui sont les produits intermédiares par exemple la Spiruline-métal dont les applications sont la nutrition et la thérapeutique sous forme d'administration orale, et les produits finaux les phycocyanines-métal ont des applications en nutrition, cosmétique et pharmaceutique sous des formes liquides ou sèches.

PRODUITS ALIMENTAIRES POUR BEBES ET TOUT JEUNES ENFANTS

CONCEPTION D'UNE GAMME DE PRODUITS ALIMENTAIRES POUR BEBES ET TOUT JEUNES ENFANTS. CETTE GAMME COMPORTERA DES JUS DE FRUITS, DES TISANES, DES COMPOTES DE FRUITS, DES PUREES SALEES. LES ALIMENTS PROPOSES AUX ENFANTS DE MOINS DE SIX MOIS AURONT LA FORME DE GLACONS CYLINDRIQUES EMBOITABLES DANS LES BIBERONS POUR LA DECONGELATION ET LA MISE A BONNE TEMPERATURE DANS LE FOUR A MICRO-ONDES. LES PRODUITS MANGEABLES SERONT PROPOSES EN ASSORTIMENTS DE FACON A PROPOSER AUX CONSOMMATEURS UN CHOIX QUI COUVRIRA LES BESOINS DE LEUR ENFANT POUR UNE SEMAINE PAR UNITE D'EMBALLAGE. CETTE INVENTION S'ADRESSE PLUS PARTICULIEREMENT AUX POSSESSEURS DE FOURS A MICRO-ONDES.

Inhibiteurs d'enzymes lipolytiques.

Inhibiteur d'enzyme comprenant comme ingrédient actif au moins une protéine de base, un polypeptide de base ou leurs sels. L'inhibiteur est utile comme agent diététique pour la prévention de l'obésité et de la lipémie ainsi que comme additif alimentaire.

WHITE PROTEIN HYDROLYSATES LUCERNE

COMPOSITION FOR THE REDUCTION OF THE BLOOD LIPIDS

Il est présenté une composition pour la réduction des lipides sanguins. Cette composition contient de la lactoferrine et un composé de chrome trivalent. Le composé de chrome trivalent de la présente invention est choisi dans le groupe constitué du chlorure de chrome (III) hexahydraté, du chlorure de chrome (III), de l'acétate de chrome (III), du sulfate de chrome (III), du picolate de chrome, du nicotate de chrome, des sels anorganiques de chrome trivalent, des sels organiques de chrome trivalent et des combinaisons de ceux-ci. La présente invention présente aussi un procédé de réduction des lipides sanguins d'un accepteur.

RAW PASTE HYPERPROTEINEE AND HYPERCALORIQUE FOR THE MANUFACTURE OF PRODUCTS, IN PARTICULAR FRIED, IMITATING THE PRODUCTS CONTAINING POTATO, AND ITS MANUFACTORING PROCESS

La présente invention a pour objet une préparation alimentaire sous forme de pâte crue, apte à être mise en forme, notamment en bâtonnets, boules, galettes ou portions, apte à être cuite directement au moment de la consommation par tout type de cuisson, notamment en friteuse, et permettant l'obtention de produits contretypant ou évoquant les produits traditionnels à base de pomme de terre, comme par exemple les frites, les pommes dauphine, les pommes noisette, les "rosti" ou les galettes de pomme de terre, ladite préparation alimentaire présentant une teneur réduite en protéines et une teneur faible en glucides et en lipides. L'invention a également pour objet les produits cuits, notamment en présence de matière grasse à haute température, obtenus à partir de ladite préparation alimentaire sous forme de pâte crue et mise en forme.

NUTRIENT COMPOSITION

COMPOSITION COMPRISING DNA WITH X-SHAPED STRUCTURE AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING ATOPIC DERMATITIS

The present invention relates to a composition for preventing or treating atopic dermatitis, the composition including DNA with an X-shaped structure (X_L_DNA) formed by complementary binding of oligonucleotides having base sequences of SEQ ID NOS: 1 to 4 as an active ingredient. When an atopic dermatitis animal model is treated with the X_L_DNA, skin lesions such as erythema, bleeding, and edema and edema of the ear are alleviated, and IgE expression is reduced. Therefore, the composition may be usefully applied as a pharmaceutical composition, health food or functional cosmetic for atopic dermatitis. COPYRIGHT KIPO 2016 ...

염화칼슘 추출을 이용한 콩류 단백질 제품의 제조

... 적어도 약 60wt%(N×6.25)d.b의 단백질 함량을 가지는 콩류 단백질 제품, 바람직하게는 적어도 약 90wt%(N×6.25)d.b의 콩류 단백질 함량을 가지는 콩류 분리단백은, 콩류 단백질원으로부터 콩류 단백질의 용해를 야기하고 콩류 단백질 수용액을 형성하기 위하여, 칼슘염 수용액, 바람직하게는 염화칼슘 용액으로 콩류 단백질원을 추출하고, 잔여 콩류 단백질원으로부터 콩류 단백질 수용액을 분리하고, 막 기술의 사용에 의해 이온 강도를 실질적으로 일정하게 유지하면서 콩류 단백질 수용액을 선택적으로 농축하고, 선택적으로 농축된 콩류 단백질 용액을 선택적으로 투석여과하고, 또한 선택적으로 농축되고 선택적으로 투석여과된 콩류 단백질 용액을 선택적으로 건조하는 단계에 의하여 제조된다.

WHEY PROTEIN COMPOSITION WITH A REDUCED ASTRINGENCY

The invention relates to a sterilized liquid or semi-solid acid enteral composition comprising per 100 ml 9 to 20 g of non-hydrolysed globular proteins, fat and at least 100 mg of divalent metal cations and having a pH ranging between 3 and 5. The invention further relates to a method for preparing a composition according to the invention, comprising a step wherein at least the non-hydrolysed globular proteins are subjected to a direct steam injection (DSI) at specific holding values, such as a holding temperature of 100 to 140 °C during a holding time of about 0.5 to 10 seconds, followed by a homogenization step and a sterilization step The composition according to the invention has a reduced astringency and can be used for medical purposes, such as for stimulating muscle protein synthesis in a mammal, in particular for treating sarcopenia, and for specific groups of people, such as elderly and sportsman.

BROWN ADIPOCYTE DIFFERENTIATION-INDUCING AGENT

The present invention addresses the problem of providing a means which is effective for the induction of the differentiation of a brown adipocyte and therefore enables a brown adipocyte to be used for and applied to, for example, the prevention/treatment of obesity or metabolic syndrome. Provided is a brown adipocyte differentiation-inducing agent containing, as an active ingredient, (1) CREG1 protein or (2) an expression vector carrying CREG1 gene.

LIQUID FOOD COMPOSITION

Provided is a liquid food composition that can be easily taken or administered through a tube and has an improved solidification ratio under the conditions in the stomach so that gastroesophageal reflux disease, vomiting, esophagitis, pneumonia, suffocation, diarrhea, etc. can be prevented and the feeling of fullness can be promoted thereby. The liquid food composition according to the present invention has an excellent solidification ratio under the acidic conditions in the stomach and, therefore, can more effectively reduce the onset risk of gastroesophageal reflux disease, vomiting, esophagitis, pneumonia, suffocation, diarrhea, etc. In addition, the liquid food composition requires no troublesome operation of separately adding a gelling agent, etc. at the administration. Furthermore, the liquid form of the food composition facilitates the intake thereof in tube feeding.

SPRAY-DRYING PROCESS FOR PRODUCING A DRY CARNITINE POWDER OR GRANULATE

The present invention relates to novel processes for preparing a dry substantially pure and/or technical carnitine powder or granulate, from a substantially unpurified starting material containing a carnitine compound and the thus produced dry carnitine powder or granulate.

HYPERCALCAEMIA

The present invention relates to a combination of a leucine source and at least one unsaturated fatty acid source for prophylactic or therapeutic treatment of hypercalcaemia. The invention further relates to a combination of a leucine source and at least one unsaturated fatty acid source for reducing or avoiding a reduction in bone mineral density in a subject or for in vivo regulating of the blood plasma calcium homeostasis.

SYSTEM FOR USE IN DYSPHAGIA DIAGNOSIS

A system comprising nutritional products with defined viscosity profiles for use in diagnosis of dysphagia. For example, the system may be used for endoscopic diagnosis of dysphagia as well as for enteral nutrition of patients suffering from dysphagia.

METHOD TO CONVERT INSECTS OR WORMS INTO NUTRIENT STREAMS AND COMPOSITIONS OBTAINED THEREBY

The present invention provides a method to convert insects or worms into nutrient streams, such as a fat-containing, an aqueous protein-containing and a solid-containing fraction. The method comprises the steps of: (a) squashing insects or worms thereby obtaining a pulp, wherein the insects or worms are reduced in size, (b) heating the pulp to a temperature of 70-100°C, and (c) subjecting the heated pulp to a physical separation step, preferably decanting and/or centrifuging, with the proviso that the method does not comprise enzymatic treatment of the pulp. The fat-containing fraction comprises at least 80 wt.% insect or worm fat of which at least 40 wt.% are saturated fats. The aqueous protein fraction can be dried to obtain dried protein material, which contains at least 50 wt.% insect or worm protein- derived matter and at most 25 wt.% insect or worm fat based on dry weight, and the protein has a pepsin digestibility of at least 50%. The resulting nutrient streams can be used in food ...

EXO-SPECIFIC AMYLASE POLYPEPTIDES, NUCLEIC ACIDS ENCODING THOSE POLYPEPTIDES AND USES THEREOF

This invention relates to amylase polypeptides, and nucleic acids encoding the polpypeptides and uses thereof. The amylases of the present invention have been engineered to have more beneficial qualities. Specifically, the amylases of the current invention show an altered exospecifity.

NUTRITIONAL PRODUCTS COMPRISING BETA-ALANINE

Disclosed are nutritional products, and particularly, nutritional liquids, comprising beta-alanine. The nutritional products not only provide benefits for individuals concerned with muscle health and functionality, but can also be administered without the adverse side-effect of paresthesia caused by ingestion of beta-alanine.

COMBINATION OF A LEUCINE SOURCE AND AN OMEGA- 3 UNSATURATED FATTY ACID SOURCE FOR USE IN THE TREATMENT OF HYPERCAEMIA

The present invention relates to a combination of a leucine source and at least one unsaturated fatty acid source for prophylactic or therapeutic treatment of hypercalcaemia. The invention further relates to a combination of a leucine source and at least one unsaturated fatty acid source for reducing or avoiding a reduction in bone mineral density in a subject or for in vivo regulating of the blood plasma calcium homeostasis.

GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF

The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.

OMEGA-3 FATTY ACID ENRICHED SOUPS AND SAUCES

The present invention relates to compositions and methods for producing a soup or sauce composition with an amount of long chain fatty acids. Specifically, the soup or sauce composition comprises an amount of stearidonic acid (SDA) enriched soybean oil that imparts improved nutritional quality with an amount of long chain fatty acids, but retains the mouthfeel, flavor, odor, and other sensory characteristics associated with typical soup or sauce compositions.

EDIBLE FUNGI INGREDIENT

A solid food ingredient comprising edible fungal particles especially consisting substantially of fungal mycelia is described. The ingredient may be combined with other ingredients to produce a wide range of foodstuffs or food ingredients including desserts (e.g. yoghurt), reconstitutable drinks or soup and extruded foodstuffs, (e.g. savoury snack foods). Foodstuffs prepared may have medical applications (e.g. for treatment of joint mobility disorders, reducing fat uptake, lowering cholesterol, immune function stimulators, use as a pre-biotic and/or for affecting satiety).

NUTRITIONAL PRODUCTS FOR AMELIORATING SYMPTOMS OF RHEUMATOID ARTHRISTIS

Disclosed are nutritional compositions for treating rheumatic diseases. The nutritional compositions contain a fat source containing at least one of: 1) at least one omega-3 long chain polyunsaturated fatty acid and 2) at least one omega-6 long chain polyunsaturated fatty acid; a carbohydrate source; a protein source; and at least one of a Boswellia extract and a Phlebodium extract. Also disclosed are methods of treating rheumatic diseases and symptoms thereof, involving administering to a subject an effective amount of the aforementioned nutritional composition.

BONE-STRENGTHENING AGENTS, FOOD COMPOSITIONS FOR STRENGTHENING BONE AND FEED COMPOSITIONS FOR STRENGTHENING BONE

Novel bone-strengthening agents, food compositions for strengthening bone and feed compositions for strengthening bone which aim at preventing a decrease in bone density in association with the onset or progress of osteoporosis. It is found out that not merely added-up effects but synergistic effects can be achieved by the combined use of CPP, which is known as promoting the absorption of calcium essentially required in normal bone and thus exerting an effect of strengthening bone, with genistein which promotes osteogenesis and thus exert an effect of strengthening bone.

COMPOSITION AND METHOD TO PRODUCE AND USE FERMENTED HYDROLYZED PRODUCTS OF METABOLISM

A method of producing a hydrolyzed fermented medium containing microorganisms such as bacteria or yeast and the products of their metabolism in high concentration, the method includes providing at least one solid plant product reduced to small pieces and mixed with sugar and a biocompatible liquid such as milk for fermentation at a temperature of between 35 and 58 degrees C until the acidity of the medium reaches the range of 300 to 900 in Terner degrees. In an alternative embodiment, the medium is prepared by mixing in predetermined amounts of sprouted grains, biocompatible liquid inoculated with at least one of a variety of non-pathogenic microorganisms, vegetables, fruits, berries, high protein products, herbs, sugar, and a chemical element such as potassium. The mixture is then fermented at a selected temperature for a specified length of time to reach high acidity and high concentration of products of bacterial metabolism. A liquid phase is separated from a solid sediment phase and ...

NUTRITIONAL OR PHARMACEUTICAL COMPOSITIONS FOR INCREASING THE CREATINE RESPONSE OF ORGANISMS

There is provided a nutritional or pharmaceutical composition comprising a protein fraction containing L-serine and an energy metabolism precursor wherein the composition is free of glycine or if glycine is present within the composition, the weight ratio of L-serine: glycine after hydrolysis of the composition is of more than 2.7:1, which composition provides an effective creatine response within mammals muscle and methylation reaction capacity of organisms.

NUTRITIONAL IRON-PROTEIN COMPLEXES FROM WASTE EFFLUENTS

Method for reducing the salt content in a foodstuff

In a foodstuff, the salt content present as such therein and imparting the flavor thereto is reduced by up to 50% by weight, without noticeable detriment to the flavor, by adding collagen hydrolysate.

Cartilage enhancing food supplements and methods of preparing the same

A food supplement, either in the form of a snack bar or a beverage, which contains one or more cartilage enhancing supplements is provided. The cartilage supplements include chondroitin, glucosamine, and hyaluronic acid. The food supplement may additionally be fortified with cetyl myristoleate. The beverage is a mixture of a juice drink base which may include a water-based fruit flavored juice prepared using a pasteurization process at a relatively high temperature and a cartilage supplement solution which includes a cartilage supplement prepared at a relatively low temperature. The beverage may be carbonated, non-carbonated or concentrated. The preferred cartilage supplement is glucosamine, preferably associated with a counter ion, more preferably as glucosamine HCl. The supplement also contains vitamin C (ascorbic acid) and calcium hydroxide powder.

Low pH antimicrobial food composition

A nutritionally balanced water soluble powdered food composition which, when mixed with water, has a low pH, extended shelf life, high antimicrobial activity, and which includes protein alpha-amino acids in solution or in suspension. The food composition utilizes a binary stabilizer system.

Thermostable amylase polypeptides, nucleic acids encoding those polypeptides and uses thereof

This invention relates to amylase polypeptides, and nucleic acids encoding the polpypeptides and uses thereof. The amylases of the present invention have been engineered to have more beneficial qualities. Specifically, the amylases of the current invention show an altered thermostability.

COMPOSITION AND METHOD FOR FACILITATING BONE HEALING

PINE NEEDLE EXTRACT

COMPOSITIONS FOR MASKING THE FLAVOR OF NUTRIENTS AND METHODS FOR MAKING SAME

Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides nutritional compositions having whey protein micelles and leucine. The nutritional compositions provide a sufficient amount of leucine to improve protein synthesis in humans, while also maintaining a low-viscosity fluid matrix and acceptable organoleptic properties. 1. A nutritional composition comprising: whey protein powder comprising whey protein micelles and leucine , wherein the total amount of leucine in the composition is between about 20% and about 40% by weight dry matter.2. The composition according to claim 1 , wherein the whey protein powder comprises at least about 20% to at least about 80% whey protein micelles.3. The composition according to claim 1 , wherein the whey protein powder comprises at least about 50% whey protein micelles.4. The composition according to claim 1 , wherein the whey protein powder has a water binding capacity of at least about 50% to about 100%.5. The composition according to claim 1 , wherein the whey protein micelles and leucine are present in a weight ratio of about 30:1 to about 1:100.6. The composition according to claim 1 , wherein the dry weight ratio of added leucine to whey protein micelles is from about 1:2 to about 1:3.7. The composition according to claim 1 , wherein the whey protein powder is obtained by a process selected from the group consisting of spray-drying and freeze-drying claim 1 , that is performed with the whey protein micelles and leucine.8. The composition according to comprising at least one ingredient selected from the group consisting of antioxidants claim 1 , vitamins claim 1 , minerals claim 1 , phytonutrients claim 1 , prebiotics claim 1 , and probiotics.9. The composition according to claim 1 , wherein the composition is a liquid and the total amount of leucine in the composition is less than about 2.5 g per 100 g of the liquid claim 1 , ...

High Protein Supplement

The present disclosure relates to high protein dietary supplements for treating various symptoms and diseases associated with protein deficiency including weight gain, obesity, catabolic diseases, fibromyalgia, anxiety reactions, posttraumatic stress and chronic fatigue syndrome. Embodiments of dietary supplements comprise combinations of proteins, essential and semi-essential amino acids including L-Lysine, L-Arginine, and/or L-Histidine. 1. A dietary supplement comprising free-form L-Lysine , free-form L-Arginine; free-form L-Histidine , free-form L-Isoleucine , free-form L-Leucine , free-form L-Threonine , free-form L-Valine , free-form Phenylalanine , free-form L-Methionine , and free-form Tryptophan , wherein the free-form L-Lysine , free-form L-Arginine; free-form L-Histidine , free-form L-Isoleucine , free-form L-Leucine , free-form L-Threonine , free-form L-Valine , free-form Phenylalanine , free-form L-Methionine , and free-form Tryptophan are the only free-form amino acids in the supplement.2. The dietary supplement of claim 1 , wherein said dietary supplement is formulated in a powder or liquid form.3. The dietary supplement of claim 1 , wherein said free-form L-Lysine claim 1 , L-Arginine claim 1 , or L-Histidine is formulated for sustained or extended release.4. The dietary supplement of wherein said second amino acid blend comprises between 10 mg and 3 g each of free-form L-Lysine claim 1 , free-form L-Arginine claim 1 , free-form L-Histidine claim 1 , L-Isoleucine claim 1 , L-Leucine claim 1 , L-Threonine claim 1 , L-Valine claim 1 , Phenylalanine claim 1 , L-Methionine claim 1 , and Tryptophan per serving of said supplement.5. The dietary supplement of wherein said first amino acid blend comprises at least 10 mg free-form L-Lysine and at least 10 mg free-form L-Arginine per serving of said supplement.6. The dietary supplement of wherein said second amino acid blend comprises at least 10 mg free-form L-Histidine per serving of said supplement.7. The ...

NON-DIGESTIBLE OLIGOSACCHARIDES FOR ORAL INDUCTION OF TOLERANCE AGAINST DIETARY PROTEINS

Compositions and methods for providing infant nutrition with partially hydrolysed proteins and non-digestible oligosaccharides for use in induction of oral tolerance against native dietary proteins. 1. At least one non-digestible oligosaccharide selected from the group consisting of fructo-oligosaccharide , non-digestible dextrin , galacto-oligosaccharide , xylo-oligosaccharide , arabino-oligosaccharide , arabinogalacto-oligosaccharide , gluco-oligosaccharide , glucomanno-oligosaccharide , galactomanno-oligosaccharide , mannan-oligosaccharide , chito-oligosaccharide , uronic acid oligosaccharide , sialyloligosaccharide and fuco-oligosaccharide for enhancing a partial protein hydrolysate-induced oral tolerance against dietary proteins , the partial protein hydrolysate comprising at least 3 wt % of peptides with a size of 5 kDa or above and at least 50 wt. % of peptides with a size below 5 kDa and wherein the partial protein hydrolysate is partial mammalian milk protein hydrolysate , partial whey protein hydrolysate or partial beta-lactoglobulin hydrolysate.2. An enteral composition comprising at least one non-digestible oligosaccharide selected from the group consisting of fructo-oligosaccharide , non-digestible dextrin , galacto-oligosaccharide , xylo-oligosaccharide , arabino-oligosaccharide , arabinogalacto-oligosaccharide , gluco-oligosaccharide , glucomanno-oligosaccharide , galactomanno-oligosaccharide , mannan-oligosaccharide , chito-oligosaccharide , uronic acid oligosaccharide , sialyloligosaccharide and fuco-oligosaccharide and at least one partial protein hydrolysate , for inducing oral tolerance against dietary proteins , the partial protein hydrolysate comprising at least 3 wt. % of peptides with a size of 5 kDa or above and at least 50 wt. % of peptides with a size below 5 kDa and wherein the partial protein hydrolysate is partial mammalian milk protein hydrolysate , partial whey protein hydrolysate or partial beta-lactoglobulin hydrolysate.3. An ...

SOLID COMPOSITION

Provided is a masticatory solid composition including the following components (A) and (B): 1. A masticatory solid composition comprising the following components (A) and (B):(A) wheat albumin, and(B) erythritol, xylitol, or a combination thereof, whereina content mass ratio of the component (B) to the component (A) [(B)/(A)] is 0.25 or more.2. The masticatory solid composition according to claim 1 , wherein a content of the wheat albumin (A) in the masticatory solid composition is 10 to 70% by mass.3. The masticatory solid composition according to claim 1 , wherein the wheat albumin (A) comprises 10 to 60% by mass of 0.19-wheat albumin (a).4. The masticatory solid composition according to claim 1 , further comprising a carbonate (C) claim 1 , whereinthe content mass ratio of the wheat albumin (A) to the carbonate (C) [(A)/(C)] in the solid composition is 1.5 to 16.5.5. The masticatory solid composition according to claim 4 , further comprising an organic acid (D) claim 4 , whereinan equivalent ratio of the organic acid (D) to the carbonate (C) [equivalent (D)/equivalent (C)] is 0.7 to 1.9.6. The masticatory solid composition according to claim 1 , wherein the solid composition is a chewable tablet.7. A masticatory solid composition comprising the following components (a) and (B):(a) 0.19-wheat albumin, and(B) erythritol, xylitol, or a combination thereof, whereina content mass ratio of the component (B) to the component (a) [(B)/(a)] is 1 or more. The present invention relates to a masticatory solid composition containing wheat albumin.Priority is claimed on Japanese Patent Application No. 2011-274580 filed Dec. 15, 2011 and Japanese Patent Application No. 2012-253952 filed Nov. 20, 2012, the content of which is incorporated herein by reference.Recently, the number of patients suffering from glucose metabolic disorders represented by obesity and type II diabetes mellitus (hyperglycemia) has been increasing due to, for example, changes in diet and the like.In ...

GLYCOMACROPEPTIDE MEDICAL FOODS FOR NUTRITIONAL MANAGEMENT OF PHENYLKETONURIA AND OTHER METABOLIC DISORDERS

Medical foods containing glycomacroprotein and additional supplemented amounts of arginine, leucine, and optionally other amino acids, such as tyrosine, are disclosed. The medical foods can be used to provide the complete protein requirements for patients having metabolic disorders such as phenylketonuria. 1. A medical food for the management of a metabolic disorder , comprising glycomacropeptide (GMP) and supplemented amounts of two or more amino acids , wherein one of the supplemented amino acids is arginine and the weight ratio within the medical food of the amino acid arginine to the total protein is from about 60 to 90 milligrams arginine/gram total protein , and wherein another of the supplemented amino acids is leucine and the weight ratio within the medical food of the amino acid leucine to the total protein is from about 100 to 200 milligrams leucine/gram total protein.2. The medical food of claim 1 , further comprising a supplemented amount of the amino acid tyrosine claim 1 , and wherein the weight ratio within the medical food of the amino acid tyrosine to the total protein is from about 62 to 93 milligrams tyrosine/gram total protein.3. The medical food of claim 2 , wherein the total weight of the additional supplemental amino acids is from about 22% to 38% of the total weight of the protein from the GMP and the supplemented amino acids together.4. The medical food of claim 2 , further comprising a supplemented amount of the amino acids tryptophan and histidine claim 2 , wherein the total weight of the additional supplemental amino acids is from about 25% to 42% of the total weight of the protein from the GMP and the supplemented amino acids together.5. The medical food of claim 2 , wherein the weight ratio within the medical food of the amino acid arginine to the total protein is about 75 milligrams arginine/gram total protein.6. The medical food of claim 2 , wherein the weight ratio within the medical food of the amino acid leucine to the total ...

USE OF GLYCOMACROPEPTIDE TO IMPROVE WOMEN'S HEALTH

Methods for improving the health of a female human or non-human animal are disclosed. The methods include the step of administering to the animal compositions including an effective amount of glycomacropeptide (GMP) for effectuating the methods. Specifically, the methods can be used to increase the rate of fat metabolism or fat oxidation, decrease percentage of body fat, increase the rate of bone mineralization, increase bone mineral content, increase bone mineral density, and/or increase bone strength in the animal. 1. A method for improving the health of a female human or non-human animal comprising administering to the animal an effective amount of a composition comprising glycomacropeptide (GMP) , whereby one or more of the following occurs:(a) the rate of fat oxidation or fat metabolism in the animal is increased;(b) the percentage of body fat in the animal is reduced;(c) the rate of bone mineralization in the animal is increased;(d) the bone mineral content or bone mineral density in the animal is increased; or(e) the bone strength in the animal is increased.2. The method of claim 1 , wherein the female animal is human.3. The method of claim 1 , wherein the composition is administered orally.4. The method of claim 3 , wherein the composition is a food product claim 3 , a nutraceutical claim 3 , or a dietary supplement.5. The method of claim 1 , wherein the animal does not have phenylketonuria (PKU).6. The method of claim 1 , wherein the effective amount of the composition is such that from 0.15 to 1.0 g GMP per kg of body weight is administered to the animal per day.7. The method of claim 1 , wherein the method is used to treat one or more conditions associated with reduced fat metabolism and/or an increased percentage of body fat.8. The method of claim 7 , wherein the condition treated is obesity.9. The method of claim 1 , wherein the method is used to treat one or more conditions associated with loss of bone mineral content or bone strength.10. The method of ...

Agent for use in the case of fructose intolerance

There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed. There is provided a method for treating or reducing the effects of fructose intolerance and health problems associated with excessive fructose intake by administration of glucose isomerase. Other embodiments are also disclosed. 1. A method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism , the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase , other than in combination with 5-D-fructose dehydrogenase.2. A method according to wherein said condition is fructose intolerance that is selected from the group consisting of (a) hereditary fructose intolerance claim 1 , (b) intestinal fructose intolerance (fructose non-absorption or fructose-malabsorption) claim 1 , (c) fructose intolerance that is due to a lack of fructose 1 claim 1 ,6-diphosphatase and (d) combinations thereof.3. A method according to claim 1 , wherein said glucose isomerase is administered prior to said subject's eating claim 1 , concurrently with said subject's eating or after said subject's eating.4. A method according to claim 1 , wherein said glucose isomerase is administered with a second enzyme which cleaves fructose from a more complex sugar.5. A method according to wherein said second enzyme is selected from the group consisting of invertase claim 4 , maltase and combinations thereof.6. A method according to claim 1 , wherein said administration comprises oral administration.7. A mammalian ingestible ...

Agent for use in the case of fructose intolerance

There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed.

Agent for use in the case of fructose intolerance

There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed. 1. A method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism , the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase , other than in combination with 5-D-fructose dehydrogenase.2. A method according to wherein said condition is fructose intolerance that is selected from the group consisting of (a) hereditary fructose intolerance claim 1 , (b) intestinal fructose intolerance (fructose non-absorption or fructose-malabsorption) claim 1 , (c) fructose intolerance that is due to a lack of fructose 1 claim 1 ,6-diphosphatase and (d) combinations thereof.3. A method according to claim 1 , wherein said glucose isomerase is administered prior to said subject's eating claim 1 , concurrently with said subject's eating or after said subject's eating.4. A method according to claim 1 , wherein said glucose isomerase is administered with a second enzyme which cleaves fructose from a more complex sugar.5. A method according to wherein said second enzyme is selected from the group consisting of invertase claim 4 , maltase and combinations thereof.6. A method according to claim 1 , wherein said administration comprises oral administration.7. A mammalian ingestible composition of matter selected from a pharmaceutical composition and a dietary supplement claim 1 , said composition of matter comprising a glucose isomerase claim 1 , a second enzyme other than 5-D-fructose dehydrogenase claim 1 , ...

BACTERIAL-DERIVED BLIS FOR TREATMENT OF ACNE

This invention relates to a treatment of acne. Specifically, the invention is directed to the use of bacteriocin-like inhibitory substances (BLIS), isolated from as bacteriocide or bacteriostat for acne-causing bacteria, namely 1. A method of treating acne of a subject , comprising administering to said subject , an effective amount of a bacteriocin-like inhibitory substance (BLIS) , thereby treating said acne.2S. salivarius, S. pyogenes, L. salivarius. The method of claim 1 , wherein the BLIS is isolated from or a combination thereof.3S. salivarius.. The method of claim 2 , wherein the bacterium is4. The method of claim 3 , wherein the BLIS is SAL A2 claim 3 , SAL B claim 3 , or a combination thereof.5S. pyogenes. The method of claim 2 , wherein the bacterium is and the BLIS is Streptin A16L. salivarius. The method of claim 2 , wherein the bacterium is and the BLIS is Salivacin 140 claim 2 , ABP-118 claim 2 , or a combination thereof.7S. aureus, P. acnes, B. melaninogenicus,. The method of claim 3 , wherein the composition further comprises BLIS derived from or a combination thereof.8. The method of claim 1 , further comprising coadministering to said subject an additional agent claim 1 , wherein the agent is isotrenitoin claim 1 , Benzoyl peroxide claim 1 , topical retinoid claim 1 , spironolactone claim 1 , an oral contraceptive or a combination thereof.9. The method of claim 1 , wherein the acne-causing bacteria is resistant to erythromycin claim 1 , tetracycline claim 1 , doxycycline claim 1 , minocycline claim 1 , oxytetracycline clindamycin claim 1 , or a combination thereof.10. A method of treating acne of a subject claim 1 , comprising administering to said subject an effective amount of a pharmaceutical preparation comprising a bacteriocin-like inhibitory substance (BLIS) claim 1 , whereby said BLIS is bacteriocidal or bacteriostatic for said acne-causing bacteria thereby treating said acne11. The method according to claim 10 , wherein said administering ...

BIOACTIVE PEPTIDE

The present invention provides a pharmaceutical or a food that comprises, as an active ingredient, at least one peptide selected from the group consisting of Val-Tyr-Leu-Pro-Arg, Tyr-Leu-Pro-Arg, and Leu-Pro-Arg, or an analog thereof. 1. At least one peptide selected from the group consisting of Tyr-Leu-Pro-Arg and Leu-Pro-Arg , or an analog thereof.2. A pharmaceutical or a pharmaceutical composition comprising at least one peptide selected from the group consisting of Val-Tyr-Leu-Pro-Arg , Tyr-Leu-Pro-Arg , and Leu-Pro-Arg , or an analog thereof.3. The pharmaceutical or the pharmaceutical composition according to claim 2 , which is an anxiolytic drug claim 2 , a sleep-inducing drug claim 2 , a sleep-enhancing drug claim 2 , a drug for treating schizophrenia claim 2 , or an antidepressant drug.4. An anxiolytic or sleep-enhancing food comprising at least one peptide selected from the group consisting of Val-Tyr-Leu-Pro-Arg claim 2 , Tyr-Leu-Pro-Arg claim 2 , and Leu-Pro-Arg claim 2 , or at least one analog thereof.5. A method for relieving anxiety or enhancing sleep claim 2 , comprising administering an effective amount of at least one peptide selected from the group consisting of Val-Tyr-Leu-Pro-Arg claim 2 , Tyr-Leu-Pro-Arg claim 2 , and Leu-Pro-Arg claim 2 , or at least one analog thereof to a subject in need thereof. The present invention provides a peptide having a neuromodulatory effect, and a pharmaceutical or a food comprising the peptide.Reflecting today's stressful society, an increasing number of individuals with psychiatric disorders such as anxiety disorders, schizophrenia, and depression has been a problem. Anxiety is inherently necessary as a warning to help living organisms avoid danger. However, it is known that excessive anxiety involves the onset or the progression of symptoms of psychiatric disorders as mentioned above, and also increases the risk of the onset of lifestyle-related diseases. Therefore, the development of foods and pharmaceuticals ...

COLLAGEN POWDER

The invention is directed to a method for preparing a collagen powder and to collagen powder that can be used for the preparation of a satiety inducing food product. The collagen powder of the invention is suitable as a food additive in food products for the reduction of hunger and as a possible treatment of obesity and its pathophysiological consequences, such as metabolic syndrome. 1. Method for preparing collagen powder , comprising the steps of: producing at a temperature of 50° C. or less a wet collagen product by subjecting a hide or skin to a size reduction step; an alkaline and/or an oxidizing treatment step; and a neutralizing step; followed by drying of said wet collagen product using a contact dryer , to obtain said collagen powder.2. Method according to claim 1 , wherein said drying is carried out using a contact dryer having a surface temperature of more than 150° C.3. Method according to the previous claim claim 1 , wherein the temperature of the steps for producing the wet collagen product is kept at 45° C. or less and preferably 40° C. or less.4. Method according to any of the previous claims claim 1 , wherein said drying of said wet collagen product is carried out at a surface temperature of said contact dryer of 155° C. or higher claim 1 , preferably 160° C. or higher claim 1 , more preferably 165±4° C.5. Method according to any of the previous claims claim 1 , wherein said animal hide or skin is selected from the group consisting of bovine claim 1 , porcine and poultry claim 1 , preferably bovine.6. Method according to any of the previous claims claim 1 , wherein claim 1 , said alkaline and/or oxidizing treatment is performed at a pH value of 10 or more claim 1 , preferably 11 or more claim 1 , more preferably 12 or more.7. Method according to any of the previous claims claim 1 , wherein the neutralizing treatment results in a pH value of 6 or less claim 1 , preferably from 5 to 6.8. Method according to any of the previous claims claim 1 , wherein ...

PROTEIN-BOUND TRYPTOPHAN FOOD COMPOSITION

A composition comprising at least partially defatted meal from a plant source containing protein-bound tryptophan, which plant source has been processed to at least partially remove oil contained therein to yield said meal having a natural source of tryptophan greater than its plant source, a carbohydrate source having a high glycemic index and a physiologically-acceptable diluent or carrier therefor for inducing sleep, alleviating an anxiety disorder, depression, obsessive compulsive aggression, chronic pain or eating disorder, in a human in need thereof, wherein said composition is in the form of a food bar further comprising a puffed cereal. The composition provides improved sleep characteristics. 1. A composition comprising at least partially defatted meal from a plant source containing protein-bound tryptophan , which plant source has been processed to at least partially remove oil contained therein to yield said meal having a natural source of tryptophan greater than its plant source , a carbohydrate source having a high glycemic index and a physiologically-acceptable diluent or carrier therefor composition is in the form of a food bar further comprising a puffed cereal.2. A composition as claimed in in the form of a food bar comprising partially defatted pumpkin seed flour claim 1 , puffed cereal and sucrose.3. A composition as claimed in comprising partially defatted pumpkin seed flour (20-40% W/W) claim 2 , puffed rice (20-40% W/W) claim 2 , and sucrose (20-40% W/W).4. Use of a composition as claimed in for inducing sleep claim 1 , or alleviating an anxiety disorder claim 1 , depression claim 1 , obsessive compulsive aggression claim 1 , chronic pain or eating disorder claim 1 , in a human in need thereof.5. Use of a composition as claimed in in the form of a food bar claim 4 , comprising partially defatted pumpkin seed flour (20-40% W/W) claim 4 , puffed rice (20-40% W/W) claim 4 , and sucrose (20-40% W/W). This invention relates to compositions comprising ...

COMPOSITION FOR PREVENTING AND TREATING NEUROLOGICAL DISEASES COMPRISING OSMOTIN

The present invention relates to a composition for preventing and treating neurological diseases, and more particularly to a composition for preventing and treating neurological diseases comprising osmotin, a health functional food composition for preventing and ameliorating neurological diseases comprising osmotin, and a method of preventing or treating neurological diseases by administering the composition. 1. A composition for preventing and treating neurological diseases comprising osmotin.2. The composition of claim 1 , wherein the neurological diseases include one or more diseases selected from the group consisting of Alzheimer's disease claim 1 , Parkinson's disease claim 1 , HIV dementia claim 1 , epilepsy claim 1 , schizophrenia claim 1 , depression claim 1 , manic depression claim 1 , neurodevelopmental disorder claim 1 , autism claim 1 , stroke claim 1 , Lou Gehrig's disease claim 1 , Huntington's disease claim 1 , and multiple sclerosis.3. The composition of claim 1 , wherein the neurological diseases are fetal alcohol syndrome (FAS).4. The composition of claim 1 , wherein the neurological diseases are alcohol-induced neurodegenerative diseases.5. The composition of claim 1 , wherein the osmotin is administered in an amount of 2-6 ug/ml.6. The composition of claim 1 , wherein the composition inhibits apoptosis of neuronal cells.7. The composition of claim 1 , wherein the osmotin inhibits apoptosis of neuronal cells of the brain of a fetus by inducing the restoration of mitochondrial membrane potential claim 1 , an increase in the Bcl-2/Bax ratio or a decrease in the concentration of Ca in cytoplasm.8. The composition of claim 1 , wherein the composition further comprises a pharmaceutically acceptable additive.9. The composition of claim 8 , wherein the additive is an excipient claim 8 , a carrier or a diluent.10. The composition of claim 1 , wherein the formulation of the composition is a powder claim 1 , granule claim 1 , tablet claim 1 , pill claim 1 , ...

CYSTEINE AND FOOD INTAKE

The present invention relates to the field of nutrition; in particular to the prevention and/or treatment of malnutrition. One embodiment of the present invention relates to a nutritional composition enriched in cysteine for use in the treatment and/or prevention of malnutrition and disorders related thereto. Such a composition may in particular, but not exclusively, be useful for the elderly population. 1. A method for the treatment of malnutrition and/or disorders related thereto comprising the step of administering to an individual in need of same cysteine.2. Method in accordance with claim 1 , wherein the cysteine is provided in a form of a cysteine precursor selected from the group consisting of cysteine bound in a protein claim 1 , a peptide hydrolysate claim 1 , a peptide.3. Method in accordance with claim 1 , wherein the cysteine increases food intake claim 1 , and/or decreases satiety and/or satiation.4. Method in accordance with claim 1 , wherein the cysteine increases appetite.5. Method in accordance with claim 1 , wherein the disorder related to malnutrition is selected from the group consisting of anorexia claim 1 , anorexia nervosa claim 1 , cachexia claim 1 , inflammatory diseases associated with decreased food intake claim 1 , and combinations thereof.6. Method in accordance with claim 1 , wherein the individual is an elderly subject.7. Method in accordance with claim 1 , wherein the cysteine treats an age related decrease in food intake.8. Method in accordance with claim 1 , wherein the cysteine is provided in the form of a nutritional composition.9. Method in accordance with claim 1 , wherein the cysteine is in a nutritional composition that contains a protein fraction comprising at least 3.0 weight % cysteine.10. Method in accordance with claim 1 , wherein the nutritional composition is to be administered through a route selected from the group consisting of orally claim 1 , enterally and parenterally claim 1 , and wherein the nutritional ...

SKIN COLLAGEN PRODUCTION-PROMOTING AGENT

A skin collagen production-promoting agent includes a milk protein fraction having following properties (a) to (c) as an active ingredient: (a) being derived from milk, (b) containing proteins having a molecular weight determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of 6000 to 150,000 daltons, and (c) containing 12 to 14 wt % of basic amino acids with respect to the constituent amino acid composition, and having a basic amino acid/acidic amino acid ratio of 0.5 to 0.7. 1. A skin collagen production-promoting agent comprising a milk protein fraction having following properties (a) to (c) as an active ingredient:(a) being derived from milk,(b) containing proteins having a molecular weight determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of 6000 to 150,000 daltons, and(c) containing 12 to 14 wt % of basic amino acids with respect to the constituent amino acid composition, and having a basic amino acid/acidic amino acid ratio of 0.5 to 0.7.2. A skin collagen production-promoting agent comprising a degradation product of a milk protein fraction having following properties (a) to (c) as an active ingredient:(a) being derived from milk,(b) containing proteins having a molecular weight determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of 6000 to 150,000 daltons, and(c) containing 12 to 14 wt % of basic amino acids with respect to the constituent amino acid composition, and having a basic amino acid/acidic amino acid ratio of 0.5 to 0.7.3. A food or beverage product for promoting skin collagen production comprising the milk protein fraction according to .4. A cosmetic for promoting skin collagen production comprising the milk protein fraction according to .5. A method for promoting skin collagen production comprising oral administration of a milk protein fraction having following properties (a) to (c) in an amount of 10 μg/day or more per adult claim 1 , or applying a ...

METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS

The invention provides an orally-administrable nutritional product comprising a dipeptide including a branched chain amino acids (BCAA). In one embodiment, the nutritional product comprises a dipeptide selected from at least one of the following: alanyl-leucine, alanyl-isoleucine, alanyl-valine, glycyl-leucine, glycyl-isoleucine, and glycyl-valine. 1. An orally-administrable nutritional product comprising:at least one dipeptide including at least one branched chain amino acid,wherein the at least one dipeptide exhibits a bitterness less than that of a free branched chain amino acid, and wherein the at least one dipeptide comprises alanyl-isoleucine.2. The orally-administrable nutritional product of claim 1 , further comprising at least one of a protein claim 1 , a fiber claim 1 , a fatty acid claim 1 , a vitamin claim 1 , a mineral claim 1 , a carbohydrate claim 1 , a flavor agent claim 1 , a medicament claim 1 , and a therapeutic agent. This application is a continuation of U.S. application Ser. No. 12/901,178, filed Oct. 8, 2010, which is a continuation of 12/089,970, filed Jun. 30, 2008 now U.S. Pat. No. 7,989,418 issued Aug. 2, 2011, which is a National Stage of International Application No. PCT/U.S.2006/041615, filed on Oct. 26, 2006, which claims priority to U.S. Provisional Appl. No. 60/731,450, filed Oct. 28, 2005, the entire contents of which are expressly incorporated herein by reference thereto.The invention relates generally to use of branched chain amino acids and more particularly to the use of dipeptides including branched chain amino acids to reduce bitterness in orally-administrable nutritional products.Amino acids are the monomeric building blocks of proteins, which in turn comprise a wide range of biological compounds, including enzymes, antibodies, hormones, transport molecules for ions and small molecules, collagen, and muscle tissues. Amino acids are considered hydrophobic or hydrophilic, based upon their solubility in water, and, more ...

Peptides containing tryptophan

The present invention relates to a process to produce a composition comprising water-soluble peptides and having a Trp/LNAA ratio of more than 0.15, which comprises hydrolyzing lysozyme, preferably hen eggs lysozyme, to prepare a hydrolysate having a DH of between 5 and 45.

METHOD OF TREATMENT

The method relates to a method of treating proteinuria comprising administering lactoferrin. 1. A method of treating proteinuria comprising administering to a subject in need thereof a therapeutically effective amount of lactoferrin.2. The method of claim 1 , wherein the proteinuria is albuminuria or microalbuminuria.3. The method of claim 1 , wherein the proteinuria is diagnosed using a urinary albumin/creatinine ratio (ACR).4. The method of claim 3 , wherein the ACR of the subject when the proteinuria is diagnosed is greater than or equal to about 2 mg/mmol.5. The method of claim 1 , wherein the proteinuria is diagnosed using a blood urea nitrogen (BUN)/creatinine ratio or a urea/creatinine ratio.6. The method of claim 1 , further comprising administering to the subject an ACE inhibitor or an ARB.7. The method of claim 1 , wherein the lactoferrin is administered orally.8. The method of claim 7 , wherein the lactoferrin is administered orally as a food claim 7 , a drink claim 7 , a supplement claim 7 , a nutraceutical claim 7 , or a medicament.9. The method of claim 7 , wherein the lactoferrin that is administered orally is encapsulated claim 7 , microencapsulated or nanoencapsulated. The invention relates to methods of treating proteinuria or diseases associated with proteinuria.All references, including any patents or patent applications, cited in this specification are hereby incorporated by reference. It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art.Urinary protein loss (proteinuria) affects some 100 million people worldwide and is a feature of kidney dysfunction, including inflammation, of glomerular origin. Proteinuria itself is a risk factor for both renal and extra-renal diseases.Proteinuria usually reflects an increase in glomerular permeability for normally non-filtered ...

FOOD PRODUCT PROVIDING SUSTAINED BLOOD LEVELS OF EXOGENOUS SUBSTANCES

The present invention relates to a food product comprising soluble fibre and at least one exogenous biologically active substance. It further relates to the uses of a mixture comprising at least soluble fibre and at least one exogenous substance in the preparation of a food product to avoid short-term peaks of the exogenous substance in serum, for example. Preferably the food product is a bar comprising caffeine. 1. A food product comprising an effective amount of soluble fibre and from about 200 to about 400 mg creatine , wherein the food product achieves a blood plasma level of creatine at 30 minutes after ingestion thereof that is less than one half of the blood plasma level of creatine at about 3 hours.2. The food product of claim 1 , wherein the soluble fibre is a viscous soluble fibre.3. The food product of comprising from about 2% to about 40% of soluble fibre by weight of the product.4. The food product of comprising at least one source of soluble fiber selected from the group consisting of barley flour and oat bran concentrate and if oat bran concentrate is present claim 1 , it comprises from about 20% to about 80% by weight raw ingredients.5. The food product of claim 1 , wherein the soluble fiber comprises from about 6% to about 10% β-glucan by weight.6. The food product of comprising from about 5% to about 20% of protein by weight of the product claim 1 , from about 1% to about 10% of fats and/or oils by weight of the product claim 1 , and from about 40% to about 70% of carbohydrates by weight of the product.7. A method for slowing down absorption rate of creatine in the gastro-intestinal tract comprising the step of administering a composition comprising an effective amount of soluble fiber and from about 200 to about 400 mg creatine claim 1 , wherein the composition achieves a blood plasma level of creatine at 30 minutes after ingestion thereof that is less than one half of the blood plasma level of creatine at about 3 hours.8. The method of claim 7 , ...

COLLAGEN HYDROLYSATE FOR USE TO IMPROVE THE HEALTH OF HUMAN SKIN, HAIR AND/OR NAILS

The invention relates to a collagen hydrolysate for use to improve the health of human skin, hair and/or nails, at least 90% by weight of the collagen hydrolysate having a molecular weight of less than 3,500 Da and the collagen hydrolysate comprising at least four characteristic peptides with a molecular weight between 600 and 1,200 Da. 1. A collagen hydrolysate for use to improve the health of human skin , hair and/or nails , wherein at least 90% by weight of the collagen hydrolysate has a molecular weight of less than 3 ,500 Da , and wherein the collagen hydrolysate comprises at least four characteristic peptides with a molecular weight between 600 and 1 ,200 Da.2. The collagen hydrolysate according to claim 1 , wherein at least 45% by weight of the collagen hydrolysate has a molecular weight of less than 1 claim 1 ,500 Da.3. The collagen hydrolysate according to claim 1 , wherein the at least four characteristic peptides in a molecular weight distribution determined by means of MALDI mass spectroscopy have an intensity of at least twice the intensity in comparison to their surroundings.4. The collagen hydrolysate according to claim 1 , wherein the collagen hydrolysate comprises a peptide having a molecular weight of between 620 and 690 Da claim 1 , a peptide having a molecular weight of between 790 and 860 Da claim 1 , a peptide having a molecular weight of between 980 and 1 claim 1 ,050 Da and a peptide having a molecular weight of between 1 claim 1 ,175 and 1 claim 1 ,245 Da.5. The collagen hydrolysate according to claim 1 , wherein the collagen hydrolysate comprises further characteristic peptides claim 1 , each peptide having a molecular weight between 1 claim 1 ,500 and 3 claim 1 ,500 Da.6. The collagen hydrolysate according to claim 1 , wherein the collagen hydrolysate has a proportion of hydroxyproline of 12% by weight or more.7. The collagen hydrolysate according to claim 1 , wherein the collagen hydrolysate is produced by enzymatic hydrolysis of gelatine ...

PEPTIDE

The invention provides a peptide comprising or consisting of SEQ ID NO: 1 and variants thereof, particularly comprising of consisting of the sequence FTY, nucleic acids encoding said peptides and pharmaceutical and nutraceutical compositions comprising said peptide(s) and/or nucleic acids. Also provided is the use of such a peptide in therapy and in vitro methods of ACE-inhibition. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. An isolated peptide consisting of the sequence FSY or FTY.8. A pharmaceutical composition comprising a peptide consisting of the sequence FSY or FTY together with a phamaceutically acceptable excipient.9. A pharmaceutical composition comprising(i) peptide of 3-20 amino acids having ACE-inhibitory activity and consisting of or comprising the sequence FSY or FTY; and(ii) a further anti-hypertensive agent.10. A pharmaceutical composition according to claim 9 , wherein said further anti-hypertensive agent is a further peptide having ACE-inhibitory activity and comprising or consisting of the sequence FSY or FTY.11. A nutraceutical composition comprising a peptide consisting of the sequence FSY or FTY together with an excipient or carrier.12. A nutraceutical composition comprising a peptide of 3-20 amino acids having ACE-inhibitory activity and consisting of or comprising the sequence FSY or FTY together with one or more nutraceutical components selected from fat claim 9 , carbohydrates claim 9 , protein claim 9 , fibres claim 9 , ash claim 9 , minerals and vitamins.13. A food or feed comprising a peptide of 3-20 amino acids having ACE-inhibitory activity and consisting of or comprising the sequence FSY or FTY.14. A food or feed according to claim 13 , wherein said food or feed is selected from instant powder products claim 13 , food bars claim 13 , meat and meat analogue products claim 13 , fish and fish analogue products claim 13 , breakfast cereals claim 13 , vegetable fat spreads claim 13 , mayonnaise claim 13 ...

FORMULATION COMPRISING ARGININE, USE AND PREPARATION THEREOF

The present invention relates to an edible formulation comprising the following ingredients (% on mix) 19 to 30 weight % of a dietary supplement comprising at least 50% of L-arginine, 20 to 35 weight % of cereal flakes, 14 to 25 weight % of puffed brown or white rice, 12 to 24 weight % of nuts, 9 to 18 weight % of orange rind (or dried fruit such as cranberries, blueberries, raspberry, blackberry) and 2 to 10 weight % of water and/or fruit juice, its use and process of preparation. 1. An edible formulation comprising the following ingredients (% on mix):19 to 30 weight % of a dietary supplement comprising at least 50% of L-arginine or a physiologically acceptable salt thereof,20 to 35 weight % of cereal flakes,14 to 25 weight % of puffed brown or white rice,12 to 24 weight % of nuts,9 to 18 weight % of orange rind (or dried fruit such as cranberries, blueberries, raspberry, blackberry), and2 to 10 weight % of water and/or fruit juice.2. The edible formulation according to comprising the following ingredients (% on mix):20 to 25 weight % of a dietary supplement comprising at least 50% of L-arginine or a physiologically acceptable salt thereof,24 to 28 weight % of cereal flakes,16 to 20 weight % of puffed brown or white rice,15 to 19 weight % of nuts,11 to 15 weight % of orange rind (or dried fruit such as cranberries, blueberries, raspberry, blackberry), and4 to 8 weight % of water and/or fruit juice.3. The edible formulation according to being in the form of a food product or a dietary supplement.4. The edible formulation according to wherein the food product is in the form of a biscuit or a bar snack.5. The edible formulation according to comprising in % wet weightat least 10 ww % of L-arginine or a physiologically acceptable salt thereof,5 to 10 ww % of proteins,25 to 32 ww % of starch,6 to 8 ww % of sugars,9 to 12 ww % of total fat, and4 to 7 ww % of total dietary fibers.6. The edible formulation according to comprising in % wet weight:11 to 15 ww % of L-arginine ...

METALLO-LACTOFERRIN-COENZYME COMPOSITIONS AND METHODS FOR WEIGHT MANAGEMENT

Formulations are provided for the management of weight. The formulations generally include a trigger complex, an elemental complex and a coenzyme-vitamin B complex. The trigger complex is high in fiber such as glucomannan and includes Metallo-Lactoferrin protein in an alkaline buffer system. The elemental complex includes one or more trace element as a suitable salt. The coenzyme-vitamin B complex includes one or more coenzyme, coenzyme precursor and/or B-vitamin. The compositions may optionally include additional components such as dihydroxy acetone (DHA), inositol, 5-hydroxy-L-tryptophan (5-HTP), choline, milk protein hydrolysate, and pyruvate. The compositions can be administered orally in a variety of forms and may substitute for one or more meals per day to manage weight. 1. A composition to manage weight in an individual comprising:a trigger complex comprising Lactoferrin (LF) comprising a zinc ion covalently bound to the LF, magnesium, citric acid, glucomannan and at least one additional hydrocolloid compound at alkaline pH,an elemental complex comprising a zinc metal salt, anda coenzyme complex comprising at least one coenzyme or coenzyme precursor, wherein the concentration of LF in the composition is from 0.2 to 5% (wt/wt).2. The composition of claim 1 , wherein the lactoferrin is lactoferrin-(TCR).3. The composition of claim 1 , wherein the additional hydrocolloid compound is selected from the group consisting of edible celluloses claim 1 , arabinoglactans claim 1 , β-glucans claim 1 , arabinoxylans claim 1 , glucuronoxylans claim 1 , xyloglucans claim 1 , galactomannans claim 1 , methyl cellulose claim 1 , hydroxypropylmethyl cellulose (HPMC) claim 1 , inulin claim 1 , oligofructans claim 1 , xanthan gum claim 1 , guar gum claim 1 , locust bean gum claim 1 , gum acacia claim 1 , gum karaya claim 1 , gum tragacanth claim 1 , resistant starches claim 1 , maltodextrins claim 1 , chemically synthesized polydextrose claim 1 , lactulose claim 1 , cellulose ...

Stabilizing Composition for Biological Materials

Dry stabilizing compositions for bioactive materials include sugars and hydrolyzed proteins, and may be formed into tablets or other forms providing enhanced stability for the bioactive material. Compositions containing the bioactive materials may be produced by a method that includes (a) combining the bioactive material with other ingredients in an aqueous solvent to form a viscous slurry; (b) snap-freezing the slurry in liquid nitrogen to form solid frozen particles, beads, droplets or strings; (c) primary drying by water removal under vacuum of the product of step (b) while maintaining it at a temperature above its freezing temperature; and (d) secondary drying of the product of step (c) at maximum vacuum and a temperature of 20° C. or higher for a time sufficient to reduce the water activity to below 0.3 Aw. 1. A dry stabilizing composition for a bioactive material , comprising a carbohydrate component comprising between about 10% and 80% oligosaccharide , between about 5% and 30% disaccharide and between about 1% and 10% polysaccharide; and a protein component comprising between about 0.5% and 40% hydrolyzed animal or plant proteins; based on the total weight of the composition.2. The composition of claim 1 , wherein the hydrolyzed protein component comprises hydrolyzed casein claim 1 , hydrolyzed whey protein claim 1 , hydrolyzed pea protein claim 1 , hydrolyzed soy protein or a mixture thereof.3. The composition of claim 2 , wherein the hydrolyzed casein claim 2 , hydrolyzed whey protein claim 2 , hydrolyzed pea protein and hydrolyzed soy protein are extensively hydrolyzed proteins.4. The composition of claim 1 , wherein the polysaccharide comprises cellulose acetate phthalate (CAP) claim 1 , carboxy-methyl-cellulose claim 1 , pectin claim 1 , sodium alginate claim 1 , salts of alginic acid claim 1 , hydroxylpropyl methyl cellulose (HPMC) claim 1 , methyl cellulose claim 1 , carrageenan claim 1 , gellan gum claim 1 , guar gum claim 1 , gum acacia claim 1 , ...

CHARGED NUTRITIVE PROTEINS AND METHODS

Charged nutritive proteins are provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g/L at pH 7. In some embodiments the nutritive proteins comprise at least one of a level of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of branch chain amino acid residues to total amino acid residues present in a benchmark protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of leucine residues to total amino acid residues present in a benchmark protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of essential amino acid residues to total amino acid residues present in a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things. 1. An isolated nutritive protein comprising a first polypeptide sequence , wherein the first polypeptide sequence comprises:a. an aqueous solubility of at least 50 g/L at pH 7,b. a simulated gastric digestion half-life of less than 10 minutes,c. a ratio of Leu residues to total amino acid residues of at least 6%,d. a ratio of essential amino acid residues to total amino acid residues of at least 34%,e. a ratio of branch chain amino acid residues to total amino acid residues of at least 18%, andf. 0, 1, 2, or 3 cysteine residues.2. The isolated nutritive protein of claim 1 , wherein the first polypeptide sequence has an aqueous ...

Sebum Secretion-Blocking Composition, and Food or Beverage Containing Same

An object is to provide a sebum secretion inhibiting composition and a food or drink product using the same. The present inventors have conducted extensive studies and consequently found that the sebum secretion is inhibited by orally ingesting a collagen peptide, which is hydrolyzed collagen, and provide an oral sebum secretion inhibiting composition comprising a collagen hydrolysate and a food or drink product containing the composition. 1. An oral sebum secretion inhibiting composition comprising a collagen hydrolysate.2. A food or drink product containing an oral sebum secretion inhibiting composition according to . The present invention relates to a sebum secretion inhibitor (blocker) and a food or drink product and a composition using the same.Sebum refers to lipid found in the human epidermis and is a mixture of a sebaceous secretion and the lipids derived from the epidermis, comprising triglycerides, fatty acids, wax esters, etc. In the human epidermis, 0.05 to 0.4 mg/cmof sebum is considered to be always present. Sebum moisturizes and softens the stratum corneum and also prevents external harmful substances and bacteria from invading and prevents substances such as water from being released out of the body. The amount of sebum varies depending on sites of the body, age, sex, the season, temperature, fat intake, etc. Generally, in humans, the sebum amount is known to be greater in men than in women, and is further abundant in fetuses and newborns, adolescents, and middle-aged to elderly men.The sebum amount is an important factor to determine the skin type. The skin with a large amount of sebum is classified as oily skin, whereas the skin with a small amount of sebum is classified as not oily skin. When the oiliness increases, the skin becomes greasy, which gives an unpleasant feeling not only to the person him or herself but also to others. Also, when a sebum amount is excessive, sebum accumulates together with the stratum corneum inside the pores and may ...

Polypeptides Having Phytase Activity and Polynucleotides Encoding Same

The present invention relates to polypeptides having phytase activity. These polypeptides have an amino acid sequence which has at least 70% identity to either of three phytases derived from the bacterium Buttiauxella , and which comprises at least one of the following amino acids at the position indicated: 119N, 120L, and/or 121E. These phytases have an improved specific activity. Additional specific amino acid substitutions are also disclosed which characterize and distinguish additional phytases of the invention having improved properties such as temperature and/or pH stability, pH activity profile, temperature activity profile, substrate profile, improved performance in animal feed in vitro or in vivo. The invention also relates to isolated polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.

Exercise Performance-Increasing Nutritional Supplement and Related Methods and Compositions

The present invention provides a nutritional supplement, comprising L-carnitine and phosphatidylserine; and optionally, further comprises at least one mineral selected from the group consisting of: iron; copper and zinc; and optionally, further comprises ferrous glycinate, copper glycinate and zinc glycinate. 1. A nutritional supplement , comprising L-carnitine; phosphatidylserine; ferrous glycinate , copper as copper glycinate; and zinc as zinc glycinate.5. A nutritional supplement of claim 1 , wherein the supplement further comprises one or more composition selected from the group consisting of: protein; carbohydrate; fiber; fat; electrolyte;stimulant; vitamin; mineral; herb; polymer; water; artificial sweetener; artificial fat; and pharmoactive molecule.6. A nutritional supplement of claim 1 , which is optimized for use in a mammal selected from the group consisting of: mouse; rat; bovine; horse; swine; dog; cat; and human.7. A nutritional supplement of claim 1 , which is optimized for use in a female human.8. A nutritional supplement of claim 1 , wherein the supplement further comprises a form selected from the group consisting of: liquid; gel; solid; tablet; capsule; crystals; and powder.9. A nutritional supplement of claim 1 , wherein the supplement further comprises a form selected from the group consisting of: multivitamin; drink; bar; gel; powdered drink mix; concentrated liquid drink mix; gel drink mix; crystalline food.10. A nutritional supplement of claim 1 , wherein the supplement is a liquid selected from the group consisting of: water; orange juice; apple juice; grape juice; mixed juice; cranberry juice; pomegranate juice; cow's milk; goat's milk; sheep's milk; nut extract; soy extract; grain extract; carbonated beverage; alcoholic beverage; flavored beverage.11. A nutritional supplement of claim 1 , wherein the supplement is a food selected from the group consisting of: dairy product; ready-to-eat cereal; cookie; cake; cracker; pretzel; honey; and ...

Agent for use in the case of fructose intolerance

There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed. There is provided a method for treating or reducing the effects of fructose intolerance and health problems associated with excessive fructose intake by administration of glucose isomerase. Other embodiments are also disclosed. 16-. (canceled)7. A mammalian ingestible composition of matter selected from a pharmaceutical composition and a dietary supplement , said composition of matter comprising a glucose isomerase , a second enzyme other than 5-D-fructose dehydrogenase , and a carrier or excipient that is acceptable for use in pharmaceutical compositions or foodstuffs.8. A composition of matter according to which is in unit dosage form.9. A composition of matter according to which is in an orally administrable form.10. A composition of matter according to which is in a form selected from (a) the group consisting of a tablet claim 9 , capsule claim 9 , gel cap claim 9 , pellet and dragee claim 9 , (b) the group consisting of a solution claim 9 , suspension or gel claim 9 , optionally in which is contained in a single-dose container claim 9 , and (c) a powder which is contained in a single-dose container.11. A composition of matter according to wherein said glucose isomerase is protected by a coating which is at least one of (a) stable at pH below 4 and (b) dissolves at a pH of 5.5 or higher.12. A composition of matter according to wherein said composition of matter is in unit dosage form and said coating protects the entire dosage unit.13. A composition of matter according to wherein said glucose isomerase is microencapsulated.14. A ...

PROTECTIVE HYDROCOLLOID FOR ACTIVE INGREDIENTS

Partially deamidated rice endosperm protein or rice endosperm protein which is partially conjugated with mono-, di-, oligo- or polysaccharides is used as novel protective hydrocolloid for fat-soluble active ingredients and/or fat-soluble colorants. The present invention further includes compositions comprising that rice endosperm protein and at least one fat-soluble active ingredient/colorant, as well as their manufacture, that rice endosperm protein itself and its manufacture. These compositions are used for the enrichment, fortification and/or coloration of food, beverages, animal feed, personal care or pharmaceutical compositions. The present invention is directed to theses uses and to food, beverages, animal feed, personal care and pharmaceutical compositions containing such a rice endosperm protein and such a composition, respectively. 136-. (canceled)37. A process for the manufacture of a rice endosperm protein which is partially deamidated starting from milled rice , whereby before milling the rice bran was removed , comprising the following steps a) to e):a) preparing an aqueous solution or suspension of milled rice, whereby the rice bran was removed before milling, whereby the solution or suspension preferably has a dry mass content of from 0.1 to 30 weight-%, based on the total amount of the aqueous solution or suspension;b) optionally removing the non-protein part or the protein part of the milled rice, whereby the rice bran was removed before milling, to obtain the rice endosperm protein;c) modifying the protein part of the milled rice, whereby the rice bran was removed before milling, by partially deamidating the protein part of the milled rice to obtain rice endosperm protein which is partially deamidated;d) optionally isolating the rice endosperm protein which is partially deamidated; ande) optionally converting the rice endosperm protein which is partially deamidated into a solid form,wherein the rice endosperm protein has an emulsion activity of ≧0. ...

HUMAN LACTOFERRIN DERIVED PEPTIDES AND THEIR USE

The present invention relates to new peptides and to use thereof, in particular for treatment and/or prevention of infections, inflammations, pain, wounds, scar and/or tumours. 5. The isolated peptide according to claim 1 , wherein a free COOH at the carboxy terminal end has been transformed into CONH.6. The isolated peptide according to claim 1 , wherein a free NH2 group at the amino terminal end has been transformed into the amide CHCONH.7. The isolated peptide according to claim 1 , wherein the amino acid Cys claim 1 , if present claim 1 , has been replaced by an acetamidomethyl-cysteine.8. A pharmaceutical composition comprising a peptide according to .9. The pharmaceutical composition according to for use in treatment and/or prevention of infections claim 8 , inflammations claim 8 , tumours claim 8 , pain claim 8 , wounds claim 8 , and scars.10. The pharmaceutical composition according to claim 9 , for use in treatment claim 9 , prophylaxis and/or prevention of impetigo claim 9 , burn wounds claim 9 , infected abrasions claim 9 , infected lacerations claim 9 , excoriations claim 9 , erysipelas claim 9 , cellulitis claim 9 , abscesses claim 9 , furuncles claim 9 , carbuncles claim 9 , sutured wounds claim 9 , surgical site infections claim 9 , secondarily infected dermatoses: atopic dermatitis claim 9 , psoriasis claim 9 , and allergic contact dermatitis claim 9 , animal bites and catheter related infection.11. The pharmaceutical composition according to formulated for oral administration claim 8 , systemic administration claim 8 , parenteral administration claim 8 , local administration or topical administration.12. A food stuff comprising a peptide according to .13. The peptide according to for use as a medicament.14. The peptide according to for use in the treatment and/or prevention of infections claim 1 , inflammations claim 1 , tumours claim 1 , pain claim 1 , wounds claim 1 , and scars.15. The peptide for use according to claim 14 , wherein said peptide ...

SKIN COLLAGEN PRODUCTION-PROMOTING AGENT

A problem of the present invention is to provide a skin collagen production-promoting agent without safety problems. Another problem of the present invention is to provide a skin collagen production-promoting food or drink product and a skin collagen production-promoting cosmetic product containing such a substance. TGF-β and/or a TGF-β degradation product, which is acquired by degrading TGF-β with a protease such as pepsin, pancreatin, etc., are used as a skin collagen production-promoting agent or the active ingredient of a skin collagen production-promoting food or drink product and a skin collagen production-promoting cosmetic product. The aforementioned TGF-β and/or TGF-β degradation product have an effect of increasing the collagen content of the skin. 1. A skin collagen production-promoting agent comprising TGF-β and/or a TGF-β degradation product as an active ingredient.2. The skin collagen production-promoting agent according to claim 1 , wherein the TGF-β degradation product is acquired by degrading TGF-β with a protease.3. The skin collagen production-promoting agent according to claim 2 , wherein the protease is one or more selected from trypsin claim 2 , pancreatin claim 2 , chymotrypsin claim 2 , pepsin claim 2 , papain claim 2 , kallikrein claim 2 , cathepsin claim 2 , thermolysin claim 2 , and V8 protease.4. The skin collagen production-promoting agent according to claim 1 , wherein the TGF-β degradation product has an average molecular weight of 500 or more and 8 claim 1 ,000 or less.5. A skin collagen production-promoting food or drink product comprising the TGF-β and/or the TGF-β degradation product according to .6. A skin collagen production-promoting cosmetic product containing the TGF-β and/or the TGF-β degradation product according to .7. A method of improving skin quality by oral ingestion of or application of TGF-β and/or a TGF-β degradation product.8. A method of improving skin quality by oral ingestion of 10 μg per day or more of TGF-β and ...

COMPOSITIONS AND METHODS FOR PERSONAL TUMOR PROFILING TREATMENT

The present invention discloses therapeutic compositions and methods for treating a patient having a tumor disease. Methods, and dietary compositions thereof, for determining a diet regime for a patient with a tumor disease include the steps of: providing a sample of the patient; profiling at least one biochemical parameter of the sample using a biochemical analyzer to obtain a profile; identifying a biologically-active molecular feature of the profile; correlating the feature with a biochemical pathway related to the tumor's metabolism or proliferation; determining the diet regime specific to the patient, wherein the diet regime includes at least one biologically-active molecule corresponding to the feature of the profile; and administering the diet regime to the patient in a therapeutically-effective dosage. Preferably, the sample is selected from the group consisting of: a tumor sample, biological tissue, an organ sample, blood, blood serum, blood plasma, and urine. 1. A method for determining a diet regime for a patient with a tumor disease , the method comprising the steps of:(a) providing a sample of the patient;(b) profiling at least one biochemical parameter of said sample using a biochemical analyzer to obtain a profile;(c) identifying a biologically-active molecular feature of said profile;(d) correlating said feature with a biochemical pathway related to the tumor's metabolism or proliferation;(e) determining the diet regime specific to the patient, wherein the diet regime includes at least one biologically-active molecule corresponding to said feature of said profile; and(f) administering the diet regime to the patient in a therapeutically-effective dosage.2. The method of claim 1 , wherein said sample is selected from the group consisting of: a tumor sample claim 1 , biological tissue claim 1 , an organ sample claim 1 , blood claim 1 , blood serum claim 1 , blood plasma claim 1 , and urine.3. A method for diagnosing a tumor in a subject claim 1 , the ...

COMPOSITION TO INCREASE JOINT AND/OR POSTURAL STABILITY

The invention is directed to a composition for the use to increase joint stability or postural stability, wherein said composition comprises branched chain amino acids. It is further directed to the use of branched chain amino acids for the preparation of a food supplement or medicament for the prophylaxis and/or treatment of joint and/or postural instability. 1. Composition for the use to increase joint stability and/or postural stability , wherein said composition comprises at least two branched chain amino acid.2. Composition according to claim 1 , wherein the composition comprises L-leucine and at least one of the branched chain amino acids L-isoleucine and L-valine.3. Composition according to claim 1 , wherein L-leucine is present in an amount from about 25 to about 80% by weight claim 1 , preferably from about 35 to about 75% by weight claim 1 , more preferably from about 45 to about 70% by weight claim 1 , most preferably about 64% by weight claim 1 , based on the total weight of all branched chain amino acids.4. Composition according to claim 1 , wherein L-leucine present in an amount in an amount from about 35 to about 80% by weight claim 1 , L-iso-leucine in an amount from about 10 to about 30% by weight and L-valine in an amount from about 10 to about 30% by weight.5. Composition according to claim 1 , wherein L-leucine claim 1 , L-iso-leucine and L-valine are present in the weight ratio of 2-6:0.5-1.5:0.5-1.5 claim 1 , preferably in a weight ratio of 3-5:0.75-1.25:0.75-1.25 claim 1 , more preferably in a weight ratio of about 3.5: about 1: about 1.6. Composition according to claim 1 , wherein the composition contains one or more further active ingredients.7. Composition according to claim 6 , wherein the active ingredients are vitamins claim 6 , such as vitamin D claim 6 , mineral substances claim 6 , such as magnesium or calcium salts and/or chondroprotectors claim 6 , such as hyaluronic acid and/or glucosamine or its derivatives claim 6 , such as ...

Protein Hydrolysate Compositions Having Enhanced CCK and GLP-1 Releasing Activity

The present invention provides protein hydrolysate compositions having enhanced cholecystokinin (CCK) and/or giuoagon-like peptide-1 (GLP-1) releasing activity and food forms incorporating the protein hydrolysate compositions, which can be used to promote satiety. 1. A protein hydrolysate composition comprising a mixture of polypeptide fragments , wherein the protein hydrolysate composition stimulates cholecystokinin (CCK) and glugacon-like peptide-1 (GLP-1) releasing activity.2. The protein hydrolysate composition of claim 1 , wherein about 30% to about 50% of polypeptides in the soluble fraction of the protein hydrolysate composition have a molecular weight greater than about 20 kDa.3. The protein hydrolysate composition of claim 1 , wherein the protein hydrolysate composition contains a soluble fraction claim 1 , an insoluble fraction claim 1 , or combinations thereof.4. The protein hydrolysate composition of claim 1 , wherein the protein hydrolysate composition consists essentially of a soluble fraction.5. The protein hydrolysate composition of claim 1 , wherein the protein hydrolysate composition is a product of hydrolysis of a plant protein material claim 1 , an animal protein material claim 1 , or combinations thereof.6. The protein hydrolysate composition of claim 1 , wherein the protein hydrolysate composition is a product of hydrolysis of a plant protein material and wherein the plant protein material is a leguminous or non-leguminous plant.7. The protein hydrolysate composition of claim 6 , wherein the plant protein material is derived from soy.8. The protein hydrolysate composition of claim 7 , wherein the plant protein material is a soy protein isolate claim 7 , a soy protein concentrate claim 7 , a soy flour claim 7 , or combinations thereof.9. The protein hydrolysate composition of claim 8 , wherein the plant protein material is a soy protein isolate claim 8 ,10. The protein hydrolysate composition of claim 1 , wherein the protein hydrolysate ...

LEARNING MOTIVATION IMPROVERS

The present invention aims to provide antidepressants which are free from the problem of side effects and are excellent in safety. The present invention also aims to provide learning motivation improvers which are useful for improvement of learning motivation and can be ingested continuously. 1. A method of treating depression comprising administering an effective amount of 2 ,5-piperazinedione ,3 ,6-bis(phenylmethyl)- ,(3S ,6S) to a subject in recognized need thereof.2. The method according to claim 1 , wherein the administration is oral administration.3. The method according to claim 1 , wherein the 2 claim 1 ,5-piperazinedione claim 1 ,3 claim 1 ,6-bis(phenylmethyl)- claim 1 ,(3S claim 1 ,6S) is present in a food claim 1 , beverage claim 1 , tablet claim 1 , capsule claim 1 , powder claim 1 , granule claim 1 , solution claim 1 , or elixir.4. The method according to claim 1 , wherein the 2 claim 1 ,5-piperazinedione claim 1 ,3 claim 1 ,6-bis(phenylmethyl)- claim 1 ,(3S claim 1 ,6S) is administered as a prophylactic and/or therapeutic agent for treatment of depression claim 1 , senile depression symptoms claim 1 , depressed mood claim 1 , hypobulia claim 1 , anxiety claim 1 , or insomnia or anorexia associated with these symptoms.5. A method of treating depression comprising administering an antidepressant comprising an effective amount of one or more members selected from the group consisting of 2 claim 1 ,5-piperazinedione claim 1 ,3 claim 1 ,6-bis(phenylmethyl)- claim 1 ,(3S claim 1 ,6S); pyrrolo[1 claim 1 ,2-a]pyrazine-1 claim 1 ,4-dione claim 1 ,hexahydro-3-(1H-imidazol-4-ylmethyl)- claim 1 ,(3 S claim 1 ,8aS); pyrrolo[1 claim 1 ,2-a]pyrazine-1 claim 1 ,4-dione claim 1 ,hexahydro-3-(1H-indo1-3-ylmethyl)- claim 1 ,(3S claim 1 ,8aS); 2 claim 1 ,5-piperazinedione claim 1 ,3 claim 1 ,6-bis(1 H-indo1-3-ylmethyl)- claim 1 ,(3S claim 1 ,6S); pyrrolo[1 claim 1 ,2-a]pyrazine-1 claim 1 ,4-dione claim 1 ,hexahydro-3-(2-methylpropyl)- claim 1 ,(3S claim 1 ,8aS); and ...

Long lasting absorption of flavonoids

The present invention relates to methods for a ong-term and sustained release of flavonoids, in particular rhamnose-containing flavonoids, and for prolonging the uptake of said flavonoids in the gastro-intestinal tract. It further relates to compositions comprising said flavonoid and α-rhamnosidase. It also encompasses compositions comprising hesperidin and hesperetin-7-gluoside.

NUTRITIONAL PRODUCTS COMPRISING CALCIUM HMB AND CONJUGATED LINOLEIC ACID

Disclosed are nutritional products comprising calcium beta-hydroxy-beta methylbutyrate, conjugated linoleic acid, and protein. The nutritional product forms include nutritional liquids and nutritional powders. The nutritional products not only provide benefits for individuals concerned with muscle health and functionality, but also exhibit physical stability, sensory and/or aesthetic benefits in each of the selected product forms. 115.-. (canceled)16. A nutritional product comprising from about 0.01% to about 10% by weight of calcium beta-hydroxy-beta-methylbutyrate , from about 0.01% to about 10% by weight of conjugated linoleic acid , and from about 1% to about 50% by weight of protein.17. The nutritional product of further comprising from about 50% to about 98% by weight of water and from about 1% to about 30% by weight of protein claim 16 , wherein the nutritional product is a nutritional liquid claim 16 , and wherein interaction between the conjugated linoleic acid and calcium reduces precipitation and sedimentation in the nutritional liquid.18. The nutritional product of comprising from about 0.1% to about 5% by weight of calcium beta-hydroxy-beta-methylbutyrate.19. The nutritional product of comprising from about 0.5% to about 2% by weight of calcium beta-hydroxy-beta-methylbutyrate.20. The nutritional product of comprising from about 0.5% to about 5% by weight of conjugated linoleic acid.21. The nutritional product of comprising from about 1% to about 3% by weight of conjugated linoleic acid.22. The nutritional product of comprising from about 1% to about 7% by weight of protein.23. The nutritional product of claim 17 , wherein the nutritional liquid is an aqueous emulsion further comprising from about 1% to about 30% by weight of fat.24. The nutritional product of claim 17 , wherein the nutritional liquid is packaged in a hermetically sealed container and is shelf stable at a temperature of from about 18° C. to about 24° C. for at least about 3 months.25. ...

FUNCTIONAL FOODS COMPRISING DIAMINE OXIDASE AND USES THEREOF

The present invention relates to functional foods comprising DAO and their use for the prevention or treatment of diseases or pathological conditions associated with high levels of histamine in blood, in particular for the prevention or treatment of migraine, chronic fatigue, fibromyalgia, spondylitis and pain caused by muscle contractures. 1. A functional food comprising DAO.2. A functional food comprising DAO claim 1 , according to claim 1 , wherein the DAO can be added to the food in free form claim 1 , in the form of powder claim 1 , lyophilized powder claim 1 , microcapsules claim 1 , nanocapsules or liposomes.3. A functional food according to claim 1 , wherein the DAO is both of biotechnological origin and from plant or animal extraction.4. A functional food according to claim 1 , wherein the DAO includes gastrointestinal protection.5. A functional food according to claim 1 , wherein the food is a dairy-based product such as yogurt claim 1 , milky beverages claim 1 , a confectionery product claim 1 , ice-cream or another beverage such as claim 1 , for example claim 1 , juice; a non-dairy-based product such as soya claim 1 , oat claim 1 , almond or rice milk; cereals and the like.6. A functional food according to claim 1 , wherein the food is a nutritional or vitamin supplement.7. A functional food according to claim 1 , wherein the DAO is present in a percentage comprised between 0.01 and 5% by weight of DAO as regards to the total weight of the food.8. A method of preventing or treating a disease or pathological condition associated with high histamine levels in blood claim 1 , comprising administering a functional food comprising DAO.9. A method of preventing or treating migraine claim 1 , comprising administering a functional food comprising DAO.10. A method of preventing or treating chronic fatigue claim 1 , fibromyalgia claim 1 , spondylitis and pain caused by muscular contractures claim 1 , the method comprising administering a functional food comprising ...

MODULATING DISEASE THROUGH GENETIC ENGINEERING OF PLANTS

In certain embodiments transgenic plants (e.g., transgenic tomatoes) are provided that comprise cells that express a peptide one or more domains of which comprise the amino acid sequence of an apolipoprotein or apolipoprotein mimetic peptide where the peptide has biological activity (e.g., lowers SAA, and/or increases paroxonase activity, and/or improves HDL inflammatory index, etc.) when the plant and/or the peptide is fed to a mammal. 1. A transgenic plant comprising cells that express a peptide one or more domains of which comprise the amino acid sequence of an apolipoprotein or apolipoprotein mimetic peptide where said transgenic plant or a portion thereof and/or said peptide has biological activity.2. The transgenic plant of claim 1 , wherein said peptide comprises one domain that comprises the amino acid sequence of said apolipoprotein or apolipoprotein mimetic peptide.3. The transgenic plant of claim 1 , wherein said peptide comprises at least two domains that comprise the amino acid sequence of said apolipoprotein or apolipoprotein mimetic peptide.4. The transgenic plant of claim 1 , wherein said amino acid sequence comprises an ApoA-I mimetic amino acid sequence and/or a G* peptide amino acid sequence claim 1 , and/or an ApoE peptide sequence.5. (canceled)6. The transgenic plant of claim 1 , wherein said amino acid sequence comprises an amino acid sequence selected from the group consisting of DWLKAFYDKFFEKFKEFF (6F claim 1 , SEQ ID NO:17) claim 1 , FFEKFKEFFKDYFAKLWD (rev6F claim 1 , SEQ ID NO: 25) claim 1 , DWFKAFYDKVAEKFKEAF (4F claim 1 , SEQ ID NO:15) claim 1 , FAEKFKEAVKDYFAKFWD (rev4F claim 1 , SEQ ID NO: 23) claim 1 , LLEQLNEQFNWVSRLANL (SEQ ID NO:609) claim 1 , and LVGRQLEEFL (SEQ ID NO:612).7. The transgenic plant of claim 6 , wherein said amino acid sequence comprises the amino acid sequence DWLKAFYDKFFEKFKEFF (6F claim 6 , SEQ ID NO:17).8. The transgenic plant of claim 1 , wherein said amino acid sequence comprises an amino acid sequence selected ...

METHODS AND COMPOSITIONS FOR TREATMENT OF ADD/ADHD, DEPRESSION, MEMORY PROBLEMS AND OTHER CONDITIONS

Disclosed herein are compositions and methods for treating a variety of mood and behavioral disorders, including attention deficit hyperactivity disorder (ADHD), anxiety, depression, memory loss, as well as other conditions. Also disclosed herein are methods for diagnosing certain conditions, such as ADHD, using these compositions. 1. A method for treating attention deficit hyperactivity disorder , comprising orally administering to a human subject affected with said disorder a composition comprising 1 to 3 homeopathic pellets of Aconite wherein each pellet is of at least 3× strength.2. The method of claim 1 , wherein the composition comprises 3 homeopathic pellets of Aconite wherein each pellet is of at least 3× strength.3. The method of claim 2 , wherein the composition comprises 10 to 15 homeopathic pellets of Aconite wherein each pellet is of at least 3× strength.4. The method of claim 1 , wherein the composition further comprises one or more nutritional supplements.5. The method of claim 2 , wherein the composition further comprises one or more nutritional supplements.6. The method of claim 3 , wherein the composition further comprises one or more nutritional supplements.7. The method of claim 4 , wherein the composition further comprises one or more nutritional supplements selected from the group consisting of GABA claim 4 , pycnogenol claim 4 , L-tyrosine claim 4 , Ginko biloba claim 4 , DMAE claim 4 , Gotu kola claim 4 , Guarana claim 4 , L-5HTP claim 4 , magnesium claim 4 , and zinc.8. The method of claim 5 , wherein the composition further comprises one or more nutritional supplements selected from the group consisting of GABA claim 5 , pycnogenol claim 5 , L-tyrosine claim 5 , Ginko biloba claim 5 , DMAE claim 5 , Gotu kola claim 5 , Guarana claim 5 , L-5HTP claim 5 , magnesium claim 5 , and zinc.9. The method of claim 6 , wherein the composition further comprises one or more nutritional supplements selected from the group consisting of GABA claim 6 , ...

DIETARY SUPPLEMENT WITH PROTEIN ACTIVATOR

A dietary supplement includes a base mixture of ingredients with at least one plant or animal protein and a plant-based protein activator. The plant-based protein activator includes a first group of plant extracts having a proteolytic activity and possibly a second group of plant extracts with an emollient and peristaltic activity, a third group of plant extracts with a carminative activity and a fourth group of plant extracts with a depurative and liver and kidney protective activity. 1. The use of a dietary supplement for the preparation of dietary foods , said dietary supplement comprising a base mixture of ingredients with at least one plant or animal protein and a plant-based protein activator consisting of:proteolytic extracts obtained from the sap or the fruit or stalk of a first group of plants selected from the group consisting of papaya, pineapple, sundew;emollient and peristaltic extracts obtained from the leaves, bark, roots or rhizomes of a second group of plants selected from the group consisting of senna, mallow, cascara, frangula, rhubarb, curly dock, aloe;carminative extracts obtained from the leaves, fruits, roots and rhizomes of a third group of plants selected from the group consisting of star anise, green anise, fennel, ginger, mint, turmeric;depurative and liver and kidney protective extracts obtained from the leaves, fruits, roots and rhizomes of a fourth group of plants selected from the group consisting of artichoke, dandelion, boldo, radish, burdock, milk thistle;wherein:a weight content of each proteolytic extract of said first group of plants is from 0.4% to 2.8%, based on the total weight of the supplement;a weight content of each emollient and peristaltic extract of said second group of plants is from 0.05% to 1.4%, based on a total weight of the supplement;a weight content of each carminative extract of said third group of plants is from 0.2% to 1.4%, based on the total weight of the supplement;a weight content of each depurative and ...

USE OF WHEY PERMEATE FOR THE TREATMENT OF METABOLIC SYNDROME

The invention relates to the use of whey permeate, preferably sweet whey permeate and more preferably hydrolysed or partially-hydrolysed sweet whey permeate for the production of a pharmaceutical composition for prophylaxis or treatment of symptoms of metabolic syndrome, type-2 diabetes and secondary diseases, said composition being provided for a mammal. 1. Use of whey permeate for producing a pharmaceutical composition for the prophylaxis or treatment of symptoms of metabolic syndrome or type 2 diabetes or of secondary diseases thereof in a mammal.2. The use according to claim 1 , wherein the symptoms are selected from glucose intolerance or insulin resistance.3. The use according to claim 1 , wherein the secondary diseases are selected from arteriosclerosis claim 1 , coronary insufficiency claim 1 , arterial occlusive diseases claim 1 , myocardial infarction claim 1 , xanthomas claim 1 , abdominal discomfort claim 1 , splenohepatomegaly claim 1 , pancreatitis claim 1 , retinal lipemia claim 1 , stroke claim 1 , or kidney failure.4. The use according to any one of to claim 1 , wherein the whey permeate is sweet whey permeate.54. The use according to any one of - claims 1 , wherein the whey permeate is reduced in lactose.6. The use according to any one of to claims 1 , wherein the composition is microencapsulated.7. The use according to any one of to claims 1 , wherein the composition is formed as an oral form of administration.8. The use according to any one of to claims 1 , wherein the oral form of administration is a lozenge claims 1 , a powder claims 1 , granules claims 1 , a syrup or a juice.9. The use according to any one of to claims 1 , wherein the composition further is a food supplement.10. The use according to claim 9 , wherein the foodstuffs are dietary foodstuffs or food supplements.11. The use according to any one of to claim 9 , wherein the composition further comprises pharmaceutically acceptable additives and/or carriers.12. The use according to ...

METHOD OF INCREASING LIVER PROTEIN SYNTHESIS

A protein synthesis promoter that exhibits a protein synthesis-promoting effect includes a whey protein hydrolyzate having a molecular weight distribution that is within a range of 10 kDa or less and has a main peak of 200 Da to 3 kDa, an average peptide length (APL) of 2 to 8, a free amino acid content of 20% or less, a branched-chain amino acid content of 20% or more, and an antigenicity equal to or less than 1/100,000th of that of β-lactoglobulin. 1. A method of increasing liver protein synthesis in a subject in need of such increase , comprising administering to the subject a protein synthesis promoter comprising a whey protein hydrolyzate , the whey protein hydrolyzate having (1) a molecular weight distribution that is within a range of 10 kDa or less and has a main peak of 200 Da to 3 kDa , (2) an average peptide length (APL) of 2 to 8 , (3) a free amino acid content of 20% or less , (4) a branched-chain amino acid content of 20% or more , and (5) an antigenicity equal to or less than 1/100 ,000th of that of β-lactoglobulin.2. The method according to claim 1 , wherein the whey protein hydrolyzate is obtained by performing a hydrolysis step that hydrolyzes and thermally denatures a whey protein at a pH of 6 to 10 and a temperature of 50 to 70° C. using a heat-resistant protease claim 1 , and an inactivation step that inactivates the protease by heating.3. The method according to claim 1 , wherein the whey protein hydrolyzate is obtained by performing a preliminary hydrolysis step that hydrolyzes a whey protein at a pH of 6 to 10 and a temperature of 20 to 55° C. using a protease claim 1 , a hydrolysis step that hydrolyzes and thermally denatures an unhydrolyzed whey protein at a pH of 6 to 10 and a temperature of 50 to 70° C. using a heat-resistant protease claim 1 , and an inactivation step that inactivates the protease by heating.4. The method according to claim 1 , wherein the whey protein hydrolyzate is obtained by performing a preliminary hydrolysis step ...

Process for the production of a powdered composition, the powdered composition obtained thereby and uses thereof

The present invention relates to a process for the production of a powdered composition from a liquid composition comprising fat, protein or both, to the powdered composition obtained thereby and products containing said powdered composition.

NGNA COMPOSITIONS AND METHODS OF USE

The present invention relates to the field of viral disorders, and in particular to viral obesity. Compositions comprising nutraceutical agents are provided for treating viral obesity. Additionally, compositions comprising nutraceutical agents targeting adenoviruses are provided. 1. A method of inducing a physiological effect selected from the group consisting of increasing energy and increasing the feeling of well-being in a subject in need thereof comprising:providing a composition comprising n-glycolylneuraminic acid,and administering said composition to said subject under conditions such that said physiological effect is induced.2EchinaceaPhyllanthus amarus/niruri.. The method of claim 1 , wherein said composition further comprises an agent selected from the group consisting of catechins claim 1 , flavenoids claim 1 , claim 1 , cascara claim 1 , soy/red clover claim 1 , rosemary/lemon balm claim 1 , selenite claim 1 , barley grass claim 1 , lauric acid claim 1 , and3. The method of claims 1 , wherein said composition comprising n-glycolylneuraminic acid is a sea cucumber extract.4. The method of claim 1 , wherein said composition is administered orally.5. The method of claim 1 , further comprising administering an anorectic agent.6. The method of claim 1 , wherein said composition is a dietary supplement.7. The method of claim 1 , wherein said composition is a nutritional supplement.8. The method of claim 1 , wherein said composition is provided in a food or a drink.9. A method of inducing a physiological effect selected from the group consisting of increasing energy and increasing the feeling of well-being in a subject in need thereof comprising:providing a sea cucumber extract comprising n-glycolylneuraminic acid,and administering said extract to said subject under conditions such that said physiological effect is induced.10EchinaceaPhyllanthus amarus/niruri.. The method of claim 1 , wherein said composition further comprises an agent selected from the group ...

Composition Comprising S-Allyl-L-Cysteine as Active Ingredient for Preventing or Treating Gastrointestinal Disorders

A composition including S-allyl-L-cysteine as an active ingredient and having an anti-activity or a gastric mucosa protective effect, a composition for preventing, relieving, or treating gastrointestinal disorders, and a method of using the compositions. 1. A method for preventing or treating a gastrointestinal disorder , comprising:administrating a pharmaceutical composition comprising S-allyl-L-cysteine, a pharmaceutically acceptable salt of S-allyl-L-cysteine, or a solvate or hydrate thereof as an active ingredient.2. The method of claim 1 , wherein the gastrointestinal disorder is selected from the group consisting of chronic gastritis claim 1 , acute gastritis claim 1 , gastric ulcer claim 1 , gastric cancer claim 1 , bleeding in gastrointestinal tract claim 1 , gastroesophageal reflux disease claim 1 , duodentis claim 1 , and duodenum ulcer.3. The method of claim 1 , wherein the S-allyl-L-cysteine is isolated from a plant belonging to the Allium genus and purified claim 1 , synthesized claim 1 , or prepared by fermentation.4. The method of claim 1 , wherein the pharmaceutical composition is formulated to a formulation selected from the group consisting of a formulation for oral administration claim 1 , a formulation for mucosal administration claim 1 , an injection formulation claim 1 , a formulation for inhalation claim 1 , and a formulation for external application.5. The method of claim 4 , wherein the formulation for oral administration is selected from the group consisting of hard and soft capsules claim 4 , tablets claim 4 , suspensions claim 4 , powder claim 4 , suspended-release formulations claim 4 , enteric formulations claim 4 , granules claim 4 , oleosacchara claim 4 , fine granules claim 4 , pills claim 4 , extracts claim 4 , liquids claim 4 , aromatic waters claim 4 , emulsions claim 4 , syrups claim 4 , elixirs claim 4 , fluid extracts claim 4 , infusodecoctions claim 4 , tinctures claim 4 , medicated spirits claim 4 , and infused oils. ...

WHEY PROTEIN- AND GLYCINE-CONTAINING COMPOSITIONS

Compositions are disclosed that include undenatured whey protein and glycine. The undenatured whey protein is preferably included at a final concentration of about 20%-80%, while the glycine is present at a final concentration of about 5%-35%. The whey protein has not been exposed to acid hydrolysis and, preferably, includes cold cross-flow membrane filtrate. The glycine is preferably 20-80 mesh in size, and exhibits a U.S. Pharmacopeia (USP) 28 grade. The composition further includes several vitamin and mineral cofactors, namely, selenomethionine, nicotinamide adenine dinucleotide (NADH), and Vitamin B3. 1. A composition that comprises undenatured whey protein and glycine , wherein the undenatured whey protein is present at a final concentration of about 20%-80% and the glycine is present at a final concentration of about 5%-35%.2. The composition of claim 1 , which further comprises selenomethionine.3. The composition of claim 1 , which further comprises nicotinamide adenine dinucleotide.4. The composition of claim 1 , which further comprises Vitamin B3.5. The composition of claim 1 , which further comprises selenomethionine claim 1 , nicotinamide adenine dinucleotide claim 1 , and Vitamin B3.6. The composition of claim 5 , wherein each of the selenomethionine claim 5 , nicotinamide adenine dinucleotide claim 5 , and Vitamin B3 are present at a final concentration between 0.1%-1%.7. The composition of claim 6 , wherein a greater amount of nicotinamide adenine dinucleotide is present than Vitamin B3 claim 6 , and a greater amount of Vitamin B3 is present than selenomethionine.8. The composition of claim 7 , wherein the whey protein has not been exposed to acid hydrolysis and comprises cold cross-flow membrane filtrate.9. The composition of claim 8 , wherein the glycine is 20-80 mesh in size claim 8 , and exhibits a U.S. Pharmacopeia (USP) 28 grade.10. A composition that is manufactured to a total mass of 50 grams claim 8 , which comprises:(a) 10 grams-40 grams of ...

NUTRITIONAL COMPOSITION

A nutritional composition is provided which has an effective prophylactic and/or improving effect for various symptoms of muscle mass decrease, decreased basal metabolism, low body temperature, suppression of obesity, suppression of visceral fat accumulation, hyperglycemia, hyperlipidemia and the like in elderly people. The nutritional composition can include n-3 fatty acid and one or more of free lysine, dipeptides containing lysine, and lysine salts, wherein the content of free lysine, dipeptides containing lysine, and/or lysine salts is 0.1 g-10.0 g per 100 kcal of the composition, and the content of the total amount of n-3 fatty acid is 0.17 g-5.00 g per 100 kcal of the composition. 1. A nutritional composition comprising:i) n-3 fatty acid, andii) an ingredient selected from the group consisting of free lysine, dipeptides containing lysine and lysine salts, and combinations thereof;wherein the ingredient is present in the composition in an amount of 0.1 g-10.0 g per 100 kcal of the composition, andwherein the n-3 fatty acid is present in the composition in an amount of 0.17 g-5.00 g per 100 kcal of the composition.2. The nutritional composition according to claim 1 , further comprising a branched chain amino acid selected from the group consisting of valine claim 1 , leucine claim 1 , isoleucine claim 1 , and combinations thereof.3. The nutritional composition according to claim 2 , wherein the branched chain amino acid is present in the composition in an amount of 1.0 g-20 g per 100 kcal of the composition.4. The nutritional composition according to claim 2 , wherein the branched chain amino acid in a free form is present in the composition in an amount of 0.1 g-15 g per 100 kcal of the composition.5. The nutritional composition according to claim 1 , wherein the n-3 fatty acid is selected from the group consisting of eicosapentaenoic acid claim 1 , docosapentaenoic acid claim 1 , docosahexaenoic acid claim 1 , and combinations thereof.6. The nutritional ...

PRODUCT AND PROCESS FOR REDUCING OIL AND FAT CONTENT IN COOKED FOOD WITH ANIMAL MUSCLE PROTEIN IN SUSPENSION

A product for cooking a food in oil and/or fat is provided. An adjusted pH protein suspension is produced in an aqueous or dry form and comprises myofibrillar proteins and sarcoplasmic proteins substantially free of myofibrils and sarcomeres. The amount of oil and/or fat absorbed by the food during cooking is substantially reduced while the food retains its color and taste. 1. A process for obtaining an adjusted pH protein suspension for application to a food for being cooked in an oil/fat material , said process comprising the steps of:A) forming an aqueous acidic protein solution,B) increasing the pH of the aqueous acidic protein solution to produce a protein precipitate,C) comminuting the precipitate, andD) recovering an aqueous adjusted pH protein suspension from the comminuted precipitate.2. The process of including the step of filtering the aqueous acidic protein solution.3. The process of additionally including the step of drying the aqueous adjusted pH protein suspension.4. A process for obtaining an adjusted pH protein suspension for application to a food for being cooked in an oil/fat material claim 1 , said process comprising the steps of:A) forming an aqueous acidic protein solution, centrifuging the acidic protein solution to obtain an aqueous phase,B) increasing the pH of the aqueous phase to produce a protein precipitate,C) comminuting the precipitate, andD) recovering an aqueous adjusted pH protein suspension from the comminuted precipitate.5. The process of including the step of filtering the aqueous acidic protein solution.6. The process of additionally including the step of drying the aqueous adjusted pH protein suspension.7. A process for obtaining an adjusted pH protein suspension for application to a food for being cooked in an oil/fat material claim 4 , said process comprising the steps of:A) forming an aqueous alkaline protein solution,B) decreasing the pH of the aqueous alkaline protein solution to produce a protein precipitate,C) ...

PROTEIN HYDROLYSATES AS AGENTS FOR OVERCOMING ADDICTION

This invention is directed to the use of a protein hydrolysate, and in particular an egg lysozyme hydrolysate to assist an animal, including a human in overcoming an addition, or by breaking an unwanted habit. 1. Use of a hydrolyzed lysozyme composition to assist an animal , including a human , in refraining from engaging in an undesired behavior , and/or refraining from indulging in an addictive behavior and/or reward-seeking behavior.2. Use according to wherein the animal is a human.3. Use according to wherein the animal is an animal in a zoo claim 1 , a farm animal claim 1 , a pet or companion animal claim 1 , or a racing animal.4. Use according to wherein the behavior is selected from the group consisting of: smoking claim 1 , alcohol abuse claim 1 , gambling claim 1 , drug abuse claim 1 , compulsive behaviors claim 1 , uncontrollable behaviors such as compulsive shopping claim 1 , eating claim 1 , hoarding claim 1 , improper sexual behaviors claim 1 , kleptomania claim 1 , pyromania claim 1 , cutting or self harm claim 1 , cravings claim 1 , and potentially harmful risky behaviors.5. Use according to wherein the behavior is a habit which the individual wishes to break.6. Use according to wherein the hydrolyzed lysozyme composition is present in a food claim 1 , feed claim 1 , nutraceutical claim 1 , or food supplement.7. Use according to as an adjunctive treatment or supportive accompanying diet during dehabituation programs claim 1 , or to assist dehabituation processes.8. Use according to wherein the hydrolyzed lysozyme composition is characterized by: a Trp/LNAA ratio between 0.15 and 0.20.9. A method of assisting an animal claim 1 , including a human claim 1 , in refraining from an undesired behavior claim 1 , and/or resisting from indulging in an addictive behavior comprising:a) administering a hydrolyzed lysozyme composition, and b) noticing abstinence from the behavior.10. A method according to wherein the animal is a human.11. A method according to ...

Anti-androgenic agent, sebum secretion blocker, hair growth stimulant, and food or beverage

Provision of an anti-androgenic agent which has a strong anti-androgenic action, is free of side effects and very safe, and a sebum secretion blocker and a hair growth stimulant containing the anti-androgenic agent as an active ingredient. Provided are the anti-androgenic agent comprising lactoferrin, the sebum secretion blocker containing the anti-androgenic agent as an active ingredient, the hair growth stimulant containing the anti-androgenic agent as an active ingredient, and a food or drink product comprising the anti-androgenic agent containing lactoferrin as an active ingredient.

BIOLOGICALLY ACTIVE FOOD ADDITIVE FOR THE PROPHYLAXIS OF ERECTILE DYSFUNCTION IN MEN

The claimed product relates to the food industry, and specifically to biologically active food additives (BAA) for the prophylaxis of erectile dysfunction in men, produced on the basis of natural components. The essence of the claimed product consists in that a biologically active food additive for the prophylaxis of erectile dysfunction in men. The claimed additive includes L-arginine and drone brood, with the following ratio of ingredients: 50-96.2% by mass of L-arginine and 3.8-50% by mass of drone brood. 1. A biologically active dietary supplement for prophylaxis of erectile dysfunctions in men , comprising: L-Arginine and drone brood in the following ratio measured in mass percent: L-Arginine: 50.00-96.2% and drone brood: 3.8-50.00%.2. The biologically active dietary supplement according to produced in one of the following forms: powder claim 1 , a tablet claim 1 , or a capsule. This application is a U.S. national stage application of an international application PCT/RU2012/000271 filed on 10 Apr. 2012, published as WO2012128672, which international application claims priority of a Russian Federation patent application RU2011110120 filed on 17 Mar. 2011.This invention relates to the food processing industry, precisely to biologically active dietary additives (BAA) for the prevention of male erectile dysfunction which is based on natural ingredients.A BAA that contains a drone brood in amounts of 1-70 mass. %-RU 2390270 C1, 27.05.2010 is known. A disadvantage of the known remedy is a long term development of therapeutic effect (up to 2 weeks).There is a remedy for prevention of erectile dysfunction that contains L-Arginine in amounts of 50-80 weight fractions (KK 20030049063 A, 25.06.2003). A disadvantage of the known remedy is: all the pharmacological effects of L-arginine are associated with its converting within the human body into molecules of nitric oxide (NO). A nitric oxide in its turn, takes part in control action of blood circulation, immunologic and ...

OLIGOSACCHARIDE INGREDIENT

An oligosaccharide ingredient comprising glycosylated amino acids and peptides of the general formula RnSacm where R is an amino acid residue, Sac is a monosaccharide selected from the group comprising N-acetyl-neuraminic acid, N-acetyl galactosamine and galactose, n has a value between 1 and 10 with the proviso that if n has the value 1 R is a threonine residue or a serine residue and if n has a value between 2 and 10 the peptide contains at least one threonine or serine residue, m has a value between 2 and 4 and at least 20 mol % of the ingredient is N-acetyl-neuraminic acid. 1. A process for producing an oligosaccharide ingredient comprising the steps of hydrolysing caseinoglycomacropeptide with an exoprotease and an endoprotease to obtain a mixture of free amino acids and peptides with a chain length between 2 and 10 and subjecting the hydrolysed mixture to nanofiltration so as to retain the fraction having a molecular weight between 1000 and 2000 Daltons. This application is a divisional application of U.S. patent application Ser. No. 12/919,650, filed on Nov. 12, 2010, which is a National Stage of International Application No. PCT/EP2009/052186, filed Feb. 25, 2009, which claims priority to European Application No. 08101975.4, filed Feb. 26, 2008, the entire contents of which are being incorporated herein by reference.The invention relates to an oligosaccharide ingredient rich in sialic acid, food products comprising said oligosaccharide ingredient and processes for producing said oligosaccharide ingredient.Human milk is known to contain a large amount of indigestible oligosaccharides. In fact, indigestible oligosaccharides represent the third largest solid component (after lactose and lipids) in breast milk, occurring at a concentration of 12-15 g/l in colostrum and 5-8 g/l in mature milk. Human milk oligosaccharides are very resistant to enzymatic hydrolysis, indicating that these oligosaccharides may display essential functions not directly related to their ...

COMBINED USE OF A CARNOSINASE INHIBITOR WITH L-CARNOSINE OR ITS RELATED SUBSTANCE AND A COMPOSITION CONTAINING THE SAME

The present invention provides combined use of a carnosinase inhibitor with L-carnosine and its related substance, and a composition containing the same, which are useful for treatment or prevention of various diseases, improvement of health conditions, improvement of exercise ability, improvement of skin health, prevention of the side effects of alcohol drinking and the like in mammals including human. 122-. (canceled)27. A method of increasing a concentration of L-carnosine or its related substance in the plasma , tissues or cells of a human or other mammal , comprising:{'claim-ref': {'@idref': 'CLM-00023', 'claim 23'}, 'administering to the human or other mammal in need thereof pharmaceutical or nutritional composition according to to increase or physiologically augment the concentration of L-carnosine or its related imidazole-containing substance which is a substrate for carnosinase in the plasma, cells or tissues of humans and other mammals to the effective biological activities, functions and potent therapeutic effects and health benefits of L-carnosine or its related substance.'}28. The method according to claim 23 , wherein in the pharmaceutical or nutritional composition the L-carnosine or its related substance which is a substrate for carnosinase comprises L-carnosine claim 23 , N-acetyl-L-carnosine claim 23 , L-anserine claim 23 , N-acetyl-L-anserine claim 23 , L-balenine claim 23 , L-homocarnosine claim 23 , N-acetyl-L-homocarnosine or a beta-alanyl comprising peptide derivative resistant to hydrolysis with human serum carnosinase.29. The method according to claim 23 , wherein the carnosinase inhibitor is β-alanine presented by the formula (II).30. The method according to claim 23 , wherein N-alkanoyl-β-alanine presented by the formula (III) is N-acetyl-β-alanine which may be esterified by a lower alkyl group.31. The method according to claim 23 , wherein at least one of the additives selected from the group consisting of a cellulose chemical compound or ...

HIGH PROTEIN, LOW FAT CRISP SNACK PRODUCT

The present invention relates to high protein low fat snack products including crisps and to methods of producing them. The products are dried and expanded products. In one embodiment the product is a heat-expanded and dried crisp snack product based on milk proteins. Other products are in effect synthetic cheese snack products. 1. A method of making an expanded high protein snack product comprising:(A) Mixing together water, protein and emulsifying salts in a pre-heated mixer at about 50 degrees centigrade;(B) Heating the mixture to about 80 degrees centigrade and adding starch;(C) Mixing until all free water is absorbed;(D) Adding a preservative;(E) Chilling the mixture and cutting it into pieces;(F) Expanding the mixture by heating in a microwave at 800-1100 MHz frequency and a power of 10-75 kW,wherein the cut pieces of step (E) are coated in vegetable oil.2. A method as claimed in wherein the microwave includes a magnetron.3. A method as claimed in wherein the microwave used is a 915 MHz microwave with a 90 KW magnetron.4. A method as claimed in wherein the heating time for expansion in step (F) is between 10 and 360 seconds.5. A method as claimed in wherein the heating time is 20 seconds.6. A method as claimed in wherein the protein is selected from the group consisting of rennet casein claim 1 , acid casein claim 1 , whey milk proteins claim 1 , soya claim 1 , tofu claim 1 , (soya curd) claim 1 , rice protein claim 1 , pea protein claim 1 , flax seed proteins and protein isolates claim 1 , linseed protein concentrate or legume protein isolates claim 1 , or combinations thereof.7. A method as claimed in wherein the starch is selected from the group consisting of maize derived starch including pre-biotic claim 1 , high amylase starch claim 1 , Hi-Maize 260™ claim 1 , other corn starches claim 1 , rice starch claim 1 , flax starch claim 1 , tapioca starch or potato starch.8. A method as claimed in wherein the ingredient mixture is 18-38% by weight of protein ...

FOOD COMPOSITION AND ITS USE

The invention concerns a synthetic composition for restoring and/or maintaining a positive net protein balance in a child, wherein the composition is administered in a dose of 0.10 to 0.55 gram of proteins per kilogram of body mass of the child, said dose being administered as at least one serving given over a period of 0 min duration to about 60 min duration. The invention also relates to a non-therapeutic method of restoring and/or maintaining a positive net protein balance in a child, said method comprising the use of a synthetic composition administered in a dose of 0.10 to 0.55 gram of proteins per kilogram of body mass of the child, said dose being administered as at least one serving given over a period of 0 min duration to about 60 min duration. Preferably the composition has a protein content of 0.075 to 10 g/100 mL, more preferably of 0.75 to 6 g/100 mL. 1. A non-therapeutic method of restoring and/or maintaining a positive net protein balance in a child at risk of protein imbalance , the method comprising administering a synthetic composition comprising proteins , wherein the composition is administered in a dose of about 0.10 to about 0.55 gram of proteins per kilogram of body mass of the child , the dose being administered as at least one serving given over a period of time of about 0 min (excluded) duration to about 60 min duration.2. The non-therapeutic method of claim 1 , wherein the proteins are milk-based proteins.3. The non-therapeutic method according to claim 1 , wherein the number of servings is at least 2.4. The non-therapeutic method according to claim 1 , wherein the composition is administered as a liquid in a volume of 15 to 50 mL of composition per kilogram of body mass of the child claim 1 , and wherein the composition has a protein content of 0.075 to 10 g/100 mL.5. The non-therapeutic method according to claim 1 , wherein the composition is especially adapted for children aged 5 to 15.6. The non-therapeutic method according to claim 1 ...

FOOD COMPOSITION CONTAINING AMINO ACIDS AND COCOA

A food composition described herein contains a protein hydrolysate from a legume and cocoa. The food composition may be in a solid or powder composition, and it may also contain creatine, especially creatine monohydrate. The food composition may also contain at least one B vitamin and/or a zinc compound. 1. Food composition containing:a) a protein hydrolysate from a legume selected from peas, beans and lentils; andb) cocoa.2. Food composition according to claim 1 , which also contains creatine.3. Food composition according to or claim 1 , which also contains at least one B vitamin and/or a zinc compound.4. Food composition according to any one of the preceding claims claim 1 , wherein the protein hydrolysate from a legume is a pea protein hydrolysate.5. Food composition containing:a) hydrolysed pea protein; andb) cocoa.6. Food composition according to claim 5 , which also contains creatine.7. Food composition according to or claim 5 , which also contains at least one B vitamin and/or a zinc compound.8. Food composition claim 5 , especially a drink powder claim 5 , containing:a) 40-80% by weight hydrolysed pea protein;b) 20-50% by weight cocoa. The present invention relates to a food composition that contains a protein hydrolysate from a legume and cocoa.Preferably, the food composition according to the invention, especially when it is a solid or powder-form food composition, also contains creatine, especially creatine monohydrate, more especially Creapure©.More preferably, the food composition according to the invention contains at least one B vitamin and/or a zinc compound.More preferably, the food composition according to the invention contains all 20 standard amino acids in the form of the free amino acid and/or in the form of peptides.In the context of the present invention, the term legume relates to beans, lentils and peas, with preference being given to peas. In the context of the present invention, the term legume does not relate to soya or soybeans, that is ...

COMPOSITION FOR MAINTAINING EFFECT OF FILLER

The present invention relates to a composition for maintaining efficacy of a filler for a long period of time by containing collagen as an active ingredient. The composition according to the present invention is useful since the composition can promote the synthesis of hyaluronic acid and inhibit activity of hyaluronidase, thereby maintaining the efficacy of a hyaluronic acid filler for a longer period of time. Therefore, even with less number of times of filler injection, the efficacy of the filler can be maintained and skin irritation can be also reduced. 1. A method for maintaining a filling effect of a hyaluronic acid filler comprising administering an effective amount of collagen to a subject in need thereof ,wherein the collagen maintains the filling effect of the hyaluronic acid filler.2. A method for promoting a hyaluronic acid synthesis comprising administering an effective amount of collagen to a subject in need thereofwherein the collagen promotes the hyaluronic acid synthesis.3. The method according to claim 1 , wherein the collagen comprises collagen peptide.4. The method according to claim 3 , wherein the collagen peptide is comprised in a composition and the composition comprises 0.01-50 wt % of the collagen peptide based on the total weight of the composition.5. The method according to claim 3 , wherein the collagen peptide comprises a Gly-X-Y collagen tripeptide.6. The method according to claim 5 , wherein the X and the Y are the same or different amino acids and the amino acid is selected from a group consisting of glycine (Gly) claim 5 , alanine (Ala) claim 5 , valine (Val) claim 5 , leucine (Leu) claim 5 , isoleucine (Ile) claim 5 , threonine (Thr) claim 5 , serine (Ser) claim 5 , cysteine (Cys) claim 5 , methionine (Met) claim 5 , aspartic acid (Asp) claim 5 , asparagine (Asn) claim 5 , glutamic acid (Glu) claim 5 , glutamine (Gln) claim 5 , lysine (Lys) claim 5 , arginine (Arg) claim 5 , histidine (His) claim 5 , phenylalanine (Phe) claim 5 , ...

WHEY PROTEIN CONCENTRATE, ITS PREPARATION AND ITS USE

The invention pertains to process for manufacturing whey protein concentrate (WPC) from whey, said process involving (a) providing acidified whey; (b) increasing the pH of said acidified whey using one or more carbonate salt(s), preceded and/or followed by ultrafiltration, and (c) subjecting the ultrafiltered carbonate-containing whey to spray drying. A WPC is provided having improved functional properties, particularly increased gel strength and reduced salt sensitivity (i.e. meaning that the functional properties of the WPC are affected by salt to a lesser extent). 114.-. (canceled)15. A process for manufacturing whey protein concentrate (WPC) from whey , the process comprising:(a) increasing the pH of acidified whey using one or more carbonate salt(s),(b) subjecting the acidified whey to ultrafiltration before and/or after increasing the pH, and(c) subjecting the ultrafiltered whey to spray drying.16. The process according to claim 15 , wherein the pH is increased to at least 6.3.17. The process according to claim 16 , wherein the pH is increased to between 6.4-7.0.18. The process according to claim 15 , wherein the pH of the whey after spray drying is higher than 7.019. The process according to claim 18 , wherein the pH of the whey after spray drying is between 7.0 and 8.5.20. The process according to claim 15 , wherein the retentate obtained after ultrafiltration is subjected to diafiltration.21. A whey protein concentrate (WPC) having (i) a whey protein content of at least 70% claim 15 , based on dry matter claim 15 , (ii) a pH of at least 6.6 claim 15 , and (iii) a total carbonate content in the concentrate of 0.7-1.4%.22. The WPC according to claim 21 , having a pH of at least 7.0.23. The WPC according to in the form of a powder.24. The WPC according to claim 21 , having a pH between 7.0 and 8.5.25. The WPC according to claim 21 , in the form of a gel claim 21 , wherein the gel has a gel strength of at least 6000 grams claim 21 , by measuring the maximum ...

Novel polypeptides having satiety hormone releasing activity

The present invention relates to novel polypeptides having satiety hormone releasing activity (e.g., cholecystokinin (CCK) and/or glucagon-like peptide-1 (GLP-1) releasing activity).

Functional peptides for obesity disorders

The present invention concerns certain peptides obtainable by hydrolysis from soy glycinin by the action of supernatant cultures of strains belonging to the genera Lactobacillus or Streptococcus . These peptides, extracts containing them and food products containing them are useful for the treatment and/or prevention of obesity and oxidative stress

COHESIVE THIN LIQUIDS TO PROMOTE SAFE SWALLOWING IN DYSPHAGIC PATIENTS

Nutritional products having improved cohesiveness for promoting safer swallowing of food boluses for patients having swallowing conditions are provided as well as methods of making and using such products. The nutritional products may include nutritional compositions and high molecular weight, water-soluble polymers such that the nutritional products have extensional viscosities that provide improved cohesiveness to the nutritional products. Methods of administering such nutritional products to patients having impaired swallowing ability and/or dysphagia are also provided. 1. A nutritional product comprising an aqueous solution of a food grade biopolymer capable of providing to the nutritional product:{'sup': '−1', 'a shear viscosity of less than about 100 mPas when measured at a shear rate of 50 s; and'}a relaxation time, determined by a Capillary Breakup Extensional Rheometry (CaBER) experiment, of more than 10 ms (milliseconds) at a temperature of 20° C.2. The nutritional product according to claim 1 , wherein shear viscosity is at least about 1 mPas when measured at a shear rate of 50 s.3. The nutritional product according to claim 1 , wherein the relaxation time is less than about 2000 ms at a temperature of 20° C.4. The nutritional product according to claim 1 , wherein the filament diameter of the nutritional product decreases less than linearly during a CaBER experiment.5. The nutritional product according to claim 1 , wherein the aqueous solution comprises a food grade biopolymer at a concentration of from at least 0.01 wt % to 25 wt %.6. The nutritional product according to in diluted form.7. The nutritional product according to claim 1 , wherein the food grade biopolymer is selected from the group consisting of botanical hydrocolloids claim 1 , microbial hydrocolloids claim 1 , animal hydrocolloids claim 1 , algae hydrocolloids and combinations thereof.8. The nutritional product according to claim 7 , wherein the algae hydrocolloids are selected from the ...

METHOD OF INSTANTIZING AMINO ACIDS

This disclosure describes a process for producing an instantized amino acid product and compositions including such instantized amino acid products. Generally, the process includes obtaining a particulate amino acid, coating the amino acid particles with an aqueous solution of a food grade gum, adhering two or more gum-coated amino acid particles to another to form an agglomerate of amino acid particles, drying the agglomerate, coating the agglomerate with an aqueous solution of a food grade surfactant, and drying the surfactant-coated agglomerate. In another aspect the process generally includes obtaining amino acid particles, coating the amino acid particles with an aqueous solution of a food grade surfactant, and drying the surfactant-coated amino acid particles. This disclosure also describes amino acid particles and agglomerates of amino acid particles. 1. A process for producing an instantized amino acid product comprising:obtaining a particulate amino acid;coating the amino acid particles with an aqueous solution of a food grade gum;adhering at least one gum-coated amino acid particle to at least one other gum-coated amino acid particle, thereby forming an agglomerate of amino acid particles;drying the agglomerate;coating the agglomerate with an aqueous solution of a food grade surfactant; anddrying the surfactant-coated agglomerate.2. The process of wherein the amino acid particles have a particle size diameter of from about 63 microns to about 400 microns.3. The process of wherein the amino acid particles have a particle size diameter of from about 100 microns to about 200 microns.4. The process of wherein the food grade gum comprises guar gum.5. The process of wherein the surfactant comprises soy lecithin or sunflower lecithin.6. The process of wherein the amino acid is a branched chain amino acid.7. The process of wherein the agglomerate is dried at a temperature of from about 110° F. to about 212° F.8. The process of claim 7 , wherein the drying occurs ...

Composition containing agmatine, and uses thereof in preparing drugs or neutraceutical substances

The present invention relates to novel compositions including a mixture of cadaverine, putrescine, spermine and spermidine at a concentration ranging from 0.31 to 0.63 nmol per gram of composition, the composition also including agmatine at a concentration ranging from 120 to 17100 nmol per gram of composition, and uses thereof in the treatment, in a patient, of pathologies associated with cellular hyperproliferation.

NUTRITIONAL COMPOSITIONS AND METHODS FOR PROMOTING COGNITIVE DEVELOPMENT

A method for enhancing cognitive development in a pediatric subject involving administering to the subject a nutritional composition which includes up to 7 g/100 Kcal of a fat or lipid; up to 5 g/100 Kcal of a protein or protein equivalent source; 0.06 g/100 Kcal to 1.5 g/100 Kcal of an enriched milk product; 5 mg/100 Kcal to 90 mg/100 Kcal of a source of long chain polyunsaturated fatty acid; and 0.015 g/100 Kcal to 1.5 g/100 Kcal of a prebiotic. 1. A method for enhancing cognitive development in a pediatric subject , the method comprising administering to the subject a nutritional composition comprising: up to 7 g/100 Kcal of a fat or lipid; up to 5 g/100 Kcal of a protein or protein equivalent source; 0.06 g/100 Kcal to 1.5 g/100 Kcal of enriched milk product; 5 mg/100 Kcal to 90 mg/100 Kcal of a source of long chain polyunsaturated fatty acid; and 0.015 g/100 Kcal to 1.5 g/100 Kcal of a prebiotic , wherein the enriched milk product is present at a level such that the nutritional composition comprises 6 mg/100 Kcal to 300 mg/100 Kcal of phospholipids , 1 mg/100 Kcal to 30 mg/100 Kcal of sphingomyelin , and 0.25 mg/100 Kcal to 6 mg/100 Kcal of gangliosides.2. The method of claim 1 , wherein the enriched milk product is present at a level of 0.3 g/100 Kcal to 1.4 g/100 Kcal.3. (canceled)4. The method of claim 3 , wherein the enriched milk product comprises an enriched whey protein concentrate.5. The method of claim 1 , wherein the nutritional composition further comprises lactoferrin at a level of 5 mg/100 Kcal to 300 mg/100 Kcal.6. The method of claim 5 , wherein the lactoferrin is lactoferrin from a non-human source.7. The method of claim 5 , wherein the lactoferrin has at least 48% homology with human lactoferrin.8. The method of claim 1 , wherein the source of long chain polyunsaturated fatty acids includes at least one of docosahexaenoic acid claim 1 , arachidonic acid claim 1 , and combinations thereof.9. The method of claim 8 , wherein the source of long ...

NUTRITIONAL COMPOSITIONS AND METHODS FOR PROMOTING COGNITIVE DEVELOPMENT

A method for enhancing cognitive development in a pediatric subject involving administering to the subject a nutritional composition which includes up to 7 g/100 Kcal of a fat or lipid; up to 5 g/100 Kcal of a protein or protein equivalent source; 0.25 g/100 Kcal to 16 g/100 Kcal of buttermilk; 5 mg/100 Kcal to 90 mg/100 Kcal of a source of long chain polyunsaturated fatty acid; and 0.015 g/100 Kcal to 1.5 g/100 Kcal of a prebiotic. 1. A method for enhancing cognitive development in a pediatric subject , the method comprising administering to the subject a nutritional composition comprising:up to 7 g/100 Kcal of a fat or lipid;up to 5 g/100 Kcal of a protein or protein equivalent source;0.25 g/100 Kcal to 16 g/100 Kcal of buttermilk;5 mg/100 Kcal to 90 mg/100 Kcal of a source of long chain polyunsaturated fatty acid; and0.015 g/100 Kcal to 1.5 g/100 Kcal of a prebiotic.2. The method of claim 1 , wherein the buttermilk is present at a level of 0.6 g/100 Kcal to 15 g/100 Kcal.3. The method of claim 2 , wherein the buttermilk is present at a level such that the nutritional composition comprises 6 mg/100 Kcal to 300 mg/100 Kcal of phospholipids claim 2 , 1 mg/100 Kcal to 60 mg/100 Kcal of sphingomyelin claim 2 , and 0.25 mg/100 Kcal to 7.5 mg/100 Kcal of gangliosides.4. The method of claim 1 , wherein the nutritional composition further comprises lactoferrin at a level of 5 mg/100 Kcal to 300 mg/100 Kcal.5. The method of claim 5 , wherein the lactoferrin is lactoferrin from a non-human source.6. The method of claim 5 , wherein the lactoferrin has at least 48% homology with human lactoferrin.7. The method of claim 1 , wherein the source of long chain polyunsaturated fatty acids includes at least one of docosahexaenoic acid claim 1 , arachidonic acid claim 1 , and combinations thereof.8. The method of claim 7 , wherein the source of long chain polyunsaturated fatty acids is present from about 5 mg/100 Kcal to about 75 mg/100 Kcal.9. The method of claim 8 , wherein the ...

HIGH-PROTEIN CRISPS UTILIZING A SINGLE PROTEIN ISOLATE

High-protein crisp products and methods of making these products are provided. The products are made from a mixture of ingredients, including a hydrolyzed soy protein isolate and a source of a Group I or Group II metal (e.g., CaCO). The mixture preferably further comprises a filler (e.g., a starch) and water. The blended dry ingredients are preferably first introduced into a preconditioner, after which they are passed through an extruder barrel to yield an extrudate that expands upon exiting the extruder outlet to form the crisp rice-like product. 1. A method of forming a high-protein crisp product , said method comprising:providing a mixture of ingredients, said ingredients comprising a hydrolyzed protein, and a source of a Group I or II metal, and said protein being present in said mixture at a level of at least about 75% by weight, based upon the total weight of the ingredients taken as 100% by weight;passing said mixture through an extruder so as to form the high-protein crisp product.2. The method of claim 1 , wherein said mixture is essentially free of nonhydrolyzed proteins.3. The method of claim 1 , wherein said hydrolyzed protein is the sole protein in the mixture.4. The method of claim 1 , wherein said hydrolyzed protein comprises soy protein isolate from a single source.5. The method of claim 1 , wherein said source of a Group I or II metal is selected from the group consisting of sources of Ca claim 1 , Mg claim 1 , Na claim 1 , and mixtures thereof.6. The method of claim 5 , wherein said metal is a source of Ca.7. The method of claim 6 , wherein said source is selected from the group consisting of tribasic calcium phosphate claim 6 , calcium chloride claim 6 , dibasic calcium phosphate claim 6 , calcium carbonate claim 6 , and mixtures thereof.8. The method of claim 1 , wherein said hydrolyzed protein comprises soy protein isolate from a single source claim 1 , and wherein said Group I or II metal is a source of Ca.9. The method of claim 1 , wherein: ...

PROCESS FOR PRODUCING FROZEN GRATIN

A frozen gratin production method involves: obtaining fresh pasta by extruding a dough including durum wheat flour at a pressure of from 100 to 200 kgf/cm; boiling and cooking the fresh pasta; and then freezing the boiled-and-cooked fresh pasta together with a sauce. It is suitable to use, as the aforementioned dough, a dough including from 2 to 6 parts by mass of a vegetable protein with respect to 100 parts by mass of the durum wheat flour. It is also suitable to boil and cook the fresh pasta such that the yield-after-boiling of the fresh pasta is from 190% to 250%. 1. A method for producing a frozen gratin , comprising:{'sup': '2', 'obtaining fresh pasta by extruding a dough including durum wheat flour at a pressure of from 100 to 200 kgf/cm;'}boiling and cooking the fresh pasta; and thenfreezing the boiled-and-cooked fresh pasta together with a sauce.2. The frozen gratin production method according to claim 1 , wherein a dough including from 2 to 6 parts by mass of a vegetable protein with respect to 100 parts by mass of the durum wheat flour is used as said dough.3. The frozen gratin production method according to claim 1 , wherein the fresh pasta is boiled and cooked such that the yield-after-boiling of the fresh pasta is from 190% to 250%.4. The frozen gratin production method according to claim 1 , wherein extrusion is performed such that the fresh pasta has a thickness of from 1.0 to 1.8 mm.5. The frozen gratin production method according to claim 2 , wherein the fresh pasta is boiled and cooked such that the yield-after-boiling of the fresh pasta is from 190% to 250%.6. The frozen gratin production method according to claim 2 , wherein extrusion is performed such that the fresh pasta has a thickness of from 1.0 to 1.8 mm.7. The frozen gratin production method according to claim 3 , wherein extrusion is performed such that the fresh pasta has a thickness of from 1.0 to 1.8 mm.8. The frozen gratin production method according to claim 5 , wherein extrusion is ...

Preparations for the Treatment of Sleep-Related Respiratory Disorders

The present invention is directed to combinations of sedating antihistamines and at least one, and preferably two or more dietary supplements, which can be indole-based, such as tryptophan, 5-hydroxytryptophan, serotonin, N-acetyl-5-hydroxytryptamine and melatonin, and to their use for treating and thereby improving the health and quality of life of those suffering from sleep-related respiratory disorders, characterized by abnormal breathing during sleep. These include snoring, sleep disordered breathing, sleep apneas, upper airway resistance syndrome, obstructive sleep apnea, central sleep apnea and obesity hypoventilation syndrome and associated ailments. 1. A pharmaceutical composition for the treatment of sleep-related respiratory disorders comprising a mixture of at least one antihistamine drug and at least one dietary supplement.2. The pharmaceutical composition according to wherein the antihistamine drug is selected from a group consisting of Cetirizine claim 1 , Chlorpheniramine claim 1 , Clemastine claim 1 , Desloratadine claim 1 , Dexchlorpheniramine claim 1 , Dimenhydrinate claim 1 , Dimetindene claim 1 , Diphenhydramine claim 1 , Doxylamine claim 1 , Ebastine claim 1 , Embramine claim 1 , Fexofenadine claim 1 , Levocetirizine claim 1 , Loratadine claim 1 , Meclozine claim 1 , Olopatadine claim 1 , Pheniramine claim 1 , Promethazine claim 1 , Triprolidine claim 1 , and pharmaceutically-acceptable salts thereof.3. The pharmaceutical composition according to wherein the dietary supplement is an indole-based compound.4. The composition according to further includes at least one vitamin and pharmaceutically acceptable minerals to enhance the effect of the indole-based compounds.5. The pharmaceutical composition of wherein the indole-based compound is L-tryptophan or a derivative of L-tryptophan.6. The pharmaceutical composition of further comprising melatonin and its pharmaceutically acceptable salts.7. The composition according to further includes ...

Composition for Preventing or Treating Sepsis

Provided in the present invention is a peptide for preventing or treating sepsis. The peptide can improve symptoms of sepsis by inhibiting production of TNF, IL-1, and IL-6, which are cytokines that are related to sepsis, or can prevent or treat sepsis. Also disclosed are a pharmaceutical composition or a food composition containing the peptide as an active ingredient, a usage of the peptide for preventing or treating sepsis, and a kit comprising the peptide and instructions 1. A composition for prevention or treatment of sepsis , comprising:(a) a peptide comprising an amino acid sequence of SEQ ID NO 1, (b) a peptide having at least 80% sequence identity with SEQ ID NO:1, or (c) a peptide fragment thereof as an active ingredient.2. The composition according to claim 1 , wherein the fragment comprises at least 3 amino acids of SEQ ID NO:1.3. The composition according to claim 1 , wherein the peptide originates from human telomerase.4. (canceled)5. The composition according to claim 1 , wherein the composition is formulated for injection.6. The composition according to claim 5 , wherein the composition is formulated for intravenous injection.7. The composition according to claim 5 , wherein the injection formulation is a freeze-dried peptide solution dissolved in saline.8. The composition according to claim 7 , wherein the peptide solution is 0.5 to 1.0 mg/mL.9. The composition according to claim 1 , wherein the peptide is administered in a single dose of 0.5 to 5.0 mg/kg.10. The composition according to claim 1 , wherein the peptide is administered in a single dose.11. The composition according to claim 1 , which is a pharmaceutical composition.12. The composition according to claim 1 , which is a food composition.13. A method for prevention or treatment of sepsis comprising: administering to a subject having sepsis: (a) a peptide comprising an amino acid sequence of SEQ ID NO: 1 claim 1 , (b) a peptide having at least 80% sequence identity with SEQ ID NO:1 claim 1 ...

MICRO-, SUBMICRO- AND NANO-STRUCTURES CONTAINING AMARANTH PROTEIN

The invention relates to micro-, submicro- or nano-structures comprising amaranth protein, optionally combined with at least one other biopolymer, which structures are suitable for use as an encapsulation matrix. In particular, the invention relates to micro-, submicro- or nano-structures comprising amaranth protein and a polysaccharide. The invention also relates to the production method thereof, said method comprising an electrospinning, electrospraying or blow spinning step. The encapsulated product is characterised in that it comprises an encapsulation matrix formed by micro-, submicro- or nano-structures of the invention and at least one functional ingredient. The invention further relates to the method for obtaining same. 1. Micro- , submicro- or nano-structures comprising amaranth protein , combined or not with at least another biopolymer.2. Micro- claim 1 , submicro- or nano-structures according to claim 1 , suitable for use as encapsulation matrixes.3. Micro- claim 1 , submicro- or nano-structures according to claim 1 , wherein they are shaped as fibre or capsule.4. Micro- claim 1 , submicro- or nano-structures according to claim 1 , wherein the biopolymer is a polysaccharide.5. Micro- claim 4 , submicro- or nano-structures according to claim 4 , wherein the polysaccharide is pullulan.6. Micro- claim 1 , submicro- or nano-structures according to claim 1 , wherein the amaranth protein to biopolymer ratio is between 30:70 and 100:0.7. Micro- claim 6 , submicro- or nano-structures according to claim 6 , wherein the amaranth protein to biopolymer ratio is between 50:50 and 80:20.8. Micro- claim 1 , submicro- or nano-structures according to claim 1 , wherein they comprise one or more additives.9. Micro- claim 8 , submicro- or nano-structures according to claim 8 , wherein the additive is a surfactant.10. Method for obtaining micro- claim 1 , submicro- and/or nano-structures as described in claim 1 , comprising an electrospinning claim 1 , electrospraying or blow ...

USES OF CASEIN COMPOSITIONS

Casein compositions for increasing the rate of gastric emptying following ingestion of the composition, increasing the digestibility of a protein composition, or increasing the rate of delivery of amino acids to the blood, or for increasing the blood serum concentration of free leucine in a subject, preferably to substantially the same level as whey protein, the casein being about 10 to about 100% calcium depleted, having a degree of hydrolysis less than about 1% and having an unmodified phosphorylation pattern. 1. (canceled)2. A method of increasing the blood serum concentration of free leucine in a subject , the method comprising administering to a subject in need thereof an effective amount of a casein composition to increase the blood serum concentration of free leucine in a subject , the casein being about 10 to about 100% calcium depleted , having a degree of hydrolysis less than about 1% and having an unmodified phosphorylation pattern.3. (canceled)4. (canceled)5. A method for increasing the rate of gastric emptying following ingestion of a protein composition by a subject , increasing the digestibility of a protein composition by a subject , or increasing the rate of delivery of amino acids to the blood of a subject , the method comprising administering to a subject in need thereof an effective amount of a casein composition , the casein being about 10 to about 100% calcium depleted , having a degree of hydrolysis less than about 1% and having an unmodified phosphorylation pattern.6. (canceled)7. A method of wherein the casein increases the blood serum concentration of free leucine in a subject within about 15 to about 60 minutes of administration.8. A method of wherein the casein increases the concentration of free leucine in the blood serum of the subject to at least about 205 to about 400 μmol/L.9. A method of wherein the casein increases the concentration of free leucine in the blood serum of the subject to at least about 205 μmol/L for at least about 5 ...

Nutritive Fragments, Proteins and Methods

Nutritive proteins are provided. In some embodiments the nutritive proteins comprise a first polypeptide sequence comprising a fragment of a naturally-occurring nutritive protein. In some embodiments the fragment comprises at least one of a) an enhanced ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein; b) an enhanced ratio of leucine residues to total amino acid residues present in the nutritive protein; and c) an enhanced ratio of essential amino acid residues to total amino acid residues present in the nutritive protein. In some embodiments, the fragment comprises at least one of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein, that is equal to or greater than the corresponding ratio present in a benchmark protein such as whey, egg or soy protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things. 1114.-. (canceled)115. A nutritive composition comprising an isolated nutritive protein comprising a polypeptide sequence that is at least about 80% homologous to a fragment of a naturally-occurring protein sequence , wherein the polypeptide sequence is at least 25 amino acids in length , wherein the first polypeptide sequence comprises a ratio of essential amino acid residues to total amino acid residues of at least 40% and at least one of: a ratio of branch chain amino acid residues to total amino acid residues of at least 18% and a ratio of Leu residues to total amino acid residues of at least 8% , wherein the first polypeptide sequence has ...

COMPOSITIONS OF NUTRITION SUPPLEMENTATION FOR NUTRITIONAL DEFICIENCIES AND METHOD OF USE THEREOF

A nutritional supplement composition for treating nutritional deficiencies caused by a medical condition in subjects is disclosed. The present application further discloses a method of using a nutritional supplements composition for treating a subject with complications resulting from sickle cell anemia. The method comprises administering to a subject an effective amount of the nutritional supplement. 127.-. (canceled)28. A method for treating conditions associated with abnormally slow energy metabolism or high energy requirement , comprising:administering to a subject in need of such treatment a daily nutritional supplement having total calories of about 700-980 kcal, wherein about 10-20% of the total calories are derived from protein, about 25-40% of the total calories are derived from fat, and about 45-65% of the total calories are derived from carbohydrate.29. The method of claim 28 , wherein the conditions associated with abnormally slow energy metabolism include malnutrition claim 28 , anorexia claim 28 , cancers claim 28 , AIDS and aging.30. The method of claim 28 , wherein the conditions associated with high energy requirement include sickle cell anemia claim 28 , pregnancy claim 28 , lactation claim 28 , growth claim 28 , exercise claim 28 , infectious diseases and recovery from surgical and other injuries.31. The method of claim 30 , wherein the condition associated with high energy requirement is sickle cell anemia.32. The method of claim 28 , wherein the nutritional supplement is administered orally in the form of a snack.33. The method of claim 32 , wherein the nutritional supplement is administered orally as the last snack before sleeping.34. The method of claim 32 , wherein the nutritional supplement is administered as snacks after each meal.35. A nutritional supplement to normal diet for treating conditions associated with abnormally slow energy metabolism or high energy requirement claim 32 , comprising:protein in an amount that provides about 10-20 ...

PRODUCTS AND METHODS USING LUNASIN ENRICHED SOY EXTRACT MIXTURES TO REDUCE FREE FATTY ACID LEVELS, INCREASE LEPTIN LEVELS AND INCREASE ADIPONECTIN LEVELS IN PLASMA

this invention relates generally to products and methods using lunasin-enriched soy extract combined with Reliv Now® to reduce free fatty acid levels and increase leptin levels and adiponectin levels in plasma for the control of obesity, type 2 diabetes and metabolic syndrome. More specifically, the present invention relates to novel compositions comprising lunasin enriched soy extract and Reliv Now® formulations, methods of using these compositions in individuals for the control of obesity, type 2 diabetes and metabolic syndrome, and methods of making compositions comprising them.

Oral Composition Containing Interferon-Alpha

The present invention provides oral compositions which contain interferon α (IFNα) as an active ingredient for preventing and/or treating periodontal disease. The number of causative microorganisms of periodontal disease can be suppressed by administering the compositions into the oral cavity. IFNα of the present invention can produce a sufficient effect even when administered at a very low dose. Furthermore, the compositions of the present invention can also be readily administered to animals such as dogs by formulating them into feed or such.

PREPARATION FOR IMPROVING MEMORY AND LEARNING AND USE THEREOF

The invention relates to a preparation for improving memory and learning comprising enzymatic protein hydrolyzate of animal nervous tissue, preferably the tissue of spinal cord of animals for slaughter, while the preferred protein being a myelin protein. The invention also relates to composition for use in treatment of memory disorders, in particular age associated memory disorders and learning impairment. Also disclosed is the method for improving memory and learning. 1. Enzymatic hydrolysate of proteins of animal tissue of nervous system for use in treatment of memory disorders.2. Enzymatic hydrolysate for use according to claim 1 , wherein said proteins are myelin proteins claim 1 , preferably myelin basic protein.3. Enzymatic hydrolysate for use according to claim 1 , wherein said tissue is spinal cord tissue of an animal for slaughter claim 1 , preferably porcine spinal cord tissue or lamb spinal cord tissue claim 1 , more preferably veal spinal cord tissue.4. Enzymatic hydrolysate for use according to claim 1 , wherein said hydrolysate is obtained in the process of hydrolysis using papain or mammalian digestive enzyme claim 1 , preferably pancreatine claim 1 , more preferably pepsin.5. Enzymatic hydrolysate for use according to claim 1 , wherein said memory disorder is age associated memory loss or age associated impaired learning.6. Composition for use in treatment of memory disorders characterised in that it comprises therapeutically effective amount of enzymatic hydrolysate according to claim 1 , and one or more pharmaceutically acceptable carriers or excipients.7. Use of enzymatic hydrolysate of proteins of animal tissue of nervous system as memory and learning enhancing agent in a food product.8. Use according to claim 7 , wherein said proteins are myelin proteins claim 7 , preferably myelin basic protein.9. Use according to claim 7 , wherein said tissue is spinal cord tissue of an animal for slaughter claim 7 , preferably porcine spinal cord tissue or ...

GLYCOPROTEIN ENRICHED COMPOSITION AS A FOOD AND/OR FEED ADDITIVE AND/OR AS A THERAPEUTIC AGENT

The present invention relates to glycoprotein enriched compositions and their use in the treatment and/or prevention of disease, more particular gastro-intestinal diseases. The present invention further relates to the use of a glycoprotein enriched composition as a food or feed additive. 1. A glycoprotein enriched composition comprising at least 10% higher concentration of glycoproteins compared to the natural glycoprotein source wherein the enriched glycoprotein fraction consists essentially of non intermolecular disulfide-bound glycoprotein-subunits as measured by non-reduced and reduced sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE.2. The glycoprotein enriched composition according to claim 1 , wherein said glycoprotein enriched composition is prepared from human blood plasma claim 1 , porcine blood plasma claim 1 , bovine blood plasma claim 1 , equine blood plasma claim 1 , ovine blood plasma or avian blood plasma.3. The glycoprotein enriched composition according to claim 1 , wherein said glycoprotein enriched composition is prepared from eggs claim 1 , whey or other glycoprotein containing natural sources.4. The glycoprotein enriched composition according to claim 1 , wherein said glycoprotein enriched composition is further characterized by comprising an at least 10% lower albumin concentration compared to the natural glycoprotein source.5. The glycoprotein enriched composition according to claim 1 , wherein said glycoprotein enriched composition is prepared from non-immunized blood plasma.6. A food or feed supplement in solid or liquid form claim 1 , characterized in that said food or feed supplement comprises a glycoprotein enriched composition according to .7. The food or feed supplement according to claim 6 , further comprising an animal feed selected from the group consisting of one or more of corn claim 6 , sorghum claim 6 , meat claim 6 , barley claim 6 , wheat claim 6 , soy claim 6 , soybean meal claim 6 , peanut claim 6 , canola ...

PRETERM INFANT NUTRITIONAL COMPOSITIONS CONTAINING BETA-HYDROXY-BETA-METHYLBUTYRIC ACID

Preterm infant nutritional compositions comprising beta-hydroxy-beta-methylbutyric acid for supporting growth, accretion of lean body mass, and a healthy body composition in preterm infants are provided. The preterm infant nutritional compositions may be liquid formulas, fortifiers, and supplements. Methods for supporting growth, accretion of lean body mass, and a healthy body composition in a preterm infant are also provided. The methods include administering a preterm infant nutritional composition comprising beta-hydroxy-beta-methylbutyric acid to the preterm infant. 1. A liquid preterm infant nutritional composition comprising from about 60 μg to about 6 ,000 mg of beta-hydroxy-beta-methylbutyric acid per liter of the composition , the composition having an energy density of from about 676 kcal to about 1014 kcal per liter.2. The preterm infant nutritional composition according to claim 1 , wherein the composition is selected from the group of: liquid infant formula; liquid human milk fortifier; and liquid protein supplement.3. The preterm infant nutritional composition according to claim 1 , wherein the beta-hydroxy-beta-methylbutyric acid is in a form selected from: free acid; salt; anhydrous salt; ester; lactone; and mixtures thereof.4. The preterm infant nutritional composition according to claim 3 , wherein the beta-hydroxy-beta-methylbutyric acid is a beta-hydroxy-beta-methylbutyric acid salt selected from: calcium salt; sodium salt; potassium salt; magnesium salt; chromium salt; and mixtures thereof.5. The preterm infant nutritional composition according to claim 1 , comprising protein in an amount from about 15 grams to about 35 grams of protein per liter of the composition.6. The preterm infant nutritional composition according to claim 1 , comprising protein in an amount from about 18 grams to about 32 grams of protein per liter of the composition.7. The preterm infant nutritional composition according to claim 2 , wherein the composition is a liquid ...

COMPOSITION AND USE

The invention provides the simultaneous, separate or sequential feeding or administration of a carnitine substance (e.g. L-carnitine) with an agent for increasing the blood/plasma insulin concentration. The agent may be protein, carbohydrate or one or more amino acids or a combination of such nutrients. The co-administration or co-feeding of the carnitine substance and the agent provide for the reduction of whole body fat mass, particularly associated with excess dietary energy intake. The disclosed co-administration may also provide for the treatment of insulin resistance, fat oxidation disorders or obesity, and for increasing energy expenditure and fat metabolism. Compositions and kits containing the carnitine substance and the agent are provided, as are methods of treatment employing the co-administration or feeding of the carnitine substance and the agent. Also described is the upregulation of several genes in response to the treatments of the invention, including ACAT1, PNPLA2, PDK2, FOXO3, TFAM and CPT1. 1. A carnitine substance for use in the reduction of whole-body fat mass accumulation , wherein the carnitine substance is administered or used as a dietary supplement together with an agent for increasing the blood/plasma insulin concentration.2. An agent for use in the reduction of whole-body fat mass accumulation , wherein the agent is administered or used as a dietary supplement together with administration of , or dietary supplementation with a carnitine substance , and wherein the agent is suitable for increasing the blood/plasma insulin concentration.3. A carnitine substance for use in the treatment of insulin resistance , fat oxidation disorders or obesity , wherein the carnitine substance is administered or used as a dietary supplement together with an agent for increasing the blood/plasma insulin concentration.4. An agent for use in the treatment of insulin resistance , fat oxidation disorders or obesity , wherein the agent is administered or used as ...

Compositions and Products for Infectious or Inflammatory Diseases or Conditions

Composition and methods for treating infectious and inflammatory diseases using saccharide based products and therapies. Products can be implemented as a nutritional supplement, a food, a feed, a food additive, a feed additive, a therapeutic product, a rehydration salt, or a rehydration solution. The present disclosure relates generally to the fields of compositions and products containing the compositions, and the use of the compositions or the products for preventing and/or treating infectious or inflammatory diseases or conditions in particular gastrointestinal and respiratory diseases (diarrhea and influenza infections) or inflammatory.

NUTRITIONAL SUPPLEMENT FOR GROWTH ENHANCEMENT

Provided are nutritional supplements designed for enhancing the growth, particularly the linear growth, of pre-pubertal children with a stature measure short compared to the norm. The nutritional composition includes an energy source, arginine and a combination of micronutrients. 1. A nutritional supplement in a powder form having per 100 g powder a total caloric content of from about 300 kcal to about 500 kcal comprising per 100 g powder arginine in an amount of from about 250 mg to about 1000 mg and a micronutrient combination comprising calcium in an amount of from about 250 mg to about 750 mg; vitamin C in an amount of from about 15 mg to about 350 mg; zinc in an amount of from about 2.0 mg to about 15 mg; iron in an amount of from about 2.0 mg to about 10 mg; vitamin A in an amount of from about 50 μg to about 350 μg; and vitamin D in an amount of from about 2 μg to about 10 μg.2. The nutritional supplement of claim 1 , wherein 40% to 70% of the total caloric content is carbohydrates.3. The nutritional supplement of claim 1 , wherein 10% to 40% of the total caloric content is lipids.4. The nutritional supplement of claim 1 , wherein 10% to 40% of the total caloric content is proteins.5. The nutritional supplement of claim 1 , said supplement comprises per 100 g powder arginine in an amount of from about 500 mg to about 1000 mg; calcium in an amount of from about 300 mg to about 400 mg; vitamin C in an amount of from about 15 mg to about 50 mg; zinc in an amount of from about 2.0 mg to about 5.0 mg; iron in an amount of from about 3.0 mg to about 5.0 mg; vitamin A in an amount of from about 50 μg to about 150 μg; and vitamin D in an amount of from about 2 μg to about 3.5 μg.6. The nutritional supplement of claim 1 , said composition having per 100 g powder a total caloric content of about 420 kcal; arginine in an amount of about 826-992 mg; calcium in an amount of about 413 mg; vitamin C in an amount of about 24-28 mg; zinc in an amount of from about 4 mg; iron ...

USE OF GLYCOMACROPEPTIDE TO IMPROVE WOMEN'S HEALTH

Methods for improving the health of a female human or non-human animal are disclosed. The methods include the step of administering to the animal compositions including an effective amount of glycomacropeptide (GMP) for effectuating the methods. Specifically, the methods can be used to increase the rate of fat metabolism or fat oxidation, decrease percentage of body fat, increase the rate of bone mineralization, increase bone mineral content, increase bone mineral density, and/or increase bone strength in the animal. 1. A method for improving the health of a female human or non-human animal comprising administering to the animal an effective amount of a composition comprising glycomacropeptide (GMP) , whereby the bone strength in the animal is increased2. The method of claim 1 , wherein the female animal is human.3. The method of claim 1 , wherein the composition is administered orally.4. The method of claim 3 , wherein the composition is a food product claim 3 , a nutraceutical claim 3 , or a dietary supplement.5. The method of claim 1 , wherein the animal does not have phenylketonuria (PKU).6. The method of claim 1 , wherein the effective amount of the composition is such that from 0.15 to 1.0 g GMP per kg of body weight is administered to the animal per day.7. The method of claim 1 , wherein the method is used to treat one or more conditions associated with bone strength.8. The method of claim 7 , wherein the condition treated is osteoporosis or osteopenia. This application is a continuation of U.S. application Ser. No. 13/755,893 filed on Jan. 31, 2013, which claims the benefit of U.S. provisional Application No. 61/593,157 filed on Jan. 31, 2012, and of U.S. provisional Application No. 61/672,555 filed on Jul. 17, 2012. Each of these applications is incorporated by reference herein in its entirety.This invention was made with government support under 11-CRHF-0-6055 awarded by the USDA/NIFA. The government has certain rights in the invention.This disclosure ...

INSULIN-CONTAINING INFANT FORMULA

The present invention provides compositions methods and kits for improved infant formula, particularly to insulin-supplements and formulae comprising same that mimic the diurnal rhythm and/or the postpartum variation of insulin in human milk. 1. A kit for insulin-supplemented infant formula , comprising:a plurality of portions of infant formula, wherein each portion comprises insulin,wherein the concentration of the insulin in each of the plurality of portions mimics the concentration of insulin in human milk at a given day and time of day postpartum,wherein the day is between day 1 to day 84 postpartum,wherein the time of day is selected from 6 AM to 12 PM, 12 PM to 6 PM, 6 PM to 12 AM, 6 AM to 6 PM and 6 PM to 6 AM; andinstructions for feeding an infant with the insulin-supplemented infant formula.2. The kit of claim 1 , wherein the concentration of insulin in each portion of formula corresponds to the concentration range of insulin indicated at a given day and time of day in Table 1.3. The kit of claim 1 , wherein the concentration of insulin in each portion of formula corresponds to the mean concentration of insulin indicated at a given day and time of day in Table 1.4. A kit for insulin-supplemented infant formula claim 1 , comprising:a plurality of portions of infant formula;a plurality of portions of insulin; andinstructions for how to mix the insulin with the formula such that the insulin concentration in the formula mimics the concentration of insulin in human milk at a given day and time of day postpartum,wherein the day is between day 1 to day 84 postpartum, wherein the time of day is selected from 6 AM to 12 PM, 12 PM to 6 PM, 6 PM to 12 AM, 6 AM to 6 PM and 6 PM to 6 AM.5. The kit of claim 4 , wherein the concentration of insulin in each portion of insulin corresponds to the concentration range of insulin indicated at a given day and time of day in Table 1.6. The kit of claim 4 , wherein the concentration of insulin in each portion of insulin ...

METHODS FOR MODULATING KINASES

A method for modulating a kinase by administering to a subject a nutritional composition comprising extensively hydrolyzed casein, extensively hydrolyzed casein fractions, or combinations thereof. A modulated kinase may be a kinase that regulates inflammatory signaling, immune tolerance, metabolic signaling, cell cycle and growth factor signaling. The nutritional composition may dose-dependently inhibit a range of serine, threonine and tyrosine kinases. 1. A method for modulating a kinase by administering to a subject a nutritional composition , the nutritional composition comprisingextensively hydrolyzed casein, extensively hydrolyzed casein fractions, or combinations thereof, having a molar mass distribution of greater than 500 Daltons.2. The method of claim 1 , wherein the nutritional composition comprises a protein equivalent source claim 1 , wherein at least 1% of the protein equivalent source comprises extensively hydrolyzed casein claim 1 , extensively hydrolyzed casein fractions claim 1 , or combinations thereof claim 1 , such that at least 1% to 80% of the protein equivalent comprises the following individual peptides: SEQ ID NO 4 claim 1 , SEQ ID NO 13 claim 1 , SEQ ID NO 17 claim 1 , SEQ ID NO 21 claim 1 , SEQ ID NO 24 claim 1 , SEQ ID NO 30 claim 1 , SEQ ID NO 31 claim 1 , SEQ ID NO 32 claim 1 , SEQ ID NO 51 claim 1 , SEQ ID NO 57 claim 1 , SEQ ID NO 60 claim 1 , and SEQ ID NO 63.3. The method of wherein the protein equivalent source is present in amount of from about 0.2 g/100 kcals to about 5.6 g/100 kcals of the nutritional composition.4. The method of claim 2 , wherein the protein equivalent source further comprises at least 10 individual peptides selected from the group consisting of SEQ ID NO 1 claim 2 , SEQ ID NO 2 claim 2 , SEQ ID NO 3 claim 2 , SEQ ID NO 5 claim 2 , SEQ ID NO 6 claim 2 , SEQ ID NO 7 claim 2 , SEQ ID NO 8 claim 2 , SEQ ID NO 9 claim 2 , SEQ ID NO 10 claim 2 , SEQ ID NO 11 claim 2 , SEQ ID NO 12 claim 2 , SEQ ID NO 14 claim 2 , ...

NUTRITIONAL COMPOSITIONS HAVING EXOGENOUS MILK FAT GLOBULE MEMBRANE COMPONENTS

Nutritional compositions including milk fat globule membrane components (“MFGM”) and at least one nutrient are provided. The milk-derived, bioactive lipids help to modulate conditions typically found in the elderly including, for example, low-grade inflammation, loss of lean body mass, skeletal muscle cell membrane instability, and joint inflammation. The nutrients may include, but are not limited to, whey protein micelles, citrulline, branched chain fatty acids, and a-hydroxycaproic acid (“α-HICA”). Methods for treating an individual having, or at risk of having, a medical condition are also provided. 1. A nutritional composition comprising milk fat globule membrane (“MFGM”) and at least one nutrient selected from the group consisting of whey protein micelles , alpha-hydroxyisocaproic acid (“α-HICA”) , citrulline , branched chain fatty acids , and combinations thereof.2. The nutritional composition of claim 1 , wherein the whey protein micelles comprise at least one branched chain amino acid selected from the group consisting of leucine claim 1 , isoleucine claim 1 , valine claim 1 , and combinations thereof.3Bifidobacterium lactisLactobacillus rhamnosusLactobacillus rhamnosusBifidobacterium longumLactobacillus ReuteriLactobacillus ReuteriLactobacillus paracaseiLactobacillus johnsoniiLactobacillus helveticusBifidobacterium breveBifidobacterium longum. The nutritional composition of comprising a probiotic selected from the group consisting of CNCM I-3446 claim 1 , GG ATCC 53103 claim 1 , CGMCC 1.3724 claim 1 , BB536 deposited under ATCC BAA-999 claim 1 , ATCC55730 claim 1 , DSM-17938 claim 1 , CNCM I-2116 claim 1 , CNCM I-1225 claim 1 , CNCM I-4095 claim 1 , CNCM I-3865 claim 1 , CNCM I-2618 claim 1 , and combinations thereof.4. The nutritional composition of claim 3 , wherein the MFGM comprises proteins or bioactive proteins able to bind with or biologically interact with the probiotic.5. The nutritional composition of claim 3 , wherein the MFGM comprises ...

Compositions Comprising Sugar-Cysteine Products

The present invention provides compositions comprising sugar, cysteine, and/or sugar-cysteine products, methods of preparing the same, and/or using the same. 1ginsengrhodiola rosea.. A composition comprising a comprising RibCys , ribose , caffeine , and one or more of the following: vitamin B1 , vitamin B2 , vitamin B3 , vitamin B6 , vitamin B12 , folic acid , panthothenic acid , biotin , chromium , magnesium , copper gluconate , quercetin , CoQ10 , , and2. The composition of claim 1 , wherein the composition is a powdered composition.3. The composition of claim 1 , wherein the composition is a beverage or a foodstuff.4ginsengrhodiola rosea.. The composition of claim 1 , wherein the composition comprises vitamin B1 claim 1 , vitamin B2 claim 1 , vitamin B3 claim 1 , vitamin B6 claim 1 , vitamin B12 claim 1 , folic acid claim 1 , panthothenic acid claim 1 , biotin claim 1 , chromium claim 1 , magnesium claim 1 , copper gluconate claim 1 , quercetin claim 1 , CoQ10 claim 1 , claim 1 , and5. The composition of claim 1 , wherein the caffeine is present in a green tea extract.6. A solution comprising a composition of .7. A solution comprising a composition of .8ginsengrhodiola roseaginsengrhodiola rosea.. A method of preparing an aqueous composition claim 4 , the method comprising contacting RibCys claim 4 , ribose claim 4 , caffeine claim 4 , and one or more of the following: vitamin B1 claim 4 , vitamin B2 claim 4 , vitamin B3 claim 4 , vitamin B6 claim 4 , vitamin B12 claim 4 , folic acid claim 4 , panthothenic acid claim 4 , biotin claim 4 , chromium claim 4 , magnesium claim 4 , copper gluconate claim 4 , quercetin claim 4 , CoQ10 claim 4 , claim 4 , and under conditions sufficient to dissolve the RibCys claim 4 , ribose claim 4 , caffeine claim 4 , and one or more of the following: vitamin B1 claim 4 , vitamin B2 claim 4 , vitamin B3 claim 4 , vitamin B6 claim 4 , vitamin B12 claim 4 , folic acid claim 4 , panthothenic acid claim 4 , biotin claim 4 , chromium claim ...

Nutraceuticals Having Sustained Release for Improved Bioavailability and Method of Production

The present disclosure describes economical processes to improve the bioavailability of nutraceuticals by formulations that induce micronization and sustained release. The inventive process can be used to increase the solubility and bioavailability of lipophilic and moderately water-soluble nutraceuticals by combining excipients that increase the solubility and induce sustained release of the active compounds. The inventive process also can be used to increase the residence time of highly water-soluble nutraceuticals that are metabolized and eliminated quickly from the body, consequently increasing the therapeutic potential. The disclosed formulations advantageously are freely flowing powders that can be used to formulate with other ingredients into tablets, capsules, or the like; or used as bulk powders. 1. A particulate nutraceutical composition , which comprise:(a) between about 1% and 60% by weight of a lipophilic nutraceutical having a particle size not substantially larger than about 10μ;(b) between about 0.5% and 20% be weight of a lipid selected from the group consisting essentially of vegetable oils, medium chain triglycerides and isopropyl or ethyl esters of fatty acids;(c) between about 10% and 30% by weight of a surfactant being one or more of a non-ionic type polysorbate, or polyglycerol esters of fatty acids with a hydrophilic-lipophilic balance (HLB) value between 8-16;(d) between about 1% and 50% by weight of a polymer being one or more of carboxymethyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, alginic acid sodium salt, or a cyclodextrin; and(e) between about 1% and 50% by weight of an excipient being one or more of a microcrystalline cellulose, silica, maltodextrin, potato starch, bamboo silica, or rice flour;where the amount of said polymer and lipid is insufficient to coat all of the nutraceutical composition particles and where said nutraceutical composition has improved bioavailability and a combination of immediate release and ...

GLUTAMINE ENRICHED NUTRITIONAL COMPOSITION FOR PRETERM INFANTS

The present invention relates to the use of nutritional compositions enriched in glutamineto improve structural brain development in preterm and/or low birth weight infants. 117-. (canceled)18. A method for increasing and/or improving growth of brain volume and/or brain mass , comprising administering to a low birth weight and/or preterm infant a nutritional composition enriched in glutamine.19. The method according to claim 18 , wherein the nutritional composition comprises at least 12 wt. % glutamine based on total protein and the glutamine is in an amount of at least 1.5 wt. % based on dry weight of the nutritional composition.20. The method according to claim 18 , wherein the glutamine is in the form of free glutamine claim 18 , glutamine dipeptide claim 18 , and/or glutamine tripeptide; and the sum of free glutamine claim 18 , glutamine dipeptide and glutamine tripeptide is at least 1.5 wt. % claim 18 , based on dry weight of the nutritional composition.21. The method according to claim 18 , wherein glutamine is administered at a daily dose of at least 0.01 to 0.5 g/kg body weight.22. The method according to claim 21 , wherein glutamine is administered at a daily dose of at least 0.03 to 0.4 g/kg body weight.23. The method according to claim 22 , wherein glutamine is administered at a daily dose of at least 0.07 to 0.35 g/kg body weight.24. The method according to claim 18 , wherein the nutritional composition is administered to the infant during the first month after birth.25. The method according to claim 18 , wherein the increase and/or improved growth in brain volume and/or mass is established in the infant at the age from 4 to 12 years.26. A method for increasing white matter volume and/or mass claim 18 , brain stem volume and/or mass claim 18 , and/or hippocampus volume and/or mass claim 18 , comprising administering to low birth weight and/or preterm infants a nutritional composition enriched in glutamine.27. The method according to claim 26 , wherein ...

Liquid Nutritional Composition Comprising Free Amino Acids

The invention relates to a liquid or gelled pasteurized or sterilized composition comprising free amino acids, calcium, a digestible carbohydrate, and preferably an indigestible carbohydrate, wherein the free amino acids are present in a concentration between 5 and 30 g/100 ml, and the dry weight of the total composition is at least 40 g/100 ml, and preferably lower than 60 g/100 ml. The composition may in particular be used in the treatment of a human suffering from a disorder selected from the group consisting of phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinaemia, propionic acidaemia, methylmalonic acidaemia, isovaleric acidaemia, urea cycle disorders and glutaric aciduria. 1. A liquid or gelled pasteurized or sterilized composition comprising free amino acids , calcium , and a digestible carbohydrate , wherein the free amino acids are present in a concentration between 5 and 30 g/100 ml , and the dry weight of the total composition is at least 40 g/100 ml.2. The composition according to claim 1 , wherein the free amino acids concentration is between 7.5 and 30 g/100 ml.3. The composition according to claim 1 , wherein the digestible carbohydrate content is between 10 and 20 g per 100 ml.4. The composition according to claim 1 , wherein the free amino acids comprise at least tyrosine in a concentration between 1-3 g/100 ml.5. The composition according to claim 1 , wherein the indigestible carbohydrates comprise claim 1 , pectin and at least one indigestible carbohydrate selected from the group of xanthan and guar gum.6. The composition according to claim 1 , wherein the liquid or gelled comprises fruit juice or fruit puree.7. The composition according to claim 1 , wherein the composition further comprises fat claim 1 , in a concentration between 0.3 and 15 g/100 ml.8. A method for the treatment of a disorder in a human comprising administering a liquid or gelled pasteurized or sterilized composition comprising free amino acids claim 1 , ...

Natural nutritional supplements

Dietary nutritional supplements specially formulated for use by high school, college and professional athletes, especially wrestlers. The nutritional supplements build strength, endurance and stamina, replenish electrolytes lost during intense sweating, provide essential nutrients, and increase and sustain energy. The nutritional supplements can be mixed with each other in various combinations to provide athletes with essential nutrients as necessary based on the activity undertaken. While designed primarily for athletes with demanding workout routines, the nutritional supplements can benefit persons of all ages by providing essential nutrients, vitamins and minerals. Through the use of natural and nontoxic ingredients, the nutritional supplements are designed to provide beneficial vitamins and minerals without leading to violations of anti-doping regulations or causing other detrimental effects. Especially preferred formulations include the combination of various essential amino acids and vitamin B combinations that are stable and can be delivered orally as a spray. 1. A nutritional supplement comprising the combination of B-Vitamin Blend including at least B1 (Thiamine) , B2 (Riboflavin) , B3 (Niacin) , B6 (Pyridoxine) , B12 (Cobalamin) and B7 (D-Biotin) and the combination of at least 8 of the following amino acids: Glycine , L-Serine , L-Threonine , L-Valine , L-Histidine , L-Arginine , cysteine , L-Proline , L-Alanine , glutamate , glutamine , aspartae , asparagine and methionine.2. The nutritional supplement of delivered in the form of a spray.3. The nutritional supplement of in which the spray container has sufficient supplement for ten 0.2 ml sprays per day for 30 days. This application is a continuation-in-part of application Ser. No. 13/451,329, filed Apr. 19, 2012 in the name of Leroy P. Kemp, Woo Chun Paik and Mia Scheid. application Ser. No. 13/451,329 is hereby incorporated by reference in its entirety.1. Field of the InventionThis invention relates ...

INFANT FORMULAS CONTAINING DOCOSAHEXAENOIC ACID AND LUTEIN

Disclosed are infant formulas and corresponding methods of using them to promote retinal health and vision development in infants. The formulas, which are free of egg phospholipids and comprise fat, protein, carbohydrate, vitamins, and minerals, including docosahexaenoic acid and, on a ready-to-feed basis, at least about 50 mcg/liter of lutein, wherein the weight ratio of lutein (mcg) to docosahexaenoic acid (mg) is from about 1:2 to about 10:1. The formulas are also believed to be especially useful in reducing the risk of retinopathy of prematurity in preterm infants. 1. A liquid human milk fortifier comprising:protein, carbohydrate, fat, docosahexaenoic acid, and at least about 50 mcg/liter of lutein;wherein the weight ratio of lutein (mcg) to docosahexaenoic acid (mg) is from about 1:2 to about 10:1; andwherein the liquid human milk fortifier is free of egg phospholipids.2. The liquid human milk fortifier of claim 1 , wherein the liquid human milk fortifier has a total solids level of about 31%.3. The liquid human milk fortifier of claim 1 , wherein the liquid human milk fortifier comprises from about 50 mcg/liter to about 1150 mcg/liter of lutein.4. The liquid human milk fortifier of claim 1 , wherein the liquid human milk fortifier comprises from about 75 mcg/liter to about 230 mcg/liter of lutein.5. The liquid human milk fortifier of claim 1 , wherein the liquid human milk fortifier comprises from about 100 mcg/liter to about 200 mcg/liter of lutein.6. The liquid human milk fortifier of claim 3 , wherein the weight ratio of lutein (mcg) to docosahexaenoic acid (mg) is from about 1.5:1 to about 9:1.7. The liquid human milk fortifier of claim 3 , wherein the weight ratio of lutein (mcg) to docosahexaenoic acid (mg) is from about 1.7:1 to about 5:1.8. The liquid human milk fortifier of claim 3 , wherein the liquid human milk fortifier further comprises beta-carotene claim 3 , lycopene claim 3 , and zeaxanthin claim 3 , and wherein the liquid human milk fortifier ...

FISH PROTEIN HYDROLYSATE HAVING A SATIETOGENIC ACTIVITY, NUTRACEUTICAL AND PHARMACOLOGICAL COMPOSITIONS COMPRISING SUCH A HYDROLYSATE AND METHOD FOR OBTAINING SAME

The present invention relates to a fish protein hydrolysate containing molecules capable of exerting a satietogenic activity and of regulating food intake in humans or animals. More specifically, the protein hydrolysate according to the invention enables stimulation of the secretion of endogenous cholescystokinins (CCKs) and of endogenous glucagon-like peptide 1 (GLP1) molecules by intestinal cells and the supply of exogenous CCKs. The fish protein hydrolysate according to the invention is obtained by enzymatic hydrolysis of at least one protein source selected from the group composed of the pelagic fish species and spp., the demersal fish species and , and the species of fish belonging to the order Siluriformes, said enzymatic hydrolysis being carried out by means of a mixture of enzymes comprising endopeptidases derived from and from , or derived from , from and from 117-. (canceled)18Bacillus amyloliquefaciensBacillus licheniformisMicromesistius poutassou. A method to exert a satietogenic effect and to regulate food intake comprising , administrating to a human or an animal a pharmaceutical or nutritional composition comprising a and endopeptidases enzyme mixture treated fish protein hydrolysate.19. The method of claim 18 , wherein the fish protein hydrolysate is obtained by a process claim 18 , comprising:{'i': 'Micromesistius poutassou', 'grinding of as protein source,'}{'i': Bacillus amyloliquefaciens', 'Bacillus licheniformis, 'enzymatic hydrolyzing said protein source at a temperature of between 40° and 63° C., at a pH situated between 6 and 9, for 1 to 5 hours, after the addition of a mixture of enzymes comprising endopeptidases derived from and , in a ratio of enzyme to protein source of between 0.01 and 2%, so as to obtain a reaction mixture,'}stopping said enzymatic hydrolysis by inactivation of the said enzymes after raising the temperature of the said reaction mixture to a level not below 70° C., for 8 to 20 minutes, andseparating the protein ...

TOBACCO-DERIVED PROTEIN COMPOSITIONS

The disclosure describes methods for the purification of protein-enriched extracts to provide concentrates and isolates and methods for incorporation of such materials into products. The purification methods are adapted for removal of one or more of ash, metal salts, alkaloids, particulates, heavy metals, and other impurities and/or contaminants from extracts, as well as modifying the sensory characteristics (e.g., odor, color, and/or taste characteristics) of extracts. The methods generally include diafiltration, treatment with functionalized resins, and supercritical extraction. A protein composition in the form of a concentrate or isolate is provided, the protein composition including RuBisCO, F2 fraction proteins, or combination thereof extracted from a plant of the species, wherein the protein composition is characterized by one or more of: an ash content of less than about 15% by weight; a nicotine content of less than about 10 μg/g, and a heavy metal content of less than about 60 μg/g. 127.-. (canceled)28. A method for modifying the sensory characteristics of a protein-enriched material , the method comprising:a) receiving a plant-derived, protein-enriched material comprising RuBisCO, F2 fraction proteins, or a combination thereof, wherein the plant-derived, protein-enriched material exhibits an initial odor and taste;b) extracting components from the protein-enriched extract with a solvent while the solvent is in a supercritical state to provide a protein concentrate or isolate having an altered odor, taste, or combination thereof; andc) separating the protein concentrate or isolate from the unextracted residue.29. The method of claim 28 , wherein the plant-derived claim 28 , protein-enriched material is in spray dried or freeze-dried form.30. The method of claim 29 , wherein the method further comprises moistening the plant-derived claim 29 , protein-enriched material prior to the extracting step with water to provide a plant-derived claim 29 , protein- ...

HYDROLYZED LACTOSE-CONTAINING NUTRITIONAL COMPOSITIONS AND USES THEREOF

A nutritional composition having enhanced sweetness perception, which includes up to about 7 g/100 kCal of a protein or protein equivalent source; up to about 7 g/100 kCal of a fat or lipid source; and at least about 5 g/100 kCal of a carbohydrate, wherein the protein or protein equivalent source has endogenous lactose which is at least 50% hydrolyzed and/or the composition includes lactose which is at least 80% hydrolyzed. 1. A nutritional composition , comprising:a. up to about 7 g/100 kCal of a protein or protein equivalent source, wherein the protein or protein equivalent source comprises endogenous lactose which is at least 50% hydrolyzed;b. up to about 7 g/100 kCal of a fat or lipid source; andc. at least about 5 g/100 kCal of a carbohydrate.2. The nutritional composition of claim 1 , wherein the lactose is at least 70% hydrolyzed.3. The nutritional composition of claim 1 , wherein the protein or protein equivalent source comprises whey protein claim 1 , whey protein isolates claim 1 , whey protein concentrates claim 1 , sweet whey claim 1 , acid whey claim 1 , or combinations thereof claim 1 , wherein the whey protein claim 1 , whey protein isolates claim 1 , whey protein concentrates claim 1 , sweet whey claim 1 , or acid whey comprises endogenous lactose.4. The nutritional composition of claim 1 , which further comprises one or more of:d. about 0.1 g/100 kCal to about 1 g/100 kCal of a prebiotic composition comprising polydextrose and galacto-oligosaccharide; ande. at least about 5 mg/100 kCal of an additional long chain polyunsaturated fatty acid, and further wherein the protein or protein equivalent source comprises lactoferrin.5. The nutritional composition of claim 4 , wherein lactoferrin is present at a level of about 10 mg/100 kCal to about 200 mg/100 kCal.6. The nutritional composition of claim 4 , wherein the additional long chain polyunsaturated fatty acids are present more preferably from about 5 mg/100 kCal to about 75 mg/100 kCal.7. The ...

LOW CALORIE INFANT FORMULA CONTAINING BETA-HYDROXY-BETA-METHYLBUTYRIC ACID

Low calorie nutritional compositions comprising beta-hydroxy-beta-methylbutyric acid which may support accretion of lean body mass and development of a healthy body composition in term infants are provided. The low calorie nutritional compositions may be liquid or powder infant formulas. 1. An infant formula comprising beta-hydroxy-beta-methylbutyric acid at from about 60 μg to about 6 ,000 mg per liter of the formula and a macronutrient , the formula having an energy density of from about 200 kcal to about 650 kcal per liter.2. The infant formula according to claim 1 , wherein the formula is a liquid.3. The infant formula according to claim 1 , wherein the beta-hydroxy-beta-methylbutyric acid is in a form selected from: free acid; salt; anhydrous salt; ester; lactone; and mixtures thereof.4. The infant formula according to claim 3 , wherein the beta-hydroxy-beta-methylbutyric acid is a beta-hydroxy-beta-methylbutyric salt selected from: sodium salt; potassium salt; magnesium salt; chromium salt; calcium salt; and mixtures thereof.5. The infant formula according to claim 1 , comprising protein in an amount of from about 0.5 grams to about 14 grams protein per liter of formula.6. The infant formula according to claim 1 , comprising protein in an amount from about 5 grams to about 10 grams protein per liter of formula.7. The infant formula according to claim 1 , comprising protein in an amount from about 7.6 grams to about 10 grams protein per liter of formula.8. The infant formula of claim 1 , comprising beta-hydroxy-beta-methylbutyric acid at less than 1 claim 1 ,500 mg per liter of the formula.9. The infant formula of claim 1 , comprising beta-hydroxy-beta-methylbutyric acid at less than 300 mg per liter of the formula.10. A method for promoting protein synthesis in a term infant claim 1 , the method comprising the step of administering to the infant a liquid infant formula comprising beta-hydroxy-beta-methylbutyric acid at from about 60 μg to about 6000 mg per ...

ANTI-AGING ANTIOXIDANT NUTRITIONAL SUPPLEMENT FOR THE IMPROVEMENT OF THE INTEGUMENTARY SYSTEM

A liquid anti-aging antioxidant nutritional supplement comprising collagen, carnosine, CoEnzyme Q10 and Resveratrol particularly suitable for reducing oxidative damage to the integumentary system. 1. A nutritional supplement comprising collagen , carnosine , CoEnzyme Q10 and Resveratrol.2. A nutritional supplement according to claim 1 , wherein said collagen is present in an amount between 0.5 and 10 g/50 ml claim 1 , preferably in an amount between 1.75 and 7.5 g/50 ml claim 1 , more preferably between 3 and 5 g/50 ml.3. A nutritional supplement according to claim 1 , wherein said carnosine is present in an amount between 10 and 250 mg/50 ml claim 1 , preferably in an amount between 20 and 160 mg/50 ml claim 1 , more preferably between 40 and 80 mg/50 ml.4. A nutritional supplement according to claim 1 , wherein said CoEnzyme Q10 is present in an amount between 5 and 250 mg/50 ml claim 1 , preferably in an amount between 9 and 200 mg/50 ml claim 1 , more preferably between 15 and 150 mg/50 ml.5. A nutritional supplement according to wherein said Resveratrol is present in an amount between 0.2 and 450 mg/50 ml claim 1 , preferably in an amount between 1.0 and 200 mg/50 ml claim 1 , more preferably between 2.0 and 80 mg/50 ml.6. A nutritional supplement according to claim 1 , further comprising an emulsion comprising borage seed oil and primrose oil.7. A nutritional supplement according to any one of to claim 1 , further comprising at least one ingredient selected among hyaluronic acid claim 1 , lycopene and black pepper extract.8. A nutritional supplement according to claim 1 , wherein said supplement further comprises at least one ingredient selected among acai berry claim 1 , pomegranate claim 1 , vitamins claim 1 , preferably vitamin C and vitamin A.9. A nutritional supplement according to claim 9 , wherein said supplement further comprises vitamins selected among vitamin B claim 9 , vitamin B claim 9 , vitamin B claim 9 , vitamin B claim 9 , vitamin C claim 9 , ...

Glycogen or polysaccharide storage disease treatment method

A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.